Official Transcript of Proceedings

NUCLEAR REGULATORY COMMISSION

Title: Advisory Committee on the Medical Uses of

Isotopes

Docket Number: (not applicable)

Location: Rockville, Maryland

Date: Wednesday, February 20, 2002

Work Order No.: NRC-248 Pages 81-384

NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers 1323 Rhode Island Avenue, N.W. Washington, D.C. 20005

	81
1	UNITED STATES OF AMERICA
2	NUCLEAR REGULATORY COMMISSION
3	+ + + +
4	ADVISORY COMMITTEE ON THE MEDICAL
5	USES OF ISOTOPES
6	(ACMUI)
7	+ + + +
8	WEDNESDAY,
9	FEBRUARY 20, 2002
10	+ + + +
11	ROCKVILLE, MARYLAND
12	+ + + +
13	
14	The Advisory Committee met at the Nuclear
15	Regulatory Commission, Two White Flint North, T2B3, 11545
16	Rockville Pike, Rockville, Maryland, at 8:00 a.m., Manuel
17	Cerqueira, Chairman, presiding.
18	COMMITTEE MEMBERS PRESENT:
19	MANUEL CERQUEIRA, M.D., Chairman
20	DAVID A. DIAMOND, M.D.
21	NEKITA HOBSON
22	RALPH P. LIETO
23	RUTH McBURNEY
24	SUBIR NAG, M.D.
25	SALLY WAGNER SCHWARZ

NEAL R. GROSS

		02
1	COMMITTEE MEMBERS PRESENT (Continued):	
2	RICHARD J. VETTER, Ph.D.	
3	JEFFREY WILLIAMSON, Ph.D.	
4	ALSO PRESENT:	
5	JOHN W.N. HICKEY	
6	ANGELA WILLIAMSON	
7	SUSAN FRANT, Ph.D.	
8	ROBERT AYERS, Ph.D.	
9	MARJORIE ROTHSCHILD	
10	PATRICIA RATHBUN	
11	NANCY DALY	
12	DONALD A. COOL, Ph.D.	
13	PAUL LOHAUS	
14	JAMES MYERS	
15	WILLIAM UFFELMAN	
16	CATHERINE HANEY	
17	JOSEPH DeCICCO	
18	FREDERICK BROWN	
19		
20		
21		
22		
23		
24		
25		

C-O-N-T-E-N-T-S

2	P	AGE
3	Action Item No. 1	93
4	Action Item No. 2	94
5	Action Item No. 3	101
6	Discussion of Board Certification	104
7	Action Item No. 4	128
8	Presentation by Dr. Susan Frant	130
9	Action Item No. 5	164
10	Status of NRC Web Site, Dr. Patricia Rathbun	164
11	Status of Electronic Forms, John Hickey	179
12	Distribution of ACMUI Minutes	184
13	Update of ACMUI Bylaws	187
14	IAEA Patient Protection, Dr. Donald Cool	190
15	Status of Board Recognitions, Dr. Robert	
16	Ayers	266
17	Report of National Materials Program, Paul	
18	Lohaus	214
19	Security of Radioactive Materials, Catherine	
20	Haney	318
21	Update on New IVB Devices, John Hickey	342
22	Mixed Doses, Joseph DeCicco	353
23	ACMUI Vacancies	364
24	Meeting Summary	368
25	Next Meeting	369

	84
1	P-R-O-C-E-E-D-I-N-G-S
2	(8:12 a.m.)
3	MR. HICKEY: Good morning.
4	PARTICIPANTS: Good morning.
5	MR. HICKEY: While we're waiting for Dr.
6	Cerqueira, I'm going on the record to make the formal
7	announcements of the meeting.
8	I'm John Hickey, Chief of the Material
9	Safety Branch for NRC.
10	This is an open meeting of the Advisory
11	Committee on Medical Uses of Isotopes. It's a
12	transcribed meeting, and it's being conducted in
13	accordance with the Federal Advisory Committee Act.
14	And we'll go off the record until Dr.
15	Cerqueira gets here, and we'll begin the discussions.
16	(Whereupon, the foregoing matter went off
17	the record at 8:13 a.m. and went back on the
18	record at 8:15 a.m.)
19	CHAIRMAN CERQUEIRA: I'd like to welcome
20	everybody, and I guess we have sort of a follow-up
21	discussion from the Commission briefing yesterday. I'd
22	also like to sort of reiterate the policy that we've
23	adopted in the past for these meetings. I'd really like
24	to generate action items.
25	In going through the material for today's

meeting, there's quite a bit of missing stuff there, and I'd like to avoid that in future meetings. What we really need to do is identify action items from the discussions, and then have clear follow-up.

about making motions, taking a vote on something if we need to, which makes it a little bit more formal, and then I think as Dr. Williamson requested, perhaps sort of for the record getting some writing back from the NRC staff Commissioners on specific items that the Committee has brought to their attention just procedurally, I think, would be very important to do that.

And at some point during the day, hopefully before open discussion, but I think there were two issues that came up yesterday that we really need to sort of go forward with, and that's the issue related to the health physicist and the authorized medical physicist, radiation safety officers, in terms of trying to resolve some of these issues.

If it's, indeed, going to take a new rulemaking, then it's better to initiate the process now rather than waiting, and at some point I'd actually like to form a subcommittee that would look into these issues and then try to move it forward, working with the staff and the Commissioners to try to identify the most

2.4

expedient way to get the problem resolved. 1 2 I think it would be very important to do 3 that. As a result of yesterday's discussions also 4 5 with some of you, some of you have close flights time-6 wise to catch, and we'll try to keep the agenda moving as 7 much as possible, and I certainly don't want to cut anybody off during the discussions, but I think if people 8 9 will sort of bear with me, if we're saying the same thing 10 or people are perhaps taking too long to get to the point, I will sort of take the Chair's initiative and try 11 12 to keep things moving. 13 DR. DIAMOND: Would you like us to suggest 14 as a first motion today that we actually take a formal 15 vote that as a policy we go and generate a list of action items for the result of our discussions, and that at the 16 17 conclusion of that meeting each of those action items 18 generates a written response from the staff? 19 CHAIRMAN CERQUEIRA: I think that's a good Do we have a second on that? 20 idea. MS. WAGNER SCHWARZ: I second. 21 CHAIRMAN CERQUEIRA: Okay. Any discussion? 22 23 John? 2.4 MR. HICKEY: If I could just state, the 25 staff has no objection to that. In fact, that is our

intent, that any resolution or action item will be responded to in writing and we'll do it in a format that, as Dr. Nag suggested, that a separate response provide responses just to resolutions and action items so that you don't have to wade through a larger document to provide those.

CHAIRMAN CERQUEIRA: And I will attempt to work with Angela Williamson to try to make these points, you know, basically so that we capture it, but I think if we make the motions, vote on it, she'll have all of the wording that's appropriate for it, and that will sort of trigger what items we need specific responses to.

Jeffrey?

DR. WILLIAMSON: Well, I was just going to ask: is there a mechanism for somebody to go through the transcript and identify all of these items? I believe that's been a problem in the past.

MR. HICKEY: Well, I think the answer to that is yes, but in terms of resources, I think it's better to make sure we identify them during the meeting. It's a problem for, you know, one person or two persons to characterize what, in fact, constitutes an action item after the fact. It's better, I think, if we address that during the meeting.

CHAIRMAN CERQUEIRA: Well, again, I think if

2.4

1	we end up taking a formal vote on it, that clearly is an
2	item, and if there are other things that we're discussing
3	and people feel that they want follow-up, I think it
4	would be appropriate at the conclusion of the discussion
5	to make a motion and take a formal vote on it.
6	That would make it very clear-cut for both
7	the Committee as well as the NRC staff.
8	MR. HICKEY: Yes. If there is a vote,
9	there's no question, but also if the Chairman and I, as
10	designated official, just announce at the end of the
11	discussion that we agree this is an action item, that
12	also will be documented for the record.
13	CHAIRMAN CERQUEIRA: Sure.
14	Again, jeffrey.
15	DR. WILLIAMSON: Is it necessary to maybe
16	appoint somebody as a recording secretary to make a list
17	during the meeting of these items? It sounds like what
18	you're proposing now.
19	CHAIRMAN CERQUEIRA: Somebody from the
20	Committee, Jeffrey?
21	DR. WILLIAMSON: Not necessarily. It could
22	be somebody from the staff.
23	CHAIRMAN CERQUEIRA: Perhaps Angela could
24	MR. HICKEY: We already have a contractor
25	making notes and a transcriber. We already have two

1	people tracking the meeting. We've found that's an
2	adequate mechanism, and in fact, we have a memo from the
3	early 2001 meeting that responded to all of the items
4	that were brought up in that meeting.
5	So we feel we have adequate tracking of
6	this. As long as it's clearly stated in the meeting, it
7	will be followed up on.
8	CHAIRMAN CERQUEIRA: Well, then perhaps it's
9	my fault that I didn't sort of try to enforce that for
10	this meeting, but I just didn't get the feeling that
11	we've got specific action items that we need to get out.
12	I think the other thing that's important is
13	the minutes of the meeting. I think all of us should
14	look at those things ahead of time, and it's important to
15	get it out I would say at a minimum of two weeks before
16	the meetings. Is that a reasonable time?
17	Ralph.
18	MR. LIETO: I would just say all of that is
19	pretty much laid out in the bylaws of the Committee. We
20	can just follow what our bylaws state, and I think that
21	has the time lines and everything like that.
22	I think what John is suggesting is more than
23	adequate for support.
24	CHAIRMAN CERQUEIRA: Okay. That sounds like
25	it's a reasonable plan.

1	Any other follow-up from the Committee from
2	the meeting with the Commissioners yesterday?
3	MR. HICKEY: If I could just add, Mr.
4	Chairman, I also believe there was an important
5	discussion on the amount of time it's going to take to
6	implement the rule and if there's a six month deadline
7	specified, the NRC staff needs to make sure the guidance
8	is completed well in advance of that six month deadline.
9	There were several discussions of concern
10	about that issue.
11	DR. DIAMOND: I'd also like to state that I
12	believe the frequency of last meeting with the
13	Commissioners in October 1999, I believe, was overdue and
14	we should make a policy to do it more frequently than
15	that, perhaps on an annual basis, and in an effort to aid
16	with scheduling, perhaps we should go in next year's
17	Commission briefing as soon as possible so that we can
18	best coordinate it.
19	CHAIRMAN CERQUEIRA: That's a good point
20	But getting back to the initial discussion
21	with the guidance documents, I think this is sufficiently
22	important as we identified with debriefing yesterday.
23	I'd sort of like to get a formal motion that guidance
24	documents be completed in a timely fashion.
25	And you know, I asked the Commissioners

1	would it be possible, but I think the Committee should go
2	on record officially as saying that it's important to get
3	the guidance documents out, you know, prior to the
4	implementation and come up with a reasonable time period.
5	DR. NAG: Yes, I make a motion that the
6	guidance document be at least three months ahead of the
7	implementation, at least three months and not just a few
8	days.
9	CHAIRMAN CERQUEIRA: So, John, a suggestion
10	has been made and a motion has been put forward that
11	do we have a second on the motion just procedurally?
12	MS. WAGNER SCHWARZ: Second.
13	CHAIRMAN CERQUEIRA: Okay, and so for
14	discussions.
15	You know, with Dr. Nag's motion, is three
16	months realistic?
17	MR. HICKEY: Well, what I want to suggest is
18	we hold the vote until the nine o'clock agenda item where
19	we're going to be talking about the issuance of NUREG
20	1556, Volume 9, which is the guidance.
21	CHAIRMAN CERQUEIRA: Okay. I should have
22	known that, but I didn't.
23	So, Dr. Nag, do
24	DR. NAG: I will hold it.
25	CHAIRMAN CERQUEIRA: Okay. So we'll

1	DR. WILLIAMSON: Mr. Chairman.
2	CHAIRMAN CERQUEIRA: Yes.
3	DR. WILLIAMSON: Could we vote? We have to
4	vote on Dr. Diamond's motion, which is still on the
5	table.
б	CHAIRMAN CERQUEIRA: That's true. We did.
7	DR. WILLIAMSON: So could we repeat the
8	motion, what it is?
9	CHAIRMAN CERQUEIRA: Okay.
10	DR. DIAMOND: As Action Item No. 2 , the
11	Advisory Committee recommends that annual meetings be
12	held to brief
13	MS. McBURNEY: It was the other one. We
14	haven't even voted on the first one.
15	DR. DIAMOND: Oh, I thought we took a formal
16	vote on it.
17	MS. McBURNEY: No.
18	DR. DIAMOND: I'm sorry. Action Item
19	No. $oldsymbol{1}$, the Advisory Committee recommends that during
20	the course of each meeting a list of action items be
21	generated expressing the wishes and the intent of the
22	Committee, and that these action items generate a written
23	and prompt response from the staff so as to demonstrate
24	their feelings on the matter.
25	CHAIRMAN CERQUEIRA: Okay. I guess we've

1	sort of all agreed to it, but perhaps a motion.
2	So a motion has been made, was seconded.
3	There has been discussion. Any further discussion?
4	(No response.)
5	CHAIRMAN CERQUEIRA: If not, I call for a
6	vote. All in favor.
7	(Chorus of ayes.)
8	CHAIRMAN CERQUEIRA: Opposed?
9	(No response.)
10	CHAIRMAN CERQUEIRA: No abstentions, and so,
11	John, this will clearly be an action item.
12	And then we have still on the table the
13	motion regarding the guidance document. So we'll sort of
14	defer that until after the discussion at nine o'clock by
15	Susan Frant.
16	DR. DIAMOND: And that would bring us to
17	Action Item No. 2, which was that the Advisory
18	Committee recommend that annual briefings be held with
19	the Commissioners to update them with the activities of
20	this Committee, and that the Advisory Committee suggest
21	that this date be scheduled as far in advance as possible
22	so as to best facilitate the scheduling of that meeting.
23	CHAIRMAN CERQUEIRA: Do we have a second on
24	that?
25	Second. Okay. Discussion? Jeffrey.

1	DR. WILLIAMSON: I think that is covered in
2	our bylaws, that we have an annual briefing with the
3	Commission. Is that not so?
4	CHAIRMAN CERQUEIRA: Yeah, I think Ralph's
5	point is a valid one. The procedure is there, and it was
6	included in the book this time, and so basically what we
7	need to do is basically just get sort of compliance with
8	the bylaws.
9	I guess the one issue that does come up,
10	David, in terms of scheduling and appointment with the
11	Commissioners, it's hard to predict the schedule. I
12	think an attempt has to be made to have all five
13	Commissioners present, and so it's hard to figure out
14	schedules, you know.
15	A year in advance may be difficult, but at
16	least if we sort of, you know, try to get it as close as
17	possible, that's reasonable.
18	MR. HICKEY: Well, Dr. Diamond said as far
19	in advance as possible, which I think is reasonable. I
20	don't think it will be done a year in advance, and if it
21	is, it would be subject to change, but six months in
22	advance certainly at least can be tentatively scheduled.
23	CHAIRMAN CERQUEIRA: All right. Dr. Nag and
24	then Jeffrey.
25	DR. NAG: Well, one thing. I mean

1	ultimately we should like to have the meeting with all
2	the Commissioners, but if it fails, at the very least, we
3	should have one Commissioner invited to the ACMUI
4	meeting. One of the things that when we were informally
5	discussing with the Commissioners after the meeting that
6	we have a meeting, we have no problem if one of us comes
7	to a meeting and at least be a representative.
8	So if a meeting cannot be held within
9	reason, then we can do it by having a meeting with a, one
10	or more, Commissioners.
11	CHAIRMAN CERQUEIRA: I just would like to
12	get clarification. I think in the past when we've
13	brought up that possibility, there is some rule for
14	government committees, that we have to meet with all five
15	Commissioners. John, am I hallucinating on that?
16	MR. HICKEY: I would have to check on that.
17	CHAIRMAN CERQUEIRA: Is there anybody from
18	the staff?
19	MR. HICKEY: Our attorneys are here, but I
20	don't know. I can check during a break to see.
21	DR. VETTER: Manny?
22	CHAIRMAN CERQUEIRA: Yes
23	DR. VETTER: I also received the message
24	that Dr. Nag just reflected. One of the Commissioners
25	mentioned to me that if at any time we would like to

visit with one of them, we are free to invite them to 1 come and meet with us as part of the meeting. 2 3 Now, that's not an official meeting with the 4 Commissioners. That's inviting one of the Commissioners to come here to discuss an issue. 5 6 CHAIRMAN CERQUEIRA: Okay. I think that 7 would be appropriate, and perhaps, you know, John, if we could get counsel to give us some information on this. 8 MR. HICKEY: We could include that. 9 10 CHAIRMAN CERQUEIRA: On what the rules are. 11 MR. HICKEY: Yeah, I might be able to get you an answer today, but if not, we could include that in 12 13 the response to the resolution. 14 CHAIRMAN CERQUEIRA: Okay. But this is an 15 action item. Hopefully by the end of the day, and if not by the end of the day, we should probably capture it. 16 17 Do we want to make a motion on this, David? DR. VETTER: David already made the motion. 18 19 CHAIRMAN CERQUEIRA: Oh, he made the motion. 20 There was a motion. Okay. Just in terms of the meeting. Well, 21 22 but there's several portion of it. One is the meeting 23 with the Commissioners annually, but then there was the 2.4 additional item in terms of infrequent meetings. Okay. All right. So do we take a vote on 25

1	the formal motion? We did to meet with the
2	Commissioners, yes, and we didn't vote on it.
3	PARTICIPANTS: No.
4	CHAIRMAN CERQUEIRA: Okay. Any further
5	discussion?
6	(No response.)
7	CHAIRMAN CERQUEIRA: And why don't you
8	restate your motion?
9	DR. DIAMOND: Sure.
10	CHAIRMAN CERQUEIRA: And I think what Ralph
11	is going to say is it's in the procedure, but it's just
12	not being enforced, but I think this will at least
13	identify it as something that needs to be addressed.
14	DR. DIAMOND: I'll try and restate then.
15	Action Item No. 2, for the sake of the
16	transcriptionist, would be that the Advisory Committee,
17	in accordance with its bylaws, requested that an annual
18	meeting be held with the Commissioners so as to update
19	them on the activities of this Committee, and that this
20	meeting be scheduled as far in advance as possible so as
21	to facilitate this meeting.
22	Should the Commissioner not be able to hold
23	this meeting, the Advisory Committee may invite as their
24	guests to one of these meetings the Commissioners to
25	attend for informal discussions.

1	CHAIRMAN CERQUEIRA: Okay. Shall we get a
2	second on that?
3	DR. DIAMOND: Do you want to wasn't that
4	the sense? The sense was that we would try and do it in
5	accordance with the bylaws. If that were not possible,
6	that we would invite individual members to attend. Is
7	that the sense that I had?
8	MS. McBURNEY: Well, I think we can do that
9	anyway. I mean in addition to a formal meeting, we can.
10	CHAIRMAN CERQUEIRA: Invite them for
11	specific issues that
12	MS. McBURNEY: If it's not possible.
13	DR. DIAMOND: Okay.
14	DR. WILLIAMSON: I would propose amending it
15	and deleting the clause
16	CHAIRMAN CERQUEIRA: We don't have John
17	Graham who is so great at making
18	DR. WILLIAMSON: Well, we do our best.
19	MS. McBURNEY: That's right.
20	DR. WILLIAMSON: I would suggest an
21	amendment that we drop the second provision of the
22	motion, which suggests we could substitute a formal
23	briefing with an informal visit. I don't think that's
24	appropriate.
25	DR. DIAMOND: Okay. Would you like me to

1	restate it again with that amendment?
2	DR. NAG: But then what happens in the
3	situation where all of us might not meet and where we
4	never hold any meeting at all?
5	DR. WILLIAMSON: We'll just put pressure on
6	the staff to you know, I don't think that all five of
7	them have to be there. What is the legal requirement,
8	three or four of them to hold a formal briefing?
9	MR. HICKEY: Three.
10	DR. WILLIAMSON: Three. So I think we have
11	to be satisfied with that minimum, but I believe there's
12	a legally quite different status according to a briefing
13	than an informal visit, and we should take advantage of
14	the formal briefing.
15	CHAIRMAN CERQUEIRA: So I guess in essence
16	what we're saying is that, you know, we need to reinforce
17	that there should be a briefing between the ACMUI
18	Committee and the Commissioners on an annual basis as
19	stated in the bylaws.
20	Is that the essence of what we're
21	DR. DIAMOND: Yes.
22	DR. WILLIAMSON: Yes.
23	CHAIRMAN CERQUEIRA: So, David, do you want
24	to make that your motion?
25	DR. DIAMOND: Sure. All right. Amended

WASHINGTON, D.C. 20005-3701

1	Action Item No. 2 would be the Advisory Committee
2	in accordance with its bylaws requests to hold an annual
3	briefing with the Commissioners so as to update them with
4	the Committee's activities.
5	In addition to this formal meeting with the
6	Commissioners
7	CHAIRMAN CERQUEIRA: Let's maybe take a vote
8	on the formal meeting.
9	DR. DIAMOND: Okay.
10	CHAIRMAN CERQUEIRA: Okay. A second on
11	that?
12	Second. Any further discussion on this?
13	(No response.)
14	CHAIRMAN CERQUEIRA: If not, we'll take a
15	vote. All in favor?
16	(Chorus of ayes.)
17	CHAIRMAN CERQUEIRA: Opposed?
18	(No response.)
19	CHAIRMAN CERQUEIRA: Anyone abstaining?
20	(No response.)
21	CHAIRMAN CERQUEIRA: Okay. So we have that
22	formal motion, and then
23	DR. DIAMOND: And then Action Item No.
24	3 would be in addition to this annual Commissioner
25	briefing, the Advisory Committee wishes to, from time to

1	time, invite individual members of the Commission to join
2	us for this meeting, period.
3	Jeff?
4	CHAIRMAN CERQUEIRA: Could we have a second?
5	DR. WILLIAMSON: That's not a motion.
6	CHAIRMAN CERQUEIRA: Well
7	DR. DIAMOND: I'm trying to it has to be
8	an informal meeting. It cannot be it's not a
9	Commission briefing, of course.
10	MS. McBURNEY: But we can do that without a
11	motion.
12	DR. WILLIAMSON: We can do that without a
13	motion.
14	CHAIRMAN CERQUEIRA: Well, the reason we're
15	doing the motion is to try to capture it. Unless there's
16	some other mechanism by which we actually state that
17	there's going to be a formal action item on this.
18	I mean, I don't want to get too formalistic
19	on all of this, but I think this will simplify things a
20	little bit in terms of getting feedback, and what I
21	propose is in subsequent meetings
22	DR. DIAMOND: I agree.
23	CHAIRMAN CERQUEIRA: we go back at the
24	beginning of the meeting on these action items.
25	Ruth?

1	MS. McBURNEY: Well, I think it's pretty
2	much a consensus of the Committee that we do that, and
3	I'm not sure that a formal motion is necessary.
4	CHAIRMAN CERQUEIRA: All right, but then we
5	want this as an action item.
6	MS. McBURNEY: Right, but as a consensus
7	rather than
8	CHAIRMAN CERQUEIRA: Okay. So for the
9	transcriptionist, if you could somehow identify this.
10	MS. McBURNEY: That it's the consensus of
11	the Committee that
12	DR. WILLIAMSON: That we meet informally
13	with the Commissioners as well as the formal briefing.
14	CHAIRMAN CERQUEIRA: Right. That the
15	appropriate that the Committee request attendance at
16	the ACMUI meetings of Commissioners who have an interest
17	or "expertise" isn't the word, but what are we looking
18	for, Jeffrey? Help me out here.
19	DR. WILLIAMSON: Okay, yes. The
20	CHAIRMAN CERQUEIRA: John Graham in the
21	making.
22	DR. WILLIAMSON: ACMUI desires that
23	Commissioners who have an interest in the regulation of
24	medical use of byproduct materials attend the ACMUI
25	meetings on an informal basis.

1	CHAIRMAN CERQUEIRA: Okay. I think we get
2	the sense of it, and we can see. You know, maybe, John,
3	your staff could look at that and what the mechanism
4	would be for us to invite I guess we could just invite
5	them. I'm sure that there's some
6	MR. HICKEY: Yeah, we can respond to that
7	CHAIRMAN CERQUEIRA: Okay.
8	MR. HICKEY: When we call for agenda items,
9	we can also get suggestions as to whether you want to
10	invite a Commissioner.
11	CHAIRMAN CERQUEIRA: Okay, all right. Any
12	other items in terms of the follow-up from yesterday's
13	meeting?
14	DR. WILLIAMSON: Do we want to hold the item
15	about creating a subcommittee and so forth for the Board
16	certification until we come to that topic with Bob Ayers
17	here or do you want to do that now?
18	CHAIRMAN CERQUEIRA: I propose we do that
19	now, and then when Bob comes we can basically, you know,
20	review that.
21	You know, in thinking about it, you know,
22	clearly it was an oversight on the part of the Committee.
23	In talking to some of the former staff for the Committee,
24	and I have to admit I don't recall the discussion, some
25	of the issues related to this were we had long

discussions about trying to make the training and 1 experience requirements specific for the isotope, the 2 3 technique as much as possible so that we didn't have 4 somebody who had just kind of general training be able to 5 operate on a system with which they had no familiarity. 6 And I guess some of the discussion amongst 7 the staff had been how do we put some teeth into the fact 8 that we needed training on specific equipment, and you 9 know, that still needs to be addressed in terms of, you 10 know, if you've got Boards, the Boards don't specifically require you to have experience with certain isotopes or 11 12 devices. 13 And so how do we assure that somebody who 14 has a general approval, i.e., Boards, meets some specific 15 training requirements? Richard, and then --16 17 DR. VETTER: I don't think the proposed Part 18 35 answers that either because it says you're either 19 Board certified or you have training, and it specifies 20 the type of training, you know, 200 hours, et cetera, et 21 cetera. So I guess without looking at -- having the 22 23 words in front of us, I think what we need to take a look 2.4 at is how we can change that regulation so that a person

can be Board certified and have that specific experience

without having the detailed listing of training and 1 requirements incorporated into the Board. 2 3 Because, for instance, let's just pick ABMP 4 for one board. For medical health physics, they require 5 a Master's degree in the appropriate area, plus five 6 years of experience, and you have to pass three exams 7 But they don't say you have to have experience with HDR. So perhaps the direction we need to 8 9 head and one of the alternatives, the Board certified 10 plus that specific experience or at least some area of 11 experience that covers most of those without prescribing that they have 200 hours in the following subjects 12 13 because that's telling the Boards what they have to have 14 for content. 15 That's the part that's problematic. 16 CHAIRMAN CERQUEIRA: Okay. Jeffrey. 17 DR. WILLIAMSON: Well, just a suggestion as 18 a philosophical approach, how to address the issue I 19 quess John raised, which is if NRC wants specific 20 training to be addressed, how could that be done. So the approach could be to decouple the 21 22 concepts of authorized user and authorized medical 23 physicist from the required modality specific training 2.4 requirements, you know, restore Board certification as 25 the default pathway for AMP, AU, or RSO, and then in the

appropriate subsections of 35, 35.4.600, for example, one 1 could have in there as part of the operating procedures 2 3 or regulations some kind of a requirement for continuing 4 education in initial modality specific education. MS. McBURNEY: In that modality. 5 6 CHAIRMAN CERQUEIRA: In that specific. 7 So modality specific training. Okay. DR. WILLIAMSON: So one might say, you know, 8 9 for example, put in some kind of a regulation that 10 captures the essence of the initial training that a physician who has no experience doing gamma stereotactic 11 would have to undergo. 12 13 CHAIRMAN CERQUEIRA: I quess just in terms 14 of what's been done to date now, is this something we could deal with in the quidance documents? 15 DR. WILLIAMSON: Potentially we could, but 16 17 the desire of the staff -- I'm speaking for them now --I think has been to avoid having de facto regulations in 18 19 guidance space and have them in regulatory space. So 20 rather than have a separate set of de facto regulations in a licensing guide, which is now what we have, we have 21 22 requirements for authorized user and authorized medical 23 physicist to have some kind of training with HDR and 2.4 gamma stereotactic, and that's done by license condition

today.

1	And so I think the desire of the staff is to
2	have essential license conditions mentioned in the
3	regulations; is that not correct?
4	MR. HICKEY: That is correct, and I'm not
5	sure, however, that even if we allowed for the guidance
6	to be the determining factor that we could do it in this
7	case because of the way that the rule is worded.
8	DR. WILLIAMSON: I think we're talking in
9	the context of the rulemaking initiative, John.
10	MR. HICKEY: Okay. So you would have a rule
11	change plus guidance?
12	DR. WILLIAMSON: We would have a rule change
13	that would address the training and experience
14	definitions of AMP authorized user and radiation safety
15	officer, plus some supplementary changes in 35.600 that
16	would address the NRC's concern about the AU and AMP not
17	having modality specific specialized training.
18	MR. HICKEY: Right, but then would you need
19	guidance?
20	DR. WILLIAMSON: Well, you always need
21	guidance, don't you?
22	MR. HICKEY: Well, no. But I mean would the
23	substantive issue be dealt with by the rule change or
24	would you need guidance to deal with the substantive
25	issue?

1	Our intent my sense is we at least
2	maybe we don't even need to talk about it. My sense is
3	we at least need a rule change to deal with the
4	substantive issue the way that the new Part 35 is worded
5	now.
6	DR. WILLIAMSON: My preference would be to
7	have such specifics of training probably in a guidance
8	document rather than making a hard and fast rule so that
9	at least individual institutions could negotiate the
10	specifics of what their training would be.
11	MR. HICKEY: Okay.
12	CHAIRMAN CERQUEIRA: We'll go around, but so
13	we've given up on the idea that there's any way we could
14	do this within the Part 35 revisions. My typo comment
15	yesterday was not
16	MR. HICKEY: I wouldn't characterize giving
17	up on anything.
18	CHAIRMAN CERQUEIRA: Right. Well, but it's
19	important because we could certainly expedite it if we
20	could do it within guidance documents at this point, and
21	who would know that, John? Would that be counsel? Would
22	that be the staff?
23	MR. HICKEY: Well, I think I know, and I
24	think some of the committee members know that the way the
25	rule is worded, I don't think guidance can fix the

1	problem.
2	CHAIRMAN CERQUEIRA: So we're saying we need
3	a new rulemaking.
4	DR. WILLIAMSON: I think so, and we don't
5	have to propose wording for the rule.
6	CHAIRMAN CERQUEIRA: Sure.
7	DR. WILLIAMSON: I think we should make a
8	motion to the effect that NRC as soon as possible
9	initiate rulemaking to restore Board certification for
10	authorized user, radiation safety officer and authorized
11	medical physicist as the default pathway.
12	CHAIRMAN CERQUEIRA: Well, just
13	procedurally, you know, we're going to form a
14	subcommittee, and it's going to work with the staff, and
15	so maybe that will be the first step, but let's get some
16	more discussion, and then we'll try to yes?
17	DR. NAG: I think the other thing, if we are
18	going back to a rulemaking, it would be very important to
19	the requirement for Board certification and the
20	requirement for using in NRC. The reason is for the
21	Board exam you need a certain body of knowledge, which is
22	what the Board certification requires.
23	For example, you don't need gamma knife
24	training to be Board certified, but the way we are making

the Board certification, we are trying to push them to

1	recruit all of these with training to become Board
2	certificate. Rather than doing that, if we decouple
3	(phonetic) them, a Board certification, the essential
4	minimum required, and then if we are going to handle
5	gamma knife or you're going to handle some of these
6	specific things, you show your additional training that
7	you had, which can be a very you know, the
8	manufacturer's training or whatever. You supplement the
9	Board requirement.
10	So if we are going to start from de novo, I
11	think we should not be trying to push the Board to show
12	you have training in all of these things. Otherwise we
13	wouldn't allow Board certification to meet the de facto
14	standard.
15	CHAIRMAN CERQUEIRA: Now all of the
16	discussion has really dealt with therapeutic radiation.
17	I mean, do we feel that as written, the diagnostic
18	requirements are okay?
19	MR. HICKEY: Mr. Chairman, I think there is
20	an issue with the statement about a preceptor. I'm not
21	sure that all of the certification Boards understand that
22	the rule requires the preceptor statement be part of the
23	Board certification process.
24	So as far as what training and experience
25	the people have, I think the rule is okay, but I think

there still is an issue with the requirement for a 1 2 preceptor statement. 3 CHAIRMAN CERQUEIRA: I thought the preceptor 4 statement was pretty clear. It had to be, you know, an 5 authorized user who basically signed off on having been 6 exposed, and in addition, being competent. 7 We spent quite a bit of time discussing 8 that. We're trying to put more teeth or more liability 9 upon the preceptor's statement, and let them, you know, 10 assume some responsibility for the people that they're 11 signing letters for. 12 MR. HICKEY: Yes, that's correct, and there 13 are already requirements in the old Part 35 for preceptor 14 statements. I'm just not sure whether the Board that 15 certifies the person requires the preceptor statement as part of the certification process or whether they view 16 17 that as another step. CHAIRMAN CERQUEIRA: Well, I think when I 18 19 guess Bob is going to be presenting things this afternoon 20 -- so we can get back to it. Richard. 21 DR. VETTER: Just to confirm what John just 22 said, at least in the physics are, radiation safety 23 2.4 officer area, the Boards feel that is a separate process,

the preceptor statement. They do not require a preceptor

1	statement for the Boards.
2	MS. McBURNEY: Right.
3	MR. HICKEY: Yeah, that was clear for the
4	American Board of Health Physics. I'm just not sure
5	whether the Medical Boards have that understanding.
6	CHAIRMAN CERQUEIRA: Jeffrey?
7	DR. WILLIAMSON: For American Board f
8	Radiology and American Board of Medical Physics, and I
9	think this covers radiation oncology, as well as physics,
10	there is a requirement. It's part of the application
11	process that letters from diplomates of the Boards
12	attesting to the competence in character of the applicant
13	be made.
14	But I do think there is a legal problem here
15	because it really doesn't say that these individuals have
16	to be authorized users or authorized medical physicists
17	on an agreement state or NRC license.
18	So I believe John may be right that even
19	though there is sort of a preceptor requirement
20	associated with many of these Boards, I'm not sure it
21	complies with the letter of the law.
22	DR. NAG: One other problem with that is
23	there is the preceptor statement, but that's done by the
24	director of the training program. It does not make
25	separately in all of the areas. You know, I will certify

1	that I have trained him in radiation oncology, but not a
2	separate statement that can handle unsealed isotope; he
3	can handle, you know, each of those things separately.
4	CHAIRMAN CERQUEIRA: All right. Who are the
5	stakeholders in this now? We've talked about authorized
6	medical physicists. We've talked about radiation safety
7	officers.
8	DR. NAG: Authorized users also.
9	CHAIRMAN CERQUEIRA: Okay.
10	DR. NAG: It depends on which, definitely of
11	authorized users.
12	CHAIRMAN CERQUEIRA: For diagnostic or
13	therapeutic?
14	DR. NAG: Therapeutic.
15	CHAIRMAN CERQUEIRA: Okay.
16	MR. HICKEY: I think that all of the Boards
17	have a potential stake. They're on the record as of
18	today as saying that there's not a problem with the rule,
19	but in looking at the preceptor issue, I think on second
20	review there may also be a concern. They're not on the
21	substance of the training but on the requirement for a
22	preceptor statement.
23	CHAIRMAN CERQUEIRA: Rather than you
24	know, because we have Bob Ayers here, who's kind of part
25	of the NRC staff that's looking at this, maybe we can

1	conclude this discussion and bring it up with Bob. But
2	I think there was a motion to form a subcommittee that's
3	going to look at the issue of training and experience.
4	Initially we were talking about the
5	authorized medical physicist, the radiation safety
6	officer, and the authorized medical user with
7	therapeutic. So I think forming a subcommittee that
8	would have, you know, members from those various groups,
9	plus maybe one or two other people, would be important
10	Ruth?
11	MS. McBURNEY: Richard or Ralph, correct me
12	if I'm wrong, but I think there is a model for the rule
13	of decoupling the Board certification from additional
14	training required for the different modalities under
15	MQSA. Isn't that right that they accept Board
16	certification as the training for the medical physicist,
17	but then if you're going to be doing a different
18	modality, you need additional continuing ed. for that?
19	DR. VETTER: I think that's correct.
20	MR. HICKEY: Could you identify that
21	organization for the record, please?
22	MS. McBURNEY: The Mammography Quality
23	Standards Act under the Food and Drug Administration.
24	CHAIRMAN CERQUEIRA: All right. Well, so I
25	propose that maybe we have Jeffrey, Dick, you know, be on

1	this committee, and since Dick has more gray hair that
2	Jeffrey, maybe we could let him be the chair of this
3	committee.
4	And I think we should get a radiation
5	oncologist. David, is that something
6	DR. DIAMOND: I'd be happy to do it, sure.
7	CHAIRMAN CERQUEIRA: So maybe David could be
8	on that committee, and I guess maybe we're going to add
9	two new members to the committee. I guess we have to
10	vote on them at this meeting.
11	MR. HICKEY: No.
12	CHAIRMAN CERQUEIRA: What's the time line?
13	We've gotten approval.
14	MR. HICKEY: No. The selection for the two
15	vacancies is still in process, and as Commissioner
16	McGaffigan mentioned yesterday, well, we have to appoint
17	a nuclear medicine physician to fill a vacancy, and then
18	as Commissioner McGaffigan mentioned yesterday, we're
19	going to add an interventional cardiologist at the
20	direction of the Commission, and those are in process
21	So we think prior to the next meeting you'll
22	have those appointees.
23	CHAIRMAN CERQUEIRA: Right, but I was sent
24	a list of people who had been nominated, and they were
25	you know, by professional medical societies, and the NRC

1	staff had sort of sent me the names of two individuals
2	for those positions, and I basically concurred that I
3	thought
4	MR. HICKEY: Well, that's still in process.
5	We can't have anymore specific public discussion while
6	that's still in process, but the process has not yet been
7	completed.
8	CHAIRMAN CERQUEIRA: But why is it taking so
9	long?
10	I think one of the things we had discussed
11	was basically trying to facilitate, and Angela certainly
12	made a
13	MR. HICKEY: Yes. The reason that the
14	interventional cardiologist is not complete is because
15	that's fairly recent. The nomination period, I believe,
16	did not close until January for that one, and the other
17	one has been delayed by the other things that the
18	Commission has been dealing with following 9/11 or it
19	would have been resolved.
20	CHAIRMAN CERQUEIRA: Is there any way we
21	could fast track it, John? I mean, in a sense, you know,
22	the professional societies have made nominations.
23	They've been reviewed by the NRC staff. They've been
24	sent to the committee chair who basically agreed with the
25	staff on these people.

1	MR. HICKEY: Yes. We're doing every I
2	mean, you can form an action item or resolution, but
3	we're doing everything we can to complete that proces
4	CHAIRMAN CERQUEIRA: Well, I guess I don't
5	fully understand why it's taking so long. I mean, we had
6	discussions to try to minimize the lag time between a
7	vacancy and filling it.
8	MR. HICKEY: Well, as I said, the
9	interventional cardiologist one should be completed
10	within 60 days of the nomination period closing, which I
11	think is reasonable, but the other one has not been
12	timely. I agree.
13	CHAIRMAN CERQUEIRA: Okay. So give me a
14	time line then. Where do we stand?
15	MR. HICKEY: I would say within 60 days
16	we'll have an announcement on both, but again, the
17	Commission has to review these. So that's assuming the
18	Commission responds promptly, which they have done in the
19	past on these.
20	CHAIRMAN CERQUEIRA: And I guess, you know,
21	all of these things like security checks and everything
22	will be all
23	MR. HICKEY: That can be done afterwards.
24	CHAIRMAN CERQUEIRA: Okay. You know, it's
25	a little disturbing because we really had emphasized at

1	the previous meetings of trying to minimize the time
2	between people going off and new people, and I had every
3	expectation based on the material that I had been sent
4	that we would have people in these positions, you know,
5	at the end of this meeting.
6	So Dr. Nag?
7	DR. NAG: At the same line, anyone who will
8	be moving off about a year from now, we should be
9	starting the process from now. So anyone from this
10	committee who is supposed to be going off about a year
11	from now? Do we have anyone?
12	DR. DIAMOND: Jeff, how much longer? ARE
13	you in your second term? Is that right?
14	DR. WILLIAMSON: I think so.
15	DR. DIAMOND: You're in your second term.
16	MR. HICKEY: I think everybody is going at
17	least until 2003, but we agree that we need
18	DR. NAG: One year.
19	MR. HICKEY: to plan better on these.
20	CHAIRMAN CERQUEIRA: Well, what I would like
21	to do is at least get a list of just Committee members,
22	when they came on, whether it's first term, second term,
23	and when their term expires, and distribute that to the
24	Committee.
25	MR. HICKEY: Yes, we have that. That's

	119
1	already made. We can copy it and give it to you.
2	CHAIRMAN CERQUEIRA: Well, if somebody could
3	
4	MR. HICKEY: We can give that to you today.
5	CHAIRMAN CERQUEIRA: just give it to us
б	today.
7	MR. HICKEY: yes.
8	CHAIRMAN CERQUEIRA: That would be useful.
9	DR. WILLIAMSON: We can make plans.
10	CHAIRMAN CERQUEIRA: But again, I'd really
11	like to, you know, identify the fact that the Committee
12	has been moving forward. I certainly have dealt with
13	some materials sent to me, and I think in order for the
14	Committee's work to be done, we certainly need a nuclear
15	medicine representative, and I think we've agreed that an
16	interventional cardiologist is an important, you know,
17	member of the Committee, given some of the things that
18	are going to be coming up.
19	And so I think we need to move forward as
20	quickly as possible to get these people appointed.
21	Jeffrey.
22	DR. WILLIAMSON: So with regard to the
23	subcommittee, the charge is to
24	CHAIRMAN CERQUEIRA: Okay. Well, again, I
25	got sidetracked there. So

MR. HICKEY: Well, let me just interject 1 that some of these items have been useful because we 2 intended to take them up later in the day, and we'll save 3 4 time later on having discussed them now. CHAIRMAN CERQUEIRA: Okay. That's true, but 5 6 still I think, you know, we've identified three people. 7 I think it would be important if we're going to deal with 8 the whole issue of intravascular brachytherapy if we 9 could have the interventional cardiologist be part of that committee. That would be useful. 10 11 That would bring us up to four people, and 12 it's always good to have somebody who's not necessarily 13 a stakeholder on the subcommittee, i.e., Ruth or Niki. 14 Niki is pointing, but, Ruth, would you be willing to? I certainly would. 15 MS. McBURNEY: CHAIRMAN CERQUEIRA: Okay. So I think the 16 17 committee would then consist of Jeffrey, Ruth, Richard, and David Diamond with Richard acting as the subcommittee 18 19 chair. 20 And the charge of the committee -- and I think we could have a little bit of discussion on this --21 22 but basically, you know, would address the issue of 23 training and experience for authorized medical 2.4 physicists, authorized physician users, and radiation

safety officers, and you know, really look at the whole

issue of the Boards and the training and experience, 1 trying to deal with both, you know, kind of general, as 2 3 well as specific training. And maybe we could spend a few minutes 4 trying to fine tune the charge to the committee. 5 Jeff and then David. 6 7 DR. WILLIAMSON: Well, I'm wondering if it would be useful to have some staff members also be on 8 9 this subcommittee. I think this is so highly juridical 10 that I wonder if the attorney from NRC shouldn't join us 11 and one of the staff members who's conversant with these 12 issues. 13 MR. HICKEY: As a procedural matter I don't 14 think that's a good idea. I think the subcommittee needs 15 to speak for the ACMUI, but we will designate contacts, both technical and legal contacts, for the subcommittee 16 17 to work with on a day-to-day basis. DR. WILLIAMSON: Good. 18 19 CHAIRMAN CERQUEIRA: So I think it would be 20 good within two weeks to have those people identified so that Richard could make contact with the people and, you 21 22 know, to try to get some useful information to at least 23 define what the requirements for sort of new rulemaking, 2.4 to explore the possibility can any of this still be done

under the revised Part 35, which we're all working on

under the assumption that it's going to be implemented in six months, or do we need to go to new rulemaking, which it's Jeffrey's feeling, and I concur with him, it probably will be required.

David.

2.4

DR. DIAMOND: My sense is just as I'm thinking about this is that this subcommittee is really going to be looking at a new rulemaking initiative in which there's going to be a sense that we restore Board certification in a parallel structure as the default pathway for the AMPs, the RSOs, and in this process attempt to decouple general from overly prescriptive site specific or modality specific training, which will give us the flexibility that we need to address new technologies, which will be parallel amongst these different fields, and which will go and maintain the status of the Boards as the premier methodology for expressing to the public an individual's competency and safety in performing the task.

I would also like to point out as an aside it's very important that the staff understand that any time -- and I'm only speaking for physicians now because that's my area of expertise -- any time a physician is desirous to obtain a hospital privilege to perform a specific modality, regardless of the Board certification,

they need to prove to the hospital that they do have a 1 certain experience in that particular field. 2 So, for example, if one wanted to do 3 4 stereotactic radiosurgery as a physician, before a 5 hospital would grant a privilege to do that, there is 6 always a final safeguard in effect that you must prove to 7 the bylaw committee or the credentialing committee that 8 you have that, and that goes on for many, many different 9 areas. 10 So just since you may not deal with this in 11 your particular role or practice, it is important for you 12 to know that there is another set of safeguards in effect 13 to protect the public in these very specific modalities 14 when it comes to the public. DR. WILLIAMSON: For example, at Washington 15 University, the radiation safety committee also serves as 16 17 an independent safeguard in this respect because our 18 license mandates certain annual training be given to 19 authorized users and AMPs for gamma stereotactic and for HDR as a condition of our license. 20 And so they monitor that, and there are 21 22 separate lists of authorized users and AMPs for these 23 different modalities. 2.4 DR. DIAMOND: Jeff, would you concur with my 25 general sense that I was trying to convey? Was I on

1	track basically with the parallel structure trying to
2	keep the Board as the premier pathway and so forth?
3	DR. WILLIAMSON: Yeah, absolutely.
4	CHAIRMAN CERQUEIRA: I think we're starting
5	to get into the specifics, and I think sort of the
6	discussion is to form the committee, and we've agreed
7	that the subcommittee consisting of Dr. Williamson,
8	Vetter, Diamond, the interventional cardiologist who will
9	come on the Committee, and Ruth McBurney, and I kind of
10	hate you know, you kind of want to give a charge to
11	the committee rather than having the committee come back,
12	you know, with what they're going to do.
13	But the basic charge is to develop
14	DR. WILLIAMSON: A draft rule.
15	CHAIRMAN CERQUEIRA: We need John.
16	draft rule for what? For?
17	DR. WILLIAMSON: Yeah, so to develop, you
18	know a subcommittee would be charged with developing
19	the outline of a draft rule to restore
20	CHAIRMAN CERQUEIRA: Just something general.
21	A draft rule
22	DR. VETTER: I think that captures it. A
23	draft rule to capture what Dr. Diamond had said.
24	CHAIRMAN CERQUEIRA: But that was too much.
25	Who can remember that?

1	DR. DIAMOND: We can do it in one sentence.
2	DR. WILLIAMSON: The subcommittee's charge
3	is to develop the concept of a draft rule that restores
4	Board certification as the primary pathway for becoming
5	authorized user, authorized medical physicist and
6	radiation safety officer.
7	CHAIRMAN CERQUEIRA: All right. Does that
8	sound like a motion?
9	PARTICIPANTS: Yes.
10	CHAIRMAN CERQUEIRA: Second?
11	MS. WAGNER SCHWARZ: Second.
12	CHAIRMAN CERQUEIRA: And any further
13	discussion?
14	MR. HICKEY: I have a comment and a
15	question, Mr. Chairman. The committee is time is of the
16	essence, and this has high visibility with the Commission
17	now. So I will tell Dr. Vetter right now I will be the
18	contact. I will let you know who other contacts are, but
19	two weeks is not going to go this isn't going to sit
20	for two weeks.
21	We're going to be continuously working on
22	this between now and the time the rule is published.
23	CHAIRMAN CERQUEIRA: All right, but we don't
24	anticipate that we're going to be able to get this
25	resolved and certainly with the rulemaking, but I think,

1	you know, basically we've formed a committee, and we
2	should have them come back to us at the next meeting.
3	So a motion has been made. We've had a
4	second. Any more discussion?
5	(No response.)
6	CHAIRMAN CERQUEIRA: Okay. I call for a
7	vote. All in favor?
8	(Chorus of ayes.)
9	CHAIRMAN CERQUEIRA: Opposed?
10	(No response.)
11	CHAIRMAN CERQUEIRA: No one is abstaining.
12	So all right.
13	DR. DIAMOND: That was Action Item No.
14	4 , then.
15	CHAIRMAN CERQUEIRA: Right.
16	MS. HOBSON: Did you mean like our next
17	ACMUI meeting?
18	CHAIRMAN CERQUEIRA: To come back and give
19	us at least a progress report on, you know, some of the
20	issues and sort of a game plan.
21	MS. HOBSON: Well, I felt a sense of urgency
22	that we need to move faster than that if possible, you
23	know. Was I reading it wrong?
24	CHAIRMAN CERQUEIRA: No. I guess part of
25	the question is I don't know, you know, what's involved

1	in the rulemaking process. I mean, having been involved
2	in Part 35, which is, in a sense, you know, NUREGs
3	DR. WILLIAMSON: I think our charge is
4	sufficiently open ended that, you know, we're not locked
5	into any specific time frame. So I think this is just
6	great. If the staff is geared up to move fast on this,
7	we're going to support and help them.
8	CHAIRMAN CERQUEIRA: One last comment from
9	Ralph, and then we have to move on.
10	MR. LIETO: I have a question for John since
11	this is a subcommittee of the Advisory Committee that's
12	working on this. Is it acceptable that if they come back
13	say they have something to present within the month.
14	Does the full Committee have to vote on that? And if so,
15	can it be done by electronically via E-mail?
16	MR. HICKEY: Yes. The actions can be done
17	by E-mail or by telecon. and, in fact, I think we're
18	going to have to plan on doing a lot of that.
19	CHAIRMAN CERQUEIRA: Yeah, I would recommend
20	that we don't necessarily need to have face-to-face
21	meetings.
22	Okay. All right. So I think we've dealt
23	with most of the procedural ways we would like the
24	Committee to proceed in the future. We've discussed the
25	Commission briefing, and maybe we can go on to the NUREG

1	1556, Volume 9.
2	MR. HICKEY: Mr. Chairman, Dr. Susan Frant
3	is here. She's the Deputy Director of Industrial,
4	Medical, and Nuclear Safety.
5	DR. FRANT: Hi. They even got a name tag so
6	that in case you forgot me.
7	(Laughter.)
8	DR. FRANT: And I have one for me so that in
9	case I forget.
10	Good morning. I've met some of you
11	individually, but not all of you as a group. So I'm
12	happy to be here this morning.
13	I've been with the Industrial Nuclear
14	Medicine Safety I think those are all of the words for
15	the division since April. Before that I worked as a
16	deputy for another division in NMSS, and before that, I
17	was in Region I, which is the northeast, as the deputy
18	that had licensing of medical licenses.
19	So I have a little familiarity, but not a
20	lot, and I come to this area with maybe a different
21	perspective than some of the folks who have been working
22	in it.
23	Part 35. We've been working on how we're
24	going to implement it, and we've been standing at the
25	starting gate for a long time waiting to kind of okay,

okay. As you know better than I, that has been a torturous time to get it into a position where it's going to be published and going to be final.

And I gathered from the meeting you had with the Commission yesterday that there are still some issues that are significant that are not settled by the current final rule as it will be published. And the Commission certainly pledged that we will work through those issues in a timely way.

And the discussion I heard when I came in was one of the mechanisms to do that, and I'm glad that you'll have a subcommittee, and if you draft language, it doesn't have to be exactly rulemaking language, but if the language is what will work to have qualified people who can protect the public in terms of radiation safety doing the procedures, regardless of whether we know what they are today or they come on the horizon, that will be, I think, a significant move forward for Part 35 as it stands.

In terms of what we're doing now to move forward in implementing Part 35, I can tell you what we're doing and take hopefully some suggestions from you on how ACMUI can be most involved effectively for us and for you and efficiently for us, hopefully efficiently for you, too.

2.4

1	CHAIRMAN CERQUEIRA: Susan.
2	DR. FRANT: Yeah.
3	CHAIRMAN CERQUEIRA: If I could just
4	interrupt for a minute now, so we're talking about the
5	guidance documents in part.
6	DR. FRANT: We're talking about implementing
7	Part 35 so that we
8	CHAIRMAN CERQUEIRA: Right, which includes
9	guidance documents?
10	DR. FRANT: It includes guidance. It
11	includes inspection, and let must briefly go through -
12	CHAIRMAN CERQUEIRA: Sure. Go through.
13	DR. FRANT: and then after I run through
14	this, then you can ask me questions, and we can talk
15	about
16	CHAIRMAN CERQUEIRA: Is there a handout or
17	slides on this?
18	DR. FRANT: No.
19	CHAIRMAN CERQUEIRA: No?
20	DR. FRANT: No.
21	CHAIRMAN CERQUEIRA: Okay.
22	DR. FRANT: As you know, we have Volume 9 of
23	the consolidated guidance, the 20 volume set that we've
24	pulled together over the last I don't know several
25	years, and Volume 9 identifies those aspects that would

be necessary to be licensed under Part 35. 1 And the current draft Volume 9 responds to 2 all of the comments that were made on a draft that went 3 4 out with the proposed rule and reflects the changes made 5 to Part 35 from the proposed rule to the final rule. 6 And I think you've seen that, have you not? 7 MS. WAGNER SCHWARZ: DR. FRANT: Yes. Okay. It still has many 8 9 things in that I would say are highly prescriptive. The 10 phrase that some people have used is that there's a group 11 of practitioners who might need "Part 35 for Dummies," 12 that is, a very detailed, pick your hand up, move it 13 here, do this. 14 I think that that is very different from other aspects of NRC that I've been involved in. In the 15 reactor world that I was in for 20 years, we never put 16 17 out procedures. We always left it to licensees to 18 develop procedures to implement the regulations. 19 And I have to tell you that it was kind of 20 strange for me to see these model procedures. At the same time, the staff who have been working with this, I 21 22 think, believe that there was a very strong need for this 23 by some practitioners. 2.4 So you have a tension between providing 25 detailed guidance and allowing mature professionals to

choose the way in which they're going to implement 1 2 regulations. I think we're trying to strike that balance, 3 4 and to do that, we're going through Volume 9 now with an 5 eye towards making it a basic document and taking these 6 model procedures and perhaps putting them in some other 7 form. It would be good, I think, if the societies 8 9 in the community would help us do that, and maybe it 10 would have been better to have joint documents, which 11 we've done in other -- I worked with NEI and I've worked 12 with other groups where we've put out joint documents. 13 For a long time I was responsible for 14 training and procedures in the reactor world, and the 15 Institute of Nuclear Power Operations developed the guidelines for training programs, and we endorsed them. 16 17 So we had a joint document that was basically developed 18 by the industry and then reviewed and accepted as an 19 acceptable way to implement the regulations. 20 There's no reason why we couldn't do that here, too, but it requires a commitment on the part of 21 22 the community to do some of the work. And I'm not sure. 23 I don't know where we are with that. 2.4 To that end --CHAIRMAN CERQUEIRA: Well, if I could --25

1	DR. FRANT: Yeah.
2	CHAIRMAN CERQUEIRA: I think the
3	community is willing to work, but there's a time frame
4	that's involved, and if we haven't initiated the process,
5	I don't know realistically
6	DR. FRANT: Well, let me tell you what.
7	CHAIRMAN CERQUEIRA: Sure.
8	DR. FRANT: I don't know how many of you
9	know Chip Cameron, but I know he's worked with Part 35.
10	So Chip and I have worked together on many things over
11	the years, and what we discussed was taking the current
12	Volume 9, making some modifications and Roger Brotus
13	who's sitting in the back is taking a few minutes out of
14	his schedule where he's totally immersed in Volume 9,
15	with a small cadre of folks to make some
16	modifications, but to get it out by March 15th as a
17	document for comment.
L 8	At the same time, Chip and I will be having
19	a planning meeting on March 14th to plan for two public
20	meetings, actually three, I think. One meeting would be
21	some kind of a workshop on Volume 9, the totality of it.
22	A second probably these are both at the
23	end of April. One is planned for April 23rd, and the
24	other is planned for April 30th. The second meeting

would be on guidance, some kind of diagnostic only

guidance that would be just a few pages that would focus 1 on what the diagnostic practitioner would need to know 2 and would not have all the volumes of material that deal 3 4 with all the variations within the therapeutic community. That guidance, I think, to the extent that 5 6 we can get help and maybe produce a joint document, that 7 would be excellent. If we can't, maybe we'll take a crack at it and have it reviewed, the point being that 8 9 there would be two documents. There would be Volume 9, 10 which would cover everything to implement Part 35, and that's necessary and we have to have something like that. 11 12 But then there would be this subset, and it 13 may be that the therapeutic community or parts of it feel that there should be some stand alone documents for other 14 15 than diagnostic, and we can work those out in the future. I'm not precluding them. It's just in terms 16 17 of time, they seem to be the things that are most needed 18 now. 19 also plan to develop inspection 20 procedures, and I think from the discussions yesterday and what I know about the way NRC does business, this 21 will be clear to having a clear message of how Part 35 22 represents some kind of paradigm shift. 23 2.4 We also plan on conducting training for both 25 our license reviewers and our inspectors, and we'll be

doing that in late May based on the guidance documents 1 and the public meetings. And I already have that set up 2 with a woman named Bev Silverberg. 3 Do any of you live in Washington? Oh, no. 4 5 Okay. Well, Bev was the voice of Metro. She used to be 6 the one that would come say, "The trains are running, and 7 it's okay." But anyway, only in snow storms mostly. Anyway, Bev has been working with NRC for a 8 9 long time, and she does a really good job in terms of 10 helping people get the message across. So we are going to take people, and we have a Part 35 team that we've 11 developed, people who will become the trainers. 12 13 MS. McBURNEY: A question. 14 training also be available to agreement state personnel? DR. FRANT: Sure, sure. And we'll probably 15 set it up in the four regions and invite appropriate 16 17 agreement states at the same time. I don't know why we 18 can't do it concurrently. Sure. 19 So that's our plan, is to train the trainers 20 some time in late May, and then hold a workshop on inspection guidance; finalize the inspection and 21 22 licensing guidance, and of course, that will include 23 ACMUI participation, and we can talk about at what key 2.4 points and at what point you want to be in a review mode,

at what point you want to be in a comment.

136 You know, I think there are lots of roles to 1 be played, and then we'll do our regional training in 2 3 June through August, depending on when -- hopefully that 4 will be on finalized guidance, but certainly guidance that's close to final. 5 6 So that what we're working towards is an 7 October implementation date in which we will have final licensing guidance by the end of spring; final inspection 8 9 guidance also by the -- this is the government. So if I 10 say late spring that could be July, you know -- but we'd 11 be working -- you know how you write "late spring"? 12 Okay. 13

But the goal is to have the training over the summer based on the finalized guidance and inspection procedures, and what I heard yesterday in the discussion with the Commission is it may be that we have to have a transition period, and when they're enforcement discretion, and we work our way through that guidance and some of the issues that may come up as we look at the rule when it's real, so to speak, you know.

And I don't understand. I hope to learn more about how the training and education issues are evolved, but there they are, and so we have to fix them.

There may be others that we find that we have to fix.

So that's our plan. It's looking towards an

14

15

16

17

18

19

20

21

22

23

2.4

October implementation effective date, but some questions have come up, and we're working through them now. Some applicants for renewal have already said, "Can I be renewed against the new Part 35?"

Well, no, you can't be renewed against something that doesn't exist. It's not published. On the other hand, you can be in timely renewal, and we can look at what it would look like once it's published, but it can't be effective until it's effective.

So that's a simple answer, you know. It can only be soup when it's soup, but on the other hand, you can't deny the fact that you can see what's coming on the horizon. So you try to work that, and we'll work that through.

We have a counterpart meeting tomorrow with the Regional Division Directors, and these are some of the issues I've got to talk through this schedule with them, get their comments, and the reason there's no handout, Dr. Cerqueira, is because I wanted to keep it fluid enough to get comments from you all, comments from the Regional Directors, and have a schedule that everybody can work with and live with, and get to the implementation date with guidance that's workable in hand, inspection procedures, license reviewers, and inspectors trained and thinking new Part 35 with the

2.4

1	performance based, risk informed mindset.
2	CHAIRMAN CERQUEIRA: Susan, that's
3	DR. FRANT: I was glad the Commissioners
4	were so confident we could do it.
5	CHAIRMAN CERQUEIRA: Well, this has been an
6	excellent presentation in the sense that you've given us
7	details. You've given us dates, and I think this is
8	tremendous.
9	I think it would be helpful if perhaps, you
10	know, when you've had a chance to sort of certainly
11	some of these dates we've been writing down, but if we
12	could get an E-mail or a copy of these out to the
13	Committee
14	DR. FRANT: Of course.
15	CHAIRMAN CERQUEIRA: that would be very
16	useful.
17	I'd also like to
18	DR. FRANT: I'll get it to Angela, who will
19	get it to you al.
20	CHAIRMAN CERQUEIRA: Yeah, that would be
20	CHAIRMAN CERQUEIRA: Yeah, that would be useful.
21	useful.
21 22	useful. I'd also like to say that, you know, we had

1	So, Angela, what happened to the white
2	they were here yesterday.
3	MS. WILLIAMSON: Oh, it was the
4	Commissioners.
5	DR. NAG: In the Commissioner meeting.
б	CHAIRMAN CERQUEIRA: Well, it would be nice,
7	especially since if we don't have notes
8	DR. FRANT: Well, Angela is off. We have a
9	supply room and
10	CHAIRMAN CERQUEIRA: Good. Okay.
11	DR. FRANT: You know, we've been on a tight
12	budget, but I think we
13	(Laughter.)
14	CHAIRMAN CERQUEIRA: No, I think that would
15	be helpful.
16	But, again, you've done a great
17	presentation, and if we can live up to those time lines,
18	that would be ideal. And I think you're bringing in an
19	approach certainly from the reactor area which I think
20	would work well within medical. And I think if we could
21	implement that, that would be great.
22	DR. FRANT: Let me ask you. The planning
23	meeting on March 14th, I would like someone from ACMUI,
24	if it's possible, to be part of that planning meeting
25	with Chip and with myself so that we could have your

1	insights on who should be included in these meetings.
2	You know, Chip has a way of running the
3	meetings, and he's very inclusive, and he's already made
4	some phone calls. I don't know if he's talked to any of
5	you, but
6	CHAIRMAN CERQUEIRA: I don't think any of us
7	have been contacted about the meeting. I mean, March
8	14th is fairly close, but we certainly would, you know,
9	try to get a representative there. Since I'm only a bus
10	ride away, I could almost do it.
11	But I think it would be important, again, if
12	the Committee wants to be involved in these kind of
13	things, and the more notice we have, the better.
14	Now, do we have questions? Jeffrey has been
15	
16	DR. FRANT: I'm sorry.
17	CHAIRMAN CERQUEIRA: chafing at the bit
18	here.
19	DR. WILLIAMSON: No, that's okay. Well, I
20	think that, as you know, the issue of training experience
21	and Board certification is sort of a mess, and I guess
22	you will be responsible for drafting the guidance that
23	the regions will be using to determine under the existing
24	rule as written
25	DR. FRANT: Right.

1	DR. WILLIAMSON: how to basically work
2	through all of these problems of deciding how a Board
3	certified physicist or physician needs to qualify for the
4	different modalities.
5	So I think there's an opportunity to
6	ameliorate this circumstance by trying to write
7	reasonable guidance which would take into account
8	existing Board certification, satisfying many of the
9	requirements and having a realistic requirement for
10	supplementary training beyond Board certification.
11	DR. FRANT: Right.
12	DR. WILLIAMSON: Which comes close to what
13	we do in the field.
14	DR. FRANT: I guess you all know Bob Ayers,
15	and he'll be talking to this. When, Bob?
16	DR. AYERS: One o'clock.
17	DR. FRANT: Okay. One o'clock, and he and
18	I have been talking about what kind of mechanism we could
19	develop that would allow for some relief while there's a
20	rulemaking in progress, and that that needs our Office of
21	General Counsel to sort of help us understand what
22	options are available that are all within, you know
23	I could speculate. I mean, there are several of them,
24	and this isn't the first time that there has been a need
25	for some kind of relief related to a regulation.

1	So that we have some mechanisms and will
2	have to come up with one and maybe, Dr. Williamson, you
3	can help us. If you're working on draft language, then
4	we can also talk about how that would what we would do
5	in the interim to
6	CHAIRMAN CERQUEIRA: I don't know if you
7	captured the discussion that we had before you came on,
8	but we are sort of forming a subcommittee.
9	DR. FRANT: Right.
10	CHAIRMAN CERQUEIRA: And then looking at the
11	ways to address the issue.
12	DR. FRANT: But the permanent solution is
13	rulemaking to amend the current no, rulemaking to
14	amend the not current, but soon to be Part 35. Okay.
15	CHAIRMAN CERQUEIRA: Other questions for
16	Susan? Niki.
17	MS. HOBSON: Well, you probably told us and
18	I just missed it. You're going to have the revised
19	document out for comment by about the middle of March?
20	DR. FRANT: Roger? Yes.
21	MS. HOBSON: And then when do you expect to
22	have the final document ready for publication or whatever
23	you do with it so that the users
24	DR. FRANT: Right.
25	MS. HOBSON: out there will know what

1	they're up against?
2	DR. FRANT: Exactly. I think though, just
3	to be clear, the rule will be published at the end of
4	March, and it's the rule that you have to comply with
5	So one of the things that we're going to
6	have to say in the guidance is that it's guidance on one
7	way to comply with the rule, and that what a licensed
8	reviewer has to make sure that you're doing is complying
9	with the rule, not the guidance.
10	That's an important part of the way we
11	implement our rules.
12	Marjorie, did you?
13	MS. ROTHSCHILD: Marjorie Rothschild from
14	the Office of General Counsel.
15	Just a couple of things. First of all, I
16	think the Commission's intent is to publish the rule in
17	mid-March 30 days from the submission of its report to
18	Congress, but you know, that's not a certain date because
19	it's possible that, you know, we could hear otherwise
20	from Congress.
21	So I just wanted to make sure. That, I
22	think, is the Commission's intent, but it's not entirely
23	certain or up to the Commission.
24	And one other comment I just wanted to make.
25	In terms of meeting with a Commissioner, I think some

1	lines may have been blurred in terms of if committees are
2	just talking about inviting Commissioners to their formal
3	meetings. That's one thing, but I think it's another
4	issue if you're talking about the Committee in whole
5	meeting, you know, privately with a Commissioner.
6	So I just want to I think
7	CHAIRMAN CERQUEIRA: Yeah, I don't think
8	that was our intent to have private meetings.
9	MS. ROTHSCHILD: Yes.
10	CHAIRMAN CERQUEIRA: It was basically to
11	have them show up at a session like this to get their
12	specific input or to, you know, address issues that are
13	of concern to the Committee directly.
14	MS. ROTHSCHILD: Right. Well, that's what
15	I assumed, but I just thought it maybe needed to be said
16	just once again.
17	And then as far a any future rulemaking,
18	there are different means for initiating rulemaking, but
19	we just have to be aware that there are certain
20	procedures and limitations actually as far as staff
21	contact if you were talking about a, you know, petition
22	for rulemaking from outside parties.
23	So I just wanted to emphasize that once
24	again. I think it may not, you know, have been as clear
25	possibly in some of the earlier discussions this morning,

1	but I just wanted to clarify that.
2	Thank you.
3	CHAIRMAN CERQUEIRA: Okay. Thank you.
4	DR. FRANT: Everybody knows Marjorie
5	Rothschild.
6	CHAIRMAN CERQUEIRA: I think she should
7	actually have a seat at this table here because
8	DR. FRANT: Right.
9	CHAIRMAN CERQUEIRA: so many of these
10	issues would be you know, if we could address her
11	directly it would be but we can call on her, can't we,
12	John, if we have
13	MR. HICKEY: Yes. That can be arranged. We
14	have another microphone up here.
15	CHAIRMAN CERQUEIRA: Yeah, well, definitely
16	because it would save us quite a bit of time on, you
17	know, just some of these procedural issues
18	DR. FRANT: Okay. Well, the planning
19	meeting March 14th, I think it would be good if you had
20	somebody at that meeting.
21	CHAIRMAN CERQUEIRA: What's the time of the
22	meeting?
23	DR. FRANT: I'll have to get back to you.
24	CHAIRMAN CERQUEIRA: Okay.
25	DR. FRANT: I know the room, but we'll

1	probably spend a good portion of the day.
2	CHAIRMAN CERQUEIRA: Again, if Angela could
3	get an E-mail out to people with time and location, and
4	we should see if somebody is interested in attending and
5	can free up their schedule to do so. I think that would
6	be important.
7	DR. FRANT: Okay, and the other role that
8	CHAIRMAN CERQUEIRA: And then on March 15th,
9	you said you would have a draft rule, a draft guidance
10	document available, and will that be put on the Web?
11	Will it be sent out to
12	DR. FRANT: Both.
13	CHAIRMAN CERQUEIRA: the Committee
14	members?
15	DR. FRANT: It will be published and
16	distributed to all medical licensees through our
17	distribution center. It will be on the Web, and it will
18	be sent to the ACMUI Committee members as part of your
19	Committee membership.
20	CHAIRMAN CERQUEIRA: Okay.
21	DR. FRANT: So it will be all three of those
22	things.
23	CHAIRMAN CERQUEIRA: Niki, you had one?
24	MS. HOBSON: Yeah, I was wondering. Between
25	now and March 15th, do you have plans to work with the

1	professional societies that you alluded to earlier, that
2	they have a lot to contribute if they have the time and
3	willingness?
4	DR. FRANT: No, I think what we're trying to
5	do is just take the document that we have, clean it up
6	based on the comments that we've gotten recently, and put
7	it out, and then at that point work with
8	MS. HOBSON: Okay, but there will be
9	involvement by the professional societies at some point?
10	DR. FRANT: Yes, and that's what these
11	meetings in April are about and the planning meeting on
12	March 14th is for how to engage that community.
13	CHAIRMAN CERQUEIRA: Just again one comment.
14	And I feel kind of bad. We don't have a nuclear medicine
15	representative on the Committee because the SNM ACNP
16	really had the most comments, criticisms of the guidance
17	document.
18	DR. FRANT: Right, but I think Chip has been
19	calling some of those folks, and the Chairman certainly
20	has corresponded with them. So I think that they're
21	aware of March 14th and will be part of the comment
22	process.
23	CHAIRMAN CERQUEIRA: Again, I think it would
24	be important to get it out to all of the professional
25	societies.

1	DR. FRANT: Exactly.
2	CHAIRMAN CERQUEIRA: In the past, this
3	Committee has in some ways been sort of a battleground
4	between various interests from physician groups and
5	everything, and I think we really should make the
б	information available to all the stakeholders,
7	And sort of in terms of these dates, if
8	people want to send now the meeting on March 14th, is
9	that open to the public?
10	DR. FRANT: Yes, of course, it would be.
11	CHAIRMAN CERQUEIRA: Okay. Again, it would
12	be important
13	DR. FRANT: It would be a noticed meeting
14	CHAIRMAN CERQUEIRA: Right.
15	DR. FRANT: And what I guess I want to
16	insure, that we have a cadre of folks that are important
17	to be part of the planning process, and then it will be
18	noticed.
19	CHAIRMAN CERQUEIRA: Good. Again, I think
20	if you could send out information to the specific groups
21	who have representation on the ACMUI, but to all other
22	stakeholders and people who have sent comments, I think
23	that would make certain that everybody with an interest
24	knows about it and can organize sending people.
25	DR. FRANT: To some extent I'm relying on

1	Chip Cameron because I think he has a long history with
2	different groups.
3	CHAIRMAN CERQUEIRA: Okay. John, you wanted
4	to?
5	MR. HICKEY: Yeah. Mr. Chairman, I just
6	wanted to clarify, first of all, to repeat that the
7	guidance document will be published for public comment,
8	not as a final document.
9	CHAIRMAN CERQUEIRA: Sure.
10	DR. FRANT: In March.
11	MR. HICKEY: And that we will be going out
12	for input and sending invitations to all stakeholders and
13	organizations. It's not our intent that ACMUI will be
14	the vehicle by which we communicate with other
15	stakeholders. The ACMUI is free to do that, and we will
16	solicit input from the ACMUI, but we are in no way saying
17	that the ACMUI is the organization that's responsible for
18	going to the other stakeholders and
19	CHAIRMAN CERQUEIRA: Sure. No, and I'm not
20	suggesting that, but I'm just saying that for all of the
21	stakeholders, they need notice to send people.
22	MR. HICKEY: Yes.
23	CHAIRMAN CERQUEIRA: And March 14th is
24	relatively close. It's three weeks away. So I think
25	it's important to get it out.

And I realize that this is a draft, but you 1 2 have gotten comments. The SNM ACNP was very specific in terms of the guidance documents, and so the closer the 3 draft can be to a final the better off it will be for 4 5 everybody. 6 So all right. Other questions or comments? 7 Jeffrey. DR. WILLIAMSON: Well, I think in preparing 8 9 the draft, when I reviewed the document as it existed 10 about a month ago, I guess, I didn't think enough effort 11 made to try and indicate the spectrum of was possibilities that users could have in implementing. I 12 13 was too focused on one set of model procedures. 14 You know, I think a lot could be done to ameliorate that by adding paragraphs here and there, 15 indicating the areas where a lot of flexibility exists so 16 17 that it's whoever reads that manual indicates -- realizes 18 that this is just a possibility, and that other options 19 can be implemented and the licensee won't be punished for 20 doing it. CHAIRMAN CERQUEIRA: I liked your comment 21 22 about sort of a minimalist document which gives people a 23 certain amount of responsibility. Obviously, you know, 2.4 it's performance based, risk adjusted. I think they're

very important, key words, and if taken to heart, I think

it would certainly reduce the amount of information 1 that's there for diagnostic and even for the therapeutic 2 3 community as well. DR. FRANT: But at the same time, I guess, 4 I'm conscious of the fact that I've heard from many staff 5 6 members, particularly license reviewers, that they're 7 is there a place I can go to --CHAIRMAN CERQUEIRA: Right. 8 DR. FRANT: -- and find a model procedure 9 10 that gives me an idea about what is expected? 11 And that, as I said, is a tension, and to 12 the extent that we could have joint documents or that it 13 could be produced by someone other than NRC as, you know, 14 this is a recommended way to go. That would be fine, and we've done that in other areas. 15 In the meantime, there's a vacuum and 16 17 something will fill that and perhaps we can take these 18 model procedures and have them someplace else that are 19 available, but they're not seen as required even with a 20 little r. think CHAIRMAN CERQUEIRA: Т the 21 22 professional medical societies would certainly all give 23 you their cooperation in an effort to get this done. The 2.4 only point I would make is to try to get sort of a broad 25 representation.

1	You know, for the reactors, you had a single
2	entity, I guess, produce a document. I think
3	DR. FRANT: You would think they are more
4	monolithic than they are, but each utility has its own
5	philosophy.
6	CHAIRMAN CERQUEIRA: Right, right. I think
7	just to keep us on time, again, being cognizant of the
8	flight schedules, I'd like to thank
9	DR. FRANT: Okay. Well, I'm going to stay
10	because I have a role in the next presentation. So
11	CHAIRMAN CERQUEIRA: Okay, but again, I
12	think it was an excellent presentation. I especially
13	like the specifics with the dates, the time lines and
14	everything else, and it would be very useful to the
15	committee if we could get Angela to E-mail those out to
16	us so that we can go back to our constituents.
17	DR. FRANT: Okay.
18	CHAIRMAN CERQUEIRA: Thank you, Susan.
19	Ralph.
20	MR. LIETO: Dr. Frant, just to clarify, the
21	March meeting and its purpose, is it to get stakeholders
22	there and how to best get the revised document addressed
23	or is it to address how these public meetings are going
24	to be conducted?
25	I'm still unsure as to what the March 14th

1	meeting
2	DR. FRANT: It's more about what the public
3	meetings what role they can play in influencing the
4	guidance document, you know, and who should be there and
5	how we can best get comments and incorporate them into
6	the final document. So it's a planning meeting for the
7	meetings in April. Is that clear?
8	MR. LIETO: Thank you.
9	CHAIRMAN CERQUEIRA: Dr. Frant, you've done
10	such a great job with time lines. I guess the one thing
11	I'm still unclear on is that, you know, we saw the
12	submission that the Commissioners sent to Representative
13	Callahan, and have they heard back? When will they hear
14	back? That's kind of a key question in this, isn't it?
15	DR. FRANT: I agree.
16	CHAIRMAN CERQUEIRA: The answer is?
17	DR. FRANT: The answer is that in the letter
18	we sent to Congress, and I guess it's been stated enough
19	times, and the Chairman, I believe, made some phone calls
20	to key congressional representatives, to make it clear
21	that the intent of the Commission was to publish the rule
22	30 days after the date it was sent to Congress.
23	So we hold our breath because if there's
24	some strong sentiment among the legislators to tell us,

no, you don't have permission to use the monies in your

1	budget to implement Part 35 and you're not to publish it,
2	that may happen. And that's what Marjorie, I think, was
3	alluding to.
4	There's no guarantees except if you buy a
5	washing machine from Sears, and sorry.
6	CHAIRMAN CERQUEIRA: Okay.
7	DR. FRANT: But, I mean, it's the truth.
8	And so at the same time, I think that just my personal
9	sense is that the Chairman and the Commissioners did some
10	leg work and fully intend to publish it and believe that
11	they won't have a legislative change, you know, with some
12	legislation.
13	So I think the optimistic glass half full
14	view is that within 30 days of sending the report to
15	Congress, we will send the Part 35 as it stands to the
16	<u>Federal Register</u> to be published and to be effective six
17	months after the date of publication.
18	We're working to that. You're assuming
19	that.
20	CHAIRMAN CERQUEIRA: Right.
21	DR. FRANT: But it isn't there until it's
22	there.
23	CHAIRMAN CERQUEIRA: That's great. That's
24	very useful then.
25	All right. Well, so this section is now

1	status of the NRC Web site in terms of security
2	restrictions, and John Hickey is going to cover
3	electronic forums; is that
4	MR. HICKEY: Correct.
5	CHAIRMAN CERQUEIRA: And the Web site is?
6	MR. HICKEY: Dr. Rathbun is here to talk
7	about the Web site.
8	DR. FRANT: Okay. Pat, before you start, I
9	want Dr. Diamond, you made some comments yesterday
10	about bad people using good stuff to do bad things, and
11	you know, there's
12	DR. DIAMOND: I like that. I like that.
13	(Laughter.)
14	DR. FRANT: So I've been working with FEMA,
15	and John Hickey has been working on a lot of not for
16	public discussion or not for public release information
17	about things that could be done with radioactive
18	material, not therapeutic and not diagnostic. And the
19	issue is I know the advisory that went out to all of our
20	materials licensees said that you should safeguard the
21	material more so than you have in the past, and I think
22	the suggestion in the advisory says something about
23	looking at it as a controlled substance and some of the
24	safeguards you have for controlled substances.
25	I have the sense that you're working on

guidance to send out to medical licensees on what they 1 can do to sort of implement that request of the 2 3 advisories to look at more safeguarding of radioactive 4 material when it's used in medical applications. 5 DR. DIAMOND: Not specifically. My general 6 comments regarding bad people doing bad things with good 7 materials was more of a general informative point that the societies are trying to go and just educate their 8 9 constituent members as far as basic resources and 10 procedures that are out there in case one of these events 11 should happen. 12 DR. FRANT: Oh, okay. So this would be in 13 response to. DR. DIAMOND: More of a response. 14 I can in many, many radiation safety 15 you that organizations or committees across the country there is, 16 17 however, a formal move to safeguard these materials much 18 more cautiously. For example, our institution, where the 19 board scope holder really serves to oversight many, many smaller facilities, we've taken steps to take some 20 programs where very, very little manual brachytherapy is 21 22 done and go and consolidate those materials into a 23 central location where obviously safekeeping and 2.4 is much better. oversight

Perhaps I can ask a member of the audience.

1	Nancy Daly is here. Nancy, do you happen to know offhand
2	any more specifics with respect to if Dr. Frant's
3	questions is actually being looked at in that committee?
4	MS. DALY: No.
5	MR. HICKEY: Step to the microphone and
6	identify yourself.
7	MS. DALY: Nancy Daly from Astro.
8	Again, we're more specific to if it were to
9	happen what would be the mechanism that would be put in
10	place, and what resources could radiation oncologists
11	offer to the communities where it happens, and
12	DR. DIAMOND: All right. Could I I'm
13	sorry.
14	DR. FRANT: What I was going to say is,
15	okay, so I misconstrued what you said because what I was
16	going to offer is if we could play a role in having our
17	safeguards group review things for you, we would be glad
18	to facilitate that.
19	DR. DIAMOND: And I was going to say that I
20	think that as you bring this up, this is an excellent
21	point that would be welcomed.
22	DR. FRANT: Okay. Because we have, of
23	course, a safeguards group that's been working with the
24	intelligence community and with others about issues
25	related to radiological dispersion devices, radiological

1	emitting devices, REDs, RDDs, and of course,
2	independently developed nuclear devices, which I think is
3	not an issue
4	DR. DIAMOND: Correct.
5	DR. FRANT: because it's fissile
6	material, but the RDDs and the REDs are things that I
7	guess there are medical use isotopes that could be
8	involved.
9	DR. DIAMOND: I think we all recognize just
10	as you're alluding to that if a bad person wanted to do
11	bad things with good materials, that going after hospital
12	supplies or materials would be, unfortunately, a way to
13	go, and therefore, we could certainly welcome that
14	advice.
15	DR. FRANT: Well, I guess if as a community
16	there's some work, then we could put you in touch with
17	some of our safeguards people.
18	MS. DALY: Yeah, and we're also working with
19	the American College of Radiology and the physics AAPM.
20	So
21	DR. FRANT: Okay.
22	CHAIRMAN CERQUEIRA: Dr. Nag had a comment.
23	DR. NAG: Dr. Cerqueira and Dr. Frant, at
24	the last ACMUI meeting there was some discussion that if
25	something bad were to happen, the ACMUI would probably be

one of the first ones contacted, and much discussion 1 about that. And there should be some formal mechanism 2 3 how the ACMUI should behave should anything happen. DR. FRANT: Well, we can talk about having 4 5 some kind of a secure briefing. 6 DR. NAG: Right, and I think one of the 7 things at the last meeting, that an action item was that the NRC would come back to whether we will have some 8 9 training session or at least some briefing session so 10 that we can know how to react to the news media, how to react to the people nearby, and you know, how we can 11 train the other people. 12 13 DR. FRANT: Well, we have some materials 14 that we've prepared with many other federal agencies, 15 including HHS and FEMA that are for federal government use. Let me see if that can be distributed. I'm not 16 17 sure. It's official use only, but I'm not sure how other -- I'm learning about the different levels of protection. 18 19 I know classified and nonclassified. There's a new one 20 coming up that I guess Pat can talk about, which is the Office of Homeland Security is coming up with a homeland 21 22 security sensitive designation, and that's something 23 we're working through. That would be a new designation. 24 At the last meeting we were DR. NAG:

talking about some official training and official

1	briefing that the ACMUI should receive.
2	DR. FRANT: Okay. Well, I'm going to let
3	John and Angela work that out.
4	CHAIRMAN CERQUEIRA: So do we want to make
5	that an action item then?
6	PARTICIPANTS: Yes.
7	CHAIRMAN CERQUEIRA: To basically
8	DR. NAG: It was made the last time. So I
9	think we would just repeat the same thing.
10	CHAIRMAN CERQUEIRA: Again, for the
11	transcribers, if you could somehow highlight this, it
12	would be important.
13	DR. NAG: The action item would be that
14	ACMUI members have a training session and/or a briefing
15	for any untoward accident in nuclear
16	DR. FRANT: Well, it would be potential
17	DR. NAG: I don't want to use the wrong
18	word.
19	DR. DIAMOND: Malevolent.
20	DR. FRANT: I can never pronounce that.
21	DR. DIAMOND: Malfeasant.
22	DR. FRANT: Right. You know, in Great Neck
23	High they never taught me that. Anyway
24	CHAIRMAN CERQUEIRA: All right. We should
25	I really want to try to keep on schedule. So why

1	don't we go on to this section, and maybe, Ms. Rathbun,
2	if you could, we've got 15 minutes, John, to do this
3	section.
4	MR. HICKEY: Yeah, that's fine.
5	DR. RATHBUN: It will be very short, not a
6	problem.
7	Thank you very much.
8	This is my name tent. Well, that's all
9	right. "Answers to the name of Pat frequently." Okay.
10	All right.
11	As you probably know, after September 11th,
12	in consultation with the Justice Department, the NRC did
13	close down the public Web. Access to ADAMS was still
14	available to those people who had already had access to
15	ADAMS.
16	CHAIRMAN CERQUEIRA: I'm sorry. What's
17	ADAMS?
18	DR. RATHBUN: All right. ADAMS is a
19	document management system for the agency called ADAMS,
20	and it's essentially where the NRC stores electronically
21	all of its documents, and if you it's available to the
22	public. You can just simply come in and look at whatever
23	documents are in there, and theoretically it is the
24	official record system of the NRC.
25	So you can see immediately there were some

1 interesting paradoxes because we had the Web closed, but 2 we had availability of ADAMS to people who had already 3 had it. So time passed, and Susan began to head a 4 5 project whereby we were making decisions about what 6 should come back to the Web, when it's available, and 7 what should be if not removed from ADAMS, at least 8 significantly safeguarded. Now, as you can imagine, this was a huge 9 10 task. It was also carried out very rapidly because, you know, people were very, very concerned. It involved both 11 12 the reactor side, as well as the NMSS side. 13 What did we really take down that could be 14 of interest to you? 15 In our fact sheets, we had a fact sheet on the medical use of radioisotopes. The reviewer said 16 17 drawings attention to the fact that some medical 18 facilities have some very hot sources. 19 At that time, that document was taken and 20 classified. Well, "classified" is the wrong word. And marked sensitive. 21 We also had another fact sheet on the 22 23 biological effects of radiation, which the reviewers at 24 that time, and you can see they were very cautious, said,

"Contains language concerning cancer threat."

1	So the current decision on these things is
2	to put the biological effects of radiation fact sheet
3	back out onto the Web, but so far not the medical use of
4	radioisotopes. So that's something that you may or may
5	not want to comment on, not necessarily here, but we're
6	going to hold that back.
7	The ACMUI transcripts are public
8	information, and they are available. IMNS Management
9	prior to you actually reviewed that and felt there was no
10	reason to pull that back. So unless I hear, you know,
11	violent opposition here today, that will be going back on
12	the Web.
13	NUREG 6642, the risk document which, you
14	know, contains the detailed we feel kind of scenarios or
15	how to make trouble, that was removed. It is still off
16	the Web. No plans to go back.
17	Now, so that's where yes, sir.
18	MR. LIETO: So none of the NUREGs are
19	available? Because it's my understanding
20	DR. RATHBUN: No.
21	MR. LIETO: the RegGuides and the NUREGS
22	are not available.
23	DR. RATHBUN: Well, let me go to that part.
24	At the same time that this was going on in
25	response to closing the Web due to the terrorist

1	activities, there was an activity going on to more or
2	less straighten out the Web and come up with a new
3	design.
4	What's happening now is documents are
5	returning to the new Web, but with this sort of cloak of
6	security. I don't know today if the NUREGs are back, but
7	unless
8	PARTICIPANT: They're not.
9	DR. RATHBUN: They're not. Okay. Unless
10	they're marked "sensitive" in ADAMS you should be able to
11	get them, but they are coming back.
12	MR. HICKEY: Excuse me. Another way to say
13	that is if they were previously public, they will be put
14	back on the Web public with a few exceptions
15	DR. RATHBUN: Right.
16	MR. HICKEY: generally that won't affect
17	medical licensees.
18	DR. RATHBUN: Yeah, I think the only one is
19	that 6642, and if there were implications in any of the
20	risk work, I know Lawrence Kokajko has spoken to you
21	about the activities of the Risk Group, the results of
22	that project are being withheld until we determine if
23	there are risk scenarios that could simply lead the way
24	to a terrorist.
25	Now, I mean, as you well know, this puts us

1	in quite a balance between what people really need to do
2	their business and what, in fact, might be used by bad
3	people to do bad things with good material. So what's
4	happening?
5	Well, we're working on definitions and
6	policies sort of very, very, very hard. I mean, there's
7	a group of people whose major job is now to work on this
8	and try to get as much information back out on the Web as
9	we possibly can.
10	We are working on this both within NRC, but
11	also with Homeland Security, and what Susan was referring
12	to is called it's a new classification for
13	information, and it's called sensitive homeland security
14	information, which people are calling "sushi." So if you
15	hear people speaking of "sushi," that's what they're
16	talking about.
17	And Homeland Security's definitions
18	currently are pretty general, but it's not at all clear
19	to us exactly where they're going.
20	Un-huh?
21	DR. WILLIAMSON: I'm a little concerned at
22	what you've just said. It seems to me
23	DR. RATHBUN: I'm not surprised.
24	DR. WILLIAMSON: that it's totally
25	ridiculous to take the medical use fact sheet off of the

1	Web. You can go to any textbook on radiological sciences
2	and learn that high intensity radiation sources are used
3	for radiotherapy or for nuclear medicine.
4	DR. RATHBUN: I totally agree with you.
5	DR. WILLIAMSON: And so I think a more
6	realistic screening of the material needs to be made. I
7	think it's appropriate to withhold details about the
8	operational characteristics of specific sites, such as
9	power plants that would perhaps aid in someone, you know,
10	launching a specific attack or action.
11	DR. RATHBUN: Right, exactly.
12	DR. WILLIAMSON: But to withhold general
13	material about the operation of the NRC, about the use of
14	radioactive materials in general, and its activities, I
15	mean, I think that's infringing upon your charge
16	DR. RATHBUN: You're absolutely right.
17	DR. WILLIAMSON: as an open and public
18	agency. So I
19	DR. RATHBUN: In that one we totally agree
20	with you, and there are about six fact sheets that at the
21	time it seemed like you know, it seemed like a good
22	idea at the time right after September 11th to pull
23	everything that even, you know, had any hint.
24	There's a whole pile of them, about seven,
25	that I suspect will go back just next week. So, you

1 know, I totally agree with you. If we erred in the beginning, I think we erred on the side of probably 2 3 overly cautious, and I think that what you see from the 4 Commission is a move now to be much more realistic. DR. FRANT: The Commission has directed us 5 6 to go back and make sure that we're not doing exactly as 7 you're suggesting. At the same time, the Sealed Source and Device Registry, for instance, we've made that 8 9 password protected, and only if you have a password can 10 you used the Sealed Source and Device Registry, on the 11 assumption that there are detailed drawings that can give 12 somebody an idea on how a device could be dismantled or 13 whatever. 14 It may be that unless you know where the device is it wouldn't matter if you knew what to do with 15 it, and you would only get that if you put one and one 16 17 together, one being the Sealed Source and Device Registry with its detailed documents and then found licensees! 18 19 names and who is using that device and a map of where 20 they were. On the other hand, it's clear from some of 21 22 the intelligence that we get that there are people who 23 are willing to do al of that leg work. So you want to 2.4 make it a little more difficult.

And we did have many, many evidences of hits

coming from all over the world to different parts of the NRC Web site, and it may be things that are in a 2 3 textbook, but the Web is very accessible, and so there 4 was a very conservative decision made right after 9/11 5 that we'll just put the Web down and wait until we figure 6 out what we can put back up. 7 And as Pat said, we're doing two things at 8 the same time, which sometimes confuses the issue, which 9 is putting things back up, but putting it back up on our 10 new Web format. So it's taking a little longer to get 11 some of the NUREGs back up, but they are slated to go 12 back up, and I don't know exactly what the date is, but they've been in waves. 13 14 And as with the rest of what we do here, the 15 reactor stuff went back up stuff, and the medical stuff will follow. 16 17 CHAIRMAN CERQUEIRA: Richard, did you have 18 a question? 19 DR. VETTER: Yeah. The information in the 20 public document room is also readily accessible. DR. FRANT: Absolutely. 21 DR. VETTER: And I'm not sure how that --22 23 sure, it's easier to go on a computer, and you can do 24 that --From anywhere in the world. 25 DR. FRANT:

1	DR. VETTER: from anywhere in the world,
2	but the public document room is also there. My question
3	relates to information that at least in the past has been
4	available in the public document room, and that is: is
5	there information either in the license literature or in
6	enforcement literature that would reveal the location of
7	radioactive materials at a medical center?
8	DR. FRANT: I'm sure there is, and I'm sure
9	in enforcement documentation this is something we have
10	been looking at. There are discussions of
11	vulnerabilities that need to be corrected, and that's
12	also problematic. Because if it hasn't been corrected
13	yet, then it says you have a problem.
14	I was leading the team that did the review
15	at NIH when they had the P-32 contamination, you know,
16	and we had documents on what the security issues were
17	DR. VETTER: Yeah, personally I would view
18	that as more problematic than having NUREGs and so forth
19	out on the Web.
20	DR. FRANT: Yeah, and I think you're exactly
21	right, and it's one of Pat's issues, is to come up with
22	guidance that helps us make those decisions so that we
23	don't make it on each document, but we make it on
24	categories of documents.
25	Right now

1	DR. RATHBUN: If possible, if possible.
2	DR. FRANT: Right now the things are in the
3	public document room partially because you have to go
4	there. You have to sign in. We know who's looking at
5	the stuff, and that's part of what we're looking at, is
6	who has access, not only
7	DR. WILLIAMSON: Maybe that is a better
8	approach to your problem, is to try to define make an
9	application system for people to get passwords so that
10	they could have access to a broader scope of information.
11	Rather than trying to classify every single
12	document, you could screen people who have access and
13	supply passwords to users from the medical center who
14	need to get into this stuff.
15	DR. FRANT: Yeah, well, we have to be
16	careful
17	CHAIRMAN CERQUEIRA: Just in terms of
18	DR. FRANT: that we don't use criteria
19	that
20	CHAIRMAN CERQUEIRA: Right. In terms of the
21	Committee, I need to give John some time for his forms.
22	What specific questions do you have for the Committee
23	relative to this?
24	DR. RATHBUN: Honestly, I didn't have any
25	questions. I just wanted

1	CHAIRMAN CERQUEIRA: Just information.
2	DR. RATHBUN: to inform you, and I'd love
3	to hear from Dr. Lieto.
4	MR. LIETO: First of all, I use ADAMS fairly
5	frequently because you can use it to confirm training and
6	experience, credentials of new users at your facility as
7	to whether they were actually licensed or not and what
8	licenses they were on.
9	Regarding Dick's question, yes, there are
10	floor plans and locations of where stuff is because
11	basically a license application is full copied in its
12	entirety. So that information is there.
13	My concern is that there's a lot of
14	information as an RSO and a physicist that you want
15	access to the regs., you know, current versions of the
16	regs., which are sometimes very difficult to get, and I
17	
18	DR. FRANT: Those should be up there. Those
19	should be up now.
20	MR. LIETO: But lots of times though
21	DR. FRANT: We'll check.
22	MR. LIETO: Part of the issue is like if you
23	want a copy of Part 35, you've got to go through and copy
24	each section. There are not entire parts that you can
25	download for distribution to users and for training

1	purposes, and so forth. The same thing with like Part
2	20, Part 19.
3	DR. WILLIAMSON: Oh, it's terrible.
4	MR. LIETO: Those types of things. So it's
5	very difficult, and I would think that that would be very
6	helpful.
7	Another comment regarding what you're
8	planning to do with the NUREG revision. To me there's
9	going to be a lot of people who can't get to these
10	meetings and so forth, and I would see that the Web site
11	is going to be really critical because of the time frame
12	for people to make comments and suggestions and want to
13	get input to the NRC.
14	So I know that when the original Part 35
15	revision when out there was a site, and I think it was at
16	Lawrence Livermore, but I could be wrong, where people
17	could have dialogue on the issues, and it was monitored,
18	I think, by the NRC staff for comment.
19	I don't know how beneficial it was to the
20	staff or not, but there's got to be, I think, that Web
21	site mechanism for communication on this Part 35 revision
22	that I think is really important.
23	And I know I'm being looked at over here
24	about the clock and so forth, but, hey, I've got the mic.
25	DR. FRANT: You bet.

MR. LIETO: So I think the Web site is a 1 2 very --3 CHAIRMAN CERQUEIRA: I could cut you off. MR. LIETO: -- is very important. 4 5 DR. FRANT: Well, I think we intend to use 6 that. I don't see Roger, but the last I heard, the staff 7 planned to have that Web site up. MR. LIETO: Now, the other issue is 8 9 regarding ADAMS. Because of the way of accessing ADAMS, 10 if you have firewalls, it's very, very difficult to 11 access ADAMS, especially for like large centers and so forth. In fact, the only way I can do it is via a modem. 12 13 I can't do it via our hospital network, which is a very 14 slow process. 15 And so if you've got a sizable document, I mean, you've got to basically kind of do this overnight. 16 17 So, you know, to look at get sizable NUREGs and things 18 like that to download, it is not easy. In fact, it's 19 very difficult to do it because you've got to do it via 20 modem. DR. FRANT: Yeah. We'll pass that on to our 21 22 CIO folks who have done the Web redesign. I think they 23 tried to address that. This has been a complaint by 2.4 many, many groups. We've been accused of using the Web

as a way to disenfranchise people who didn't have

1	computers and elitists and all of that.
2	CHAIRMAN CERQUEIRA: I suggest that we take
3	a break. Let John cut into Don Cool's time a little bit,
4	and if people have
5	DR. RATHBUN: That's fine.
6	CHAIRMAN CERQUEIRA: No, but if people have
7	specific questions for Dr. Frant and Rathbun, just ask
8	them now. Okay?
9	DR. RATHBUN: Yeah.
10	DR. FRANT: We'll be here.
11	CHAIRMAN CERQUEIRA: Thank you very much.
12	(Whereupon, the foregoing matter went off
13	the record at 10:06 a.m. and went back on
14	the record at 10:22 a.m.)
15	CHAIRMAN CERQUEIRA: I was talking to John
16	during the break, and we have every intent of being
17	completed by three o'clock. A lot of the items after the
18	three o'clock break were really sort of dealt with to
19	some extent.
20	I'd also like to mention that, you know, I
21	think the Committee meets. Most of us, this is not our
22	main line of work, and for some of these this was very
23	informative, but it would be very useful if we had some
24	questions that they wanted to ask us specifically, and if
25	they're going to sort of update us on something, having

the material sent to us ahead of time would allow us to 1 view it on the plane, if nothing else, so that we could 2 provide some useful input into the NRC on these items. 3 So, again, I think some of these updating 4 the Committee on factual items, we should get the 5 material ahead of time, and if there are specific 6 7 questions that they have for the Committee, I think these, again, should be clearly stated. Otherwise we 8 9 just have a nice dialogue and we get a little bit of 10 information and we exchange cards, but we could be much 11 more useful and productive if we knew ahead of time what 12 they're going to present and what information they want 13 from us specifically. 14 MR. HICKEY: Yes, we agree with that, but let me just point out a couple of considerations. One is 15 this was in response to a request from the Committee to 16 17 place this on the agenda. It wasn't that the staff --CHAIRMAN CERQUEIRA: Right. 18 19 MR. HICKEY: -- had questions they wanted to 20 bring to the ACMUI. 21 The other is we agree that we need to 22 provide you with material advance, but an example in this 23 particular case is where it involves security 24 considerations we have to be careful what we put down on 25 paper.

1	CHAIRMAN CERQUEIRA: Sure.
2	MR. HICKEY: And was you heard, this is a
3	dynamic situation where it's unclear what's being release
4	to the public and what's not.
5	CHAIRMAN CERQUEIRA: That's understood, and
6	we are certainly aware of those factors, but again, to
7	get more business done, it's important to have it.
8	All right. Well, the next item then is
9	going to be John with the electronic forms.
10	MR. HICKEY: Yes. Dr. Cool is in a meeting
11	that should have ended by now. So we're expecting him
12	momentarily, and Mr. Lohaus is in a meeting also, but we
13	expect him to be here on time.
14	With respect to the electronic forms, and I
15	think some of Ralph Lieto's remarks were a good
16	introduction to this, we would like for the Web site to
17	be more user friendly and more useful, and so we will be
18	putting electronic forms, in general, up ont he Web more,
19	and in particular in the medical area where there are
20	forms that are useful, such as an application form or a
21	reporting form.
22	We're going to have that as part of the
23	medical tool kits, Web tool kits, so to speak, that
24	that's another resource that instead of having to get the

forms through the mail in hard copy or Xerox them out of

1	something, you can download them and fill them out, and
2	perhaps even submit them electronically.
3	So that is one thing we're working on, and
4	we're also looking at other user friendliness issues.
5	Ralph pointed out one that's come up before,
6	the issue of our regulations. If you're reading them the
7	way that they are on the Web, if you're just reading them
8	on the Web it's fine, but if you want to download the
9	whole document, you can't just click Part 20 download.
10	You've got to click 20.201, 20.203 and download each one
11	of those individually.
12	So that's an agency-wide issue, not just a
13	medical issue, but that's something else we'll have to
14	work on.
15	CHAIRMAN CERQUEIRA: Good. So that's it on
16	forms.
17	MR. HICKEY: That's it. I'll take any
18	questions.
19	CHAIRMAN CERQUEIRA: And Dr. Cool is still
20	not here.
21	MR. HICKEY: Unfortunately. We just called
22	up there. He's going to come down as soon as he gets out
23	of his other meeting.
24	DR. VETTER: Can I just make one comment?
25	CHAIRMAN CERQUEIRA: Yes, please.

1	DR. VETTER: The public document room does
2	provide I don't know if that's it's some electronic
3	connection of the public not public document room
4	The Government Printing Office. You can
5	download entire chapters from that. At least, unless
6	something happened since September, I have done that in
7	the past.
8	MR. HICKEY: From the Code of Federal
9	Regulations.
10	DR. VETTER: Yes.
11	MR. HICKEY: Yes, but that's not user
12	friendly for you to have to go you know, we'd like to
13	have it you go to the NRC Web site; you go to the medical
14	area; and it's all right there. That's our goal.
15	DR. VETTER: Can you link?
16	MR. HICKEY: We can, but I don't know if
17	that's the best way to do it because that involves, you
18	know, relying on another server and going out of the
19	system and coming back into the system.
20	CHAIRMAN CERQUEIRA: Yes. Now for the sake
21	of time, it looks like the next two speakers are not
22	going to be here. Bob Ayers is here. John and I had
23	talked that there's some sort of stakeholders. I guess
24	is there is there a reason we couldn't move that up on
25	the agenda now?

1	DR. AYERS: I don't have my slides here.
2	CHAIRMAN CERQUEIRA: Okay. So I guess we
3	can't do that.
4	DR. AYERS: I can go up and get them, but it
5	would take a few minutes.
6	CHAIRMAN CERQUEIRA: Well, maybe you should,
7	and what about na update on new IVB devices?
8	MR. HICKEY: I can go ahead and talk about
9	intravascular brachytherapy.
10	CHAIRMAN CERQUEIRA: Yeah.
11	MR. HICKEY: Before you do that, would you
12	like to talk about the three o'clock, to see if we could
13	
14	CHAIRMAN CERQUEIRA: We could touch
15	MR. HICKEY: To the extent that the three
16	o'clock items need further discussion, we could close
17	those out.
18	DR. WILLIAMSON: Or we could decide the next
19	meeting date.
20	CHAIRMAN CERQUEIRA: Okay.
21	DR. WILLIAMSON: There are some other
22	administrative things we could prepare.
23	CHAIRMAN CERQUEIRA: All right. So the
24	distribution of ACMUI meetings.
25	MR. HICKEY: Minutes.

1	CHAIRMAN CERQUEIRA: Minutes. I think we've
2	agreed that it's, you know, two weeks before the time of
3	the meeting itself, if not sooner, is idea, so people can
4	review it if there are issues.
5	And I'm certainly willing to look at the
6	items as they come to me. I will not commit to going
7	through the transcript of the entire meeting. I think
8	we've simplified it, you know, with Dr. Diamond's
9	suggestion to try to come up with specific agenda items.
10	So
11	MR. HICKEY: To be clear, the minutes will
12	be clear on what the action items and resolutions were
13	and what the staff's response was to those as a separate
14	document.
15	CHAIRMAN CERQUEIRA: So, again, we've got a
16	policy, and we just have to enforce it.
17	Ralph?
18	MR. LIETO: I just had a question. Where
19	are the transcripts of the minutes or excuse me of
20	the meetings? They're in ADAMS only? Is that where
21	they're at or are those supposed to get distributed to
22	the members?
23	MR. HICKEY: Well, let me ask Angela. I'm
24	not sure you want them distributed, but go ahead. Speak
25	into the mic.

1	CHAIRMAN CERQUEIRA: Trust me. You don't.
2	It's huge.
3	MR. LIETO: Well, I was just thinking of
4	MR. HICKEY: Well, let Angela answer the
5	first questions.
6	MS. WILLIAMSON: The transcript is placed
7	into ADAMS after Dr. Cerqueira certifies it, and that can
8	typically take from the time that we get the transcript,
9	that can typically take about 30 days.
10	Yes, Dr. Williamson.
11	DR. WILLIAMSON: Is it possible we can have
12	access provided to ADAMS for the members of the Committee
13	and then E-mail given to us to direct us or to inform us
14	when the transcript and minutes are available, and then
15	we could go look at them on line?
16	MS. WILLIAMSON: That's a routine
17	announcement that's made in the <u>Federal Register</u> notice
18	about when the transcript is available. So you're asking
19	for us to notify you precisely when it's available?
20	DR. WILLIAMSON: Right, because we don't all
21	read the <u>Federal Register</u> every day.
22	MS. WILLIAMSON: Right, but it is in your
23	MR. HICKEY: We can notify you by E-mail of
24	the availability and how to access it. Anybody can
25	access ADAMS. You don't have to be given access to

1	ADAMS. Any member of the public
2	DR. WILLIAMSON: Okay, but if you can tell
3	us when and where
4	MR. HICKEY: And how, yes.
5	DR. WILLIAMSON: it's on the Web, and
6	how, that would be really nice because we're not going to
7	read the <u>Federal Register</u> every day to find out.
8	MR. HICKEY: Go ahead.
9	MR. LIETO: I was going to say because
10	usually documents have sort of a weird ID number, if I'm
11	not mistaken, in ADAMS. So you know, if we even have
12	that number so that we can go in and find it.
13	CHAIRMAN CERQUEIRA: Okay. Dr. Cool is
14	here, and while he's getting set up, an update of the
15	ACMUI bylaws. What did we change? Were there any
16	changes or is this
17	MR. HICKEY: It was pointed out that there
18	needs to be an update with respect to the terms. The
19	length of terms of members has been changed, but the
20	bylaws haven't been updated. So we will update that and
21	any other administrative changes.
22	And I would suggest that we contact the
23	Committee by E-mail with the revision, and then for the
24	next meeting the approval of the change would just be a
25	formality. It would have already been reviewed.

1	But the main concern was they did not
2	reflect the correct length of terms. They just had not
3	been updated.
4	CHAIRMAN CERQUEIRA: Okay. I have to admit
5	I haven't read them for a while, but they're here now.
6	Is this a revision that okay.
7	MR. HICKEY: Can you explain what's been
8	handed out, Angela?
9	MS. WILLIAMSON: To save time, I handed out
10	the proposed change to the bylaws so that when we get to
11	the point in the agenda when we talk about updating the
12	bylaws you can read what the proposed change is, and you
13	have the current version of the bylaws already in your
14	briefing binders.
15	So that's all that that is.
16	CHAIRMAN CERQUEIRA: So the only thing
17	that's changed is the term of an appointment to the
18	Committee is three years and the Commission has
19	determined that no member may serve more than two
20	consecutive terms, or a total of six years.
21	MS. WILLIAMSON: Right. The total amount of
22	time hasn't changed. It's just that the terms have been
23	lengthened.
24	CHAIRMAN CERQUEIRA: Okay.
25	MS. WILLIAMSON: That's the only difference.

1	CHAIRMAN CERQUEIRA: Does anybody have any
2	concerns about that, questions or disagreement with those
3	changes?
4	MR. LIETO: No, I think we've just got to
5	vote on it.
6	CHAIRMAN CERQUEIRA: Yeah. Do I hear a
7	motion to approve?
8	MR. LIETO: I make a motion to amend the
9	bylaws, Section 3.1, to reflect the Committee appointment
10	term length as documented here.
11	DR. NAG: One question.
12	CHAIRMAN CERQUEIRA: Yes.
13	DR. NAG: How would those who are appointed
14	for two years and now we have a three year I mean the
15	new appointee, no problem. What happens to the old
16	appointees?
17	MS. WILLIAMSON: Can I answer that? It's
18	simply an administrative change so that the appointment
19	process
20	MR. HICKEY: No, the question is: is there
21	anybody on the Committee now that was appointed for two
22	years?
23	DR. NAG: Yes.
24	CHAIRMAN CERQUEIRA: I think most of us.
25	DR. NAG: All.

	185
1	MS. WAGNER SCHWARZ: All of us.
2	CHAIRMAN CERQUEIRA: Was it for three years?
3	DR. WILLIAMSON: The bylaws are out of step
4	with the current process.
5	MS. McBURNEY: With the process.
6	CHAIRMAN CERQUEIRA: So it sounds like, you
7	know, the process was changed, but the bylaws weren't
8	MR. HICKEY: Correct.
9	CHAIRMAN CERQUEIRA: I have to okay. All
10	right. So that's been clarified.
11	MR. LIETO: Second Ralph's motion.
12	CHAIRMAN CERQUEIRA: Second Ralph's motion.
13	Any discussion?
14	(No response.)
15	CHAIRMAN CERQUEIRA: All the vote. All in
16	favor?
17	(Chorus of ayes.)
18	CHAIRMAN CERQUEIRA: Opposed? Abstentions?
19	(No response.)
20	CHAIRMAN CERQUEIRA: Okay. So this has been
21	passed, and we've dealt with that.
22	Dr. Cool, I apologize for taking some of
23	your time, but we'll give it to you if you need it.
24	DR. COOL: Thank you, Dr. Cerqueira.
25	And let me welcome you here. With the

number of the other things going on in the agency I haven't had the time I would have liked to have had to be with you on the large variety of subjects today. This may, in fact, not necessarily need as much time as may have been on the agenda. So I may, in fact, be able to help you just a little bit.

On the other hand, this is an area which is a little bit different from that which the Committee typically has an opportunity to get a view of because I wanted to spend a few minutes and let the Committee have a little bit of information about some of the activities that are going on internationally because there is a great deal of activity going on outside of the United States, outside of this particular set of activities that we have here in the Nuclear Regulatory Commission.

And both because it is of general interest because of the interactions that we and the states and various professional societies may be engaging on in another one of our lives, as well as the potential implications that this may have long term for some of the activities or interactions that we may have, and because I believe it poses a new opportunity for us to at least consider ways to influence activities on a broader scale, and so for those variety of reasons, I wanted to give you a little bit of background information of some of the

things that are going on and some of the recent discussions that have taken place.

The particular event which tripped my request to spend a few minutes was an International Atomic Energy Agency Technical Committee meeting which took place about two and a half weeks ago, and it was titled the "Development of an Action Plan for Radiological Protection of Patients."

Now, that might seem like a very strange title for someone from the Nuclear Regulatory Commission to then be headed overseas on, but, in fact, under that title lies the current set of IAEA, International Atomic Energy Agency, activities related to the practice of medicine and radiation.

IAEA, as the states have here in the United States, has a view for all of the different kinds of uses of radiation in medicine. This is everything from the esclorays (phonetic) and the fluoroscopy to the biopartic (phonetic) materials to the PET, to the entire gamut of activity. So it goes well beyond NRC's particular jurisdiction.

And they have had in place for almost as long as the agency has been in place a series of activities that they've been looking at to try and support their member states in the safe use of radiation

and radioactive materials.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

25

The International Atomic Energy Agency is a U.N. agency, and so their member states constitute in the broadest terms the membership of the United Nations. In more specific terms, there are a set of member states of IAEA, somewhat of a subset, but it's still some 150 or so different countries, and so they face a rather interesting challenge of everything from things like the United States and Great Britain, France, the various folks in the European Union, and others who have rather developed and refined programs, longstanding sets of regulations, practices, and activities and focuses, to folks in some of the smaller countries, some of the newly independent states in a variety of places where the first is there any sort of and foremost question is: regulatory infrastructure and information? Does anyone know what they actually have and what they're actually doing in using the radioactive materials not only in medicine, but in all of the various attributes, a lot of the industrial sources, radiography and other things? But medicine tends to be the area where they are more likely to actually have large sources in some of these under developed or just developing member states as

physician, a physicist, some combination of folks

a result of teletherapy units or other things.

returning to their country, having been educated here or
in Europe, and taking with them sources and equipment in
order to set of practices, and that has over the course
of time, of course, gotten people into trouble in various
and sundry forms both in terms of the securing and
control of the material witness, for example, the
Guyana event for now more than ten years where a
teletherapy unit was no longer being used, was more or
less abandoned. Some thieves came in and thought this
would be wonderful scrap metal, got into the source, and
saw, oh, what cool stuff. This cesium powder glows in
the dark, and several people died, and they made a
horrendous mess of a large number of acres there in
Guyana, to similar sorts of things where teletherapy
heads, for example, in Thailand here a couple of years
ago, three of them picked up by scrap brokers. Again,
they didn't know what they had. There was no ongoing
accountability and control, and there were a number of
individuals who got very severe exposures to rather
serious consequences as a result of actually attempting
medical treatment. Witness, for example, the most recent
couple of cases in Costa Rica and Panama, for example,
where there have been rather severe consequences, a
number of individuals actually dying as a result of not
being aware that a treatment planning system output was

б

190 not what they had thought they were putting in. 1 system didn't respond the way they thought it was going 2 3 to. So there's a whole set of issues that are 4 5 going on. The International Atomic Energy Agency and its 6 Board of Governors in a general conference back several 7 years ago, the Board of Governors challenged the IAEA 8 Secretariat to convene an international conference to try 9 and examine the issues and lay out some recommendations 10 for how to move forward in the area. 11 That resulted in a conference that was held 12 in Malagra, Spain back a bit over a year ago. 13 Commissioner Diaz from here; Dr. Fred Metler actually 14 chaired the conference, University of Mexico. A number of other individuals from various places within the 15 United States attended the conference. There were over 16 17 800 participants.

That resulted in a series of recommendations coming out of the conference, documented in the proceedings which are publicly available. It's a book about yea thick, a couple inches thick. A wide variety; contains all of the text of the talks and the dialogue sessions.

The general conference in September of last year asked the IAEA Secretariat, the staff to then move

18

19

20

21

22

23

2.4

to the next step, which in typical international activities is to more formulated specific action plan, which the IAEA could then engage specific actions on over some period of time.

That's the short history that got to the meeting that was held the end of January, the first few days of February this year, taking the results of that conference and taking a look at the current IAEA programs and what things could be done and what things should be done by whom. Because the IAEA is only one of a large number of organizations that have international roles.

The conference and this technical committee was attended by representatives of the World Health Organization, WHO, Pan American Health Organization, PAHO, a whole series of various international professional societies, the International Organization of Medical Physics, International Radiation Protection Association, International Society of Radiation Oncology, International Society of Radiological Technologists, International Society of Radiology.

That gives you a flavor, a wide variety of these, all of whom have various activities going on to one extent or another, trying to look at improving the delivery of medical care internationally.

The discussions during the week and the

2.4

focus of the action plan being developed. I have a very drafty draft that I brought back, which they were going to go work on, polishing and adding to some things, picks up on the primary mechanisms that the IAEA can utilize to influence member states, which is coordinating research where that may be appropriate to gain a better knowledge of the things to do; promoting education and training, which was, in fact, one of the primary focuses of this activity; providing assistance to member states, which is something that the IAEA does through both technical assistance activities, some peer review activities, a variety of things that they do with developing member states; fostering information exchange, such as the conference and other activities; and in some cases actually specifically rendering some services to some of the member states, where they will actually come in and perform certain functions for a period of time.

The outgrowth of that is a whole series of suggestions for actions to be taken, some of them over the next year, some of them a little bit longer time frame.

Once I have a better version of this draft or if that's not forthcoming from the IAEA within the next couple of weeks, I will circulate this particular version around. I will get you a copy recognizing what

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

it is, that it is a draft.

2.4

The process in IAEA is then to have this proposed action plan approved by the Board of Governors, and what would then transpire is over the next year, couple of years, the IAEA in coordination and cooperation with some of the other international agencies, particularly folks like WHO and PAHO, would be looking to try and implement some of these activities.

Many of the things in this action plan are not actually things which the Nuclear Regulatory Commission in and of itself would likely play any specific role in. They are nevertheless good things, trying to foster education and training, trying to look at what are good practices in terms of some of the protocols that they can give to folks to be able to utilize to improve information, how to foster getting the right kind of information into the hands of the people who need it.

There are some things related to some of IAEA's activities in standards and guidance. There the planning activity looks very much like the directionality that we have here with NRC and in the United States to move towards performance based sort of activity, to be trying to look at the relative risks associated with it.

And at this point in IAEA, their primary

focus is things like the fluoroscopy, some of the 1 interventional radiology, some of the very high dose rate 2 3 procedures where their view of risk is perhaps a number 4 of years behind some of the thinking and views that ours would be. 5 6 They will have some efforts to revise some 7 of the guidance documents that have been used in working with member states, their so-called model program. 8 9 To give you a quick side bar related to 10 that, their model program is an effort with now some 58 11 member states where they have gone in and started from, 12 in essence, scratch. There's no regulatory structure; there's no regulatory authority. 13 There's 14 understanding of the sources and uses and activities. 15 Through a series of steps working to build a basic infrastructure, a basic understanding, a basic 16 17 capturing of registration or licensing of the kinds of 18 sources that are to gradually move to a point where there 19 is a basic system of control, inspection, and licensing. They've developed associated with that some 20 documents that a member state could use, not necessarily 21 22 unlike model procedures. If someone doesn't have the 23 capability to work on developing their own, they can use 2.4 these . They've committed to doing some revisions 25

related to those, to in a number of cases make them less prescriptive and to provide some flexibility. There were a number of observations that a bunch of the places here couldn't do everything that was in the list of some of those best practice documents that existed out there, and how could you possibly expect someone in Ghana or some other very small developing place to ever be able to implement that sort of program?

So I bring this to your attention not that

So I bring this to your attention not that it requires specific action by the part of the Committee, but to make you aware that there is a whole other sphere of activities, and that I would expect a number of things that the IAEA and the WHO and others to be doing and moving forward with this might well be things which you as individual Committee members and some of the societies and groups that you represent would want to become involved in.

Ruth is shaking her head up and down. I think the states and both OAS and particularly CRCPD will want to get into a number of these because they are actually more closely aligned with some of the work that IAEA will be doing.

We, in fact, thought that Paul Schmitt might be able to attend this, and when Paul was not able to, that's why we defaulted back on a relatively short

2.4

1	time frame. We made the decision that this was the kind
2	of meeting developing actions where the U.S. simply
3	couldn't afford not to have some representation or to
4	make sure that they didn't move in a direction which
5	would get to be prescriptive and might have ramifications
6	coming back for our particular programs.
7	So there are going to be a lot of ongoing
8	opportunities. If this action plan is anything like some
9	of the other action plans that the International Atomic
10	Energy Agency has, it will assume a life of its own for
11	at least some period of time.
12	It will likely go through some updates and
13	revisions over the next two years as things start to be
14	accomplished and they start to look to what additional
15	things might be done. I would expect that they would
16	want to have a follow-up international conference to take
17	a look at progress that's being made.
18	No such thing has been scheduled, but I
19	would guess by 2004 or so they might be looking to have
20	another conference to assess the activities.
21	And with that I would be glad to entertain
22	questions or you might want to go with this other area of
23	activities.
24	Dr. Nag.
25	DR. NAG: I've been involved with the IAEA

consulting for the last about eight years, and I have 1 been involved in the developing section on the research 2 3 program, and one of the things they have done is taking 4 developing countries and pairing them with a number of 5 developed countries. 6 And we formulate what are the protocols that 7 can be used in developing countries to treat cancers, and 8 we develop the guidelines and we sort of supervise the 9 treatment there. 10 I think that's a very good exchange. 11 give some of the brain power, and they have different problems and different kinds of basic populations, and 12 13 you know, we help develop those. 14 We also do guidelines for things like guidelines for developing countries, for HDR. 15 places are now using HDR, but they don't know how to use 16 17 them, and we had to develop quidelines for them. And we have also done publications to 18 19 standardize brachytherapy in developing countries. So 20 those are things that have been ongoing now for the last 21 eight years. DR. COOL: Yes, and this action plan will, 22 23 I think, continue those, maybe give them a little bit 2.4 higher hat in terms of some visibility and focus and

trying to move forward. A number of the things related

to education, training, the best practices, guidelines, 1 a number of those things are the key components that 2 3 relate to this action plan and trying to get those sorts 4 of things available for use. There was a recognition in the conference, 5 6 and I think it's also reflected in what Dr. Nag just 7 said, for some of these folks, I think it's fair to say they don't have clue or they have very little clue. 8 9 They're out there on their own. And that which we take for granted in terms 10 11 of being able to interact with peers, understand where 12 best practices are going doesn't exist. They don't have 13 an ongoing access to that kind of information. 14 So the first step and one of the themes of 15 this whole thing was can we arrange a system which will 16 enable anyone to make progress from where they are, and 17 some of the tools which now we might not want to have at 18 a very forceful level are, in fact, necessary to have 19 perhaps a higher degree of force within a country that's 20 just starting in order to be able to leverage the initial 21 steps of the process. CHAIRMAN CERQUEIRA: Don, I saw the minutes 22 23 of the meeting and then some subsequent drafted minutes,

and PET got singled out quite a bit. There was quit an

emphasis on PET.

2.4

But if you look at sort of penetration and 1 usage, it's relatively small. Did you get some idea as 2 to why PET was sort of identified as an area of concern 3 4 or need to monitor? 5 DR. COOL: It was viewed as something that's 6 emerging. At the risk of sounding just a little bit 7 silly, it was also a pet of several of the folks who were 8 there. (Laughter.) 9 10 DR. COOL: As with all meetings of this 11 type, the individual specialties of some of the representatives and their particular concerns tended to 12 13 show up in some of the discussions and activities. 14 So one of the things that I have found interesting in a variety of international forums that I 15 have had the opportunity to participate in is the need to 16 17 actually sit back and literally change your hat, to take a view with regard to where things need to go and the 18 19 things that are necessary in an international context, 20 which may be different from the local contexts. And the degree to which the committee of the 21 22 whole was doing that varied a bit across the week, as you 23 might expect. So there was some discussions of all sorts 2.4 of modalities.

There was a great deal of focus on medical

physicists and the need to get more medical physicists, 1 and quite a bit of actually side bar discussion on the 2 fact that a number of the legislation and other 3 4 activities don't allow a medical physicist to be 5 recognized. 6 And so none of the regulatory authorities 7 believe that a medical physicist is necessary, and they just draw a little arrow, and somewhere they're over 8 9 here, and how to get a recognition of the importance of 10 some of the components, again, that we more or less take 11 for granted as being important to a team, which for 12 various legal or other reasons haven't got that same 13 degree of recognition some other places. 14 CHAIRMAN CERQUEIRA: Jeffrey. 15 DR. WILLIAMSON: Yeah, well, it really is challenging. I, too, have been involved in the IAEA 16 17 activities, and they're really trying to not just create 18 a regulatory system, but they're trying to leverage and 19 create basic quality assurance standards --20 DR. COOL: Precisely. -- and standards of DR. WILLIAMSON: 21 22 practice. And you know, in this country standards of 23 2.4 practice arose independently and the regulatory system

came later as, you know, it was felt necessary to have

oversight as a consequence of various instances. So they really have a different challenge.

DR. COOL: Yeah, and just to reinforce that point, something that I was attempting to allude to, but you've made it a little bit more clear. A lot of the standards and practices, standards of practice and guidelines which we have at a level of the users in the professional societies in which the NRC and others deliberately stay out of so that you can continue to move your best practices, in the international context at this point need a much higher level.

They're actually talking about them in terms of the regulator and others in order to get the initial step of even getting anything in place. It's a bit jarring, except for the recognition of the situations which they're dealing with.

And part of what I was attempting to do was to make sure that in the action plan and in the activities that the descriptions and the flexibility was such that that couldn't in some way inadvertently come back to haunt us. And I think it's a challenge for all of us as we participate in some of the various forums and consultants and otherwise just to continue to promote that message and help everyone make progress.

CHAIRMAN CERQUEIRA: Other questions for Dr.

2.4

1	Cool?
2	(No response.)
3	CHAIRMAN CERQUEIRA: Well, if not, thank you
4	for sharing your information with us.
5	DR. COOL: I appreciate the opportunity, and
6	as I said, I do hope to circulate some version of this.
7	If I don't have a final version within a few days, I'm
8	going to put out the report with the version that I got,
9	and at that point we will make sure that individual
10	members of the Committees have a copy of that so that you
11	can see where it is in its drafty state, unapproved by
12	the Board and heaven only knows.
13	CHAIRMAN CERQUEIRA: Thank you.
14	Now, is
15	MR. HICKEY: I'm not sure if Mr. Lohaus is
16	going to be here on time, but Dr. Ayers is ready to
17	proceed in the meantime in any case.
18	CHAIRMAN CERQUEIRA: Good. Now, is anyone
19	aware of any groups that were coming to this meeting
20	specifically to hear the information on the Board
21	recognition who may be disadvantaged by having to switch
22	the time?
23	PARTICIPANT: Bill Malagan (phonetic) was
24	going to be here about 11:15.
25	CHAIRMAN CERQUEIRA: Yeah. I think he can

1	get enough feedback.
2	DR. AYERS: Good morning. I managed to get
3	my slides down.
4	Just to preface my presentation, my
5	presentation and what I'm going to talk about, the
6	Boards, is all predicated on the current draft new Part
7	35, not any dealing with any of the discussions which I
8	think were useful, and you're heading in the proper
9	directions on modifying the rule language, but for what
10	I have to work with now is what we have for the current
11	rule language.
12	CHAIRMAN CERQUEIRA: And, Bob, I think
13	realistically that's what we're going to deal with
14	because all that we've talked about with these other
15	changes would require a rulemaking, and that's going to
16	take some time.
17	DR. AYERS: Yeah.
18	CHAIRMAN CERQUEIRA: Is that
19	DR. AYERS: Well, if I can have the next
20	slide, the Boards, just to review, that have applied in
21	one form or another for recognition are the nuclear
22	medicine, pharmaceutical specialties, medical physics,
23	health physics, Board of Radiology, and in the next slide
24	several others.
25	If I can have the next slide, please.

The Board of Nuclear Medicine Radiology, 1 Science and Nuclear Medicine, and the Certification Board 2 3 of Nuclear Cardiology. Next slide. 4 The American Board of Medical Physics 5 6 applied for recognition under 3551(a), which is authorize 7 medical physicist, and we're all aware of the problems with the full recognition is not possible under the Board 8 9 system because of the specific requirements for training 10 in each of the modalities. 11 But it certainly does look like partial recognition may be possible to work with the Board, and 12 13 what one or more of the components does the Board have 14 sufficient training in that could grant recognition? And the recognized physicist could come in 15 as has been discussed previously with specific training 16 17 and experience, say, on the gamma knife for a teletherapy unit or a vendor's training on the remote after loader 18 19 and add those authorizations. 20 CHAIRMAN CERQUEIRA: Bob, just how would that be done? How would partial recognition be done? 21 DR. AYERS: Well, we're in the process of 22 23 preparing letters to the Board, and we ask -- and the 2.4 letter, the draft letter in this case says, "Well, okay.

Come back and tell us which one of these components does

1	your current Board recognition process encompass."
2	And if they can show us that it encompasses
3	one or two or more, we should be able to work towards
4	granting the recognition for 35, 400 manual brachytherapy
5	plus teletherapy, whatever the combination might be.
6	DR. WILLIAMSON: So when you say partial
7	recognition you mean four more modalities.
8	DR. AYERS: For modality based recognition,
9	yes.
10	DR. WILLIAMSON: Modality based recognition.
11	Well.
12	CHAIRMAN CERQUEIRA: Jeffrey, does that
13	answer some of the issues that we've brought up and how
14	could
15	DR. WILLIAMSON: Not really. I mean, I'm
16	not sure that there is is there a requirement for an
17	authorized medical physicist in 35.400 at all, except for
18	decay of Strontium-90?
19	DR. AYERS: That's one of the requirements.
20	DR. WILLIAMSON: That's the only
21	requirement, right?
22	DR. AYERS: I'd have to review it in a
23	little more detail to answer your question.
24	DR. WILLIAMSON: But I don't believe that
25	they will be able to comply with any of those three.

1	DR. AYERS: Okay. Well, I mean, it's an
2	option if they are, and the letter is starting the
3	process of going back and forth to find out where we are.
4	DR. WILLIAMSON: I, frankly, think a more
5	fruitful approach or an additional approach you might
6	consider is to give them credit for if someone has this
7	ABMP certification, that that automatically takes care of
8	the various years of experience and is evidence for
9	having an appropriate degree.
10	DR. AYERS: Well, that's what you're talking
11	about in the rulemaking space.
12	DR. WILLIAMSON: No, I was talking about in
13	guidance space. You could use it as a criterion for
14	determining who meets the basic training and experience
15	requirements and, you know, hours of experience per se,
16	and having the degree. You could accept that.
17	DR. AYERS: Well, that's another form of
18	partial recognition, yeah. We can
19	DR. WILLIAMSON: That's a form of partial
20	recognition.
21	DR. AYERS: Yeah, we could say four plus
22	DR. WILLIAMSON: I believe you could
23	implement in guidance space to preserve some recognition
24	of the Board's certification process, and then you would
25	have to ask on top of this. You'd have to have

1	reasonable criteria for supplementary training in these
2	three modalities.
3	DR. AYERS: Yeah, that's a form of the
4	partial recognition. The partial recognition imbeds in
5	it none of the specific modalities, but it says it meets
6	all of the training experience requirements, except the
7	specific device.
8	DR. WILLIAMSON: Yes.
9	DR. AYERS: The material which and that's
10	another four. This is what the process that we can work
11	on. That's one direction we can go.
12	CHAIRMAN CERQUEIRA: Dr. Nag.
13	DR. NAG: Yeah. One important thing, in
14	your impartial recognition, you have to give the credit
15	that when you have gone through a Board, you may not have
16	specifically done remote after load (phonetic), that
17	you're not getting your credit for after load, but you
18	got the 500 hours separately for the
19	DR. AYERS: Yeah, that's what we were
20	talking about, yeah. That's a possibility, yeah. The
21	process is on hold now to start the information exchange
22	between us and the Board until the rule's status is
23	clarified.
24	CHAIRMAN CERQUEIRA: Bob, I kind of hate to
25	have brought you up here and now our other speaker is

1	here. I think this is important and we should come back
2	to it and see if it could help us out of our dilemma to
3	some extent, but, John, do you think we should switch
4	gears here?
5	MR. HICKEY: Yeah. Mr. Lohaus is here. So
6	I think we should proceed.
7	DR. AYERS: And I just started.
8	MR. HICKEY: And Bob can come back to his
9	presentation later.
10	DR. AYERS: Right. I just started. I can
11	pick it up again after lunch.
12	CHAIRMAN CERQUEIRA: A few more
13	opportunities to skewer him. Okay.
14	DR. AYERS: No problem.
15	(Laughter.)
16	CHAIRMAN CERQUEIRA: Thanks for your
17	tolerance of the Committee here, Bob.
18	MR. HICKEY: I'd like to introduce Mr. Paul
19	Lohaus, the Director of the Office of State and Tribal
20	Program, and Mr. James Myers from the same office.
21	MR. LOHAUS: Good morning.
22	CHAIRMAN CERQUEIRA: Welcome.
23	MR. LOHAUS: I welcome the opportunity to
24	meet with you.
25	Let me recognize Jim Myers. I understand

you wanted to talk about the National Materials Program and current status and where we're going. Jim was cochair for the National Materials Program working group, along with Kathy Allen, who at that time was chair for the Organization of Agreement States.

But maybe by way of background just a couple of introductory remarks. Part of the genesis for the National Materials Program really comes out of the growth in the number of agreement states. If you look at the number of states that were projected, we're at 32 today. We're projected to go to 35 by FY 2004, and the proportion of licensees that the agreement states had responsibility for, really they're going to have about 75 percent of the total number of licensees in the country.

And in recognition of that, what the Commission did is directed the establishment of working group to look at options in terms of how should we function in the future relative to our program, and that's where the term for the National Materials Program comes from, relative to both NRC and the agreement states, given this continued shift in the program with the states having the larger proportion of licensees.

And the process that was used was the working group was set up of NRC and agreement state staff, and they worked for about a year and a half and

2.4

developed a report which was provided to the Commission 1 in May of last year, and we brought with us copies of 2 3 that Commission paper. You may have copies. If not, we brought 4 5 copies. So if you'd like you can take a copy with you. 6 CHAIRMAN CERQUEIRA: Yeah, it would be good 7 to give it out to the Commission. MR. LOHAUS: And basically what the working 8 9 group did is examined a number of options, and they range 10 from some rather what I would term drastic changes in the 11 program whereby you would shift the program back to NRC 12 complete responsibility for 13 jurisdiction over all licensees in all states to an 14 option where all states would take over that authority, 15 with the exception of a few categories of licensees where at least by current law NRC would need to maintain 16 17 regulatory jurisdiction. For example, federal facilities where 18 19 jurisdiction resides with the federal government, as 20 opposed to the state government. There were a number of middle options, and 21 22 the option that the working group settled on and is 23 really their recommendation is what's called an alliance 2.4 option, and basically the alliance option is a program

structure that's very reflective of the current evolution

of the program today.

2.4

In other words, what it reflects is a sharing of regulatory responsibilities among the states and NRC. There would be a process of using centers of expertise, for example; a process of using working groups, coalitions of technical staff among the agreement states and NRC to help develop regulatory products that are needed to support the program, and those products could then be used by either NRC or the agreement states.

It sort of pushed the envelope on this concept, but at the same time, that option is reflective of current evolution of the program where there's a lot of activity and a lot of sharing in utilization of expertise within both the states and within NRC staff to address common problems, to identify solutions to those problems, and help, you know, basically bring the best expertise and the best talent to addressing those problems.

There's a couple of questions or big issues when you look at this that we're going to be examining in some follow-on work, and one of these questions is: will the states be able to take on increased responsibility and provide the resources that would be necessary under this alliance type concept, you know, if we were to move in that direction, and produce a product on schedule that

could be used by the states and also by NRC?

2.4

And at the same time there's sort of a question on the other side, and that is, you know, will NRC be able to use a product that's developed by the states and fold that into its regulatory program without a tremendous amount of additional staff effort. In other words, there would be some savings and reduction in the FTE loading that NRC would experience in terms of development of the regulatory infrastructure and supporting products that it would need for its program.

So what we have under preparation today is a second paper for consideration by the Commission, which would identify what I would term some pilot programs to provide further opportunity for the NRC and the state staff to work together, to help provide some of the demonstrations that are, I think, necessary to help support the concepts and the thinking that's reflected in the working group report and their concept of the alliance program.

And some of these pilots could be very simple. For example, developing a new guidance document or taking an existing guidance document and maintaining that document up to date, in other words, insuring that it meets current practice, reflects current state of the art, et cetera.

Other cases it may be that there may be a 1 rule area that's identified that's in need of attention. 2 3 That may be an item that could be addressed through a 4 working group and a rule package prepared that could be 5 used both by the States and by NRC to address that 6 particular rule area. 7 looking number of But we're at а different --8 DR. WILLIAMSON: I'm sorry. Could you make 9 10 clear what alliance is as a regulatory structure and how 11 it differs from the current overall regulatory structure 12 with respect to the domain of NRC, whether it's NARM or 13 byproduct material? It's not clear at all what you're 14 saying. MR. LOHAUS: Well, I think some of the 15 points you mentioned are some of the issues that would 16 17 have to be addressed as a part of this program. 18 Presently, as you're aware, NRC does not have regulatory 19 jurisdiction over NARM materials. 20 The states do. This is an area that the Commission did ask the staff to prepare some proposals, 21 22 which are with the Commission for consideration. But 23 this is an issue that, you know, when I spoke earlier 2.4 saying the alliance sort of represents the current

evolution of the program, but there are additional parts

1	to that that would need to be addressed in the future.
2	And this could certainly be one of the areas
3	in terms of whether NRC should assert and maintain
4	regulatory jurisdiction over NARM as a part of the
5	alliance process for those states where we have
6	regulatory jurisdiction or whether we would continue with
7	the current situation. But I think those are some of the
8	issues.
9	What I might do is maybe ask Jim if he could
10	maybe talk through in more detail some of the thing.
11	CHAIRMAN CERQUEIRA: People are getting kind
12	of anxious and raising their hands, and I kind of hate to
13	defer questions.
14	MR. LOHAUS: Okay.
15	CHAIRMAN CERQUEIRA: So maybe we could let
16	people ask questions to the specific things that you've
17	identified so far.
18	MR. LOHAUS: Sure.
19	CHAIRMAN CERQUEIRA: I mean, how many of you
20	are aware of this ongoing process?
21	(Show of hands.)
22	CHAIRMAN CERQUEIRA: So really it was only
23	Ruth, and I think the rest of us are a little bit
24	DR. NAG: In the dark.
25	CHAIRMAN CERQUEIRA: in the dark about

this, and I think it would be important here --1 Excuse me. 2 MR. HICKEY: Mr. Lieto had 3 requested a presentation on this topic. CHAIRMAN CERQUEIRA: Which I think is very 4 5 important. I mean, Ralph is asking all of the right 6 questions, you know. Just as a new member, I think he's 7 -- and I think this is very important and really impacts on a lot of things we've done with the Part 35 revision. 8 9 But why don't we take questions now and then 10 we could -- so Dr. Nag. 11 DR. NAG: Yeah. How would the role of the 12 ACMUI play in this National Materials Program? We are 13 giving our input to the NRC. How would that impact the 14 National Materials Program? And the second thing is how would this 15 National Materials Program help to insure that there is 16 17 some similarity between the different states. 18 example, you know, the rule in one state may be quite 19 different from the rule in another state, and doctors go 20 from one state to the other, and you know, that makes some problems. 21 MR. LOHAUS: I think both of the items you 22 23 raise are very good questions and very good issues and 2.4 are things that would need to be addressed and explored 25 as a part of future work.

Let me back up and make a very clear 1 statement. There is no preferred option that has been 2 identified at this point in time. The report of the 3 4 working group was provided to the Commission for 5 consideration, and we are preparing the second paper I 6 mentioned, but I want to make a point that, quote, the 7 alliance option which was the preferred option 8 recommended by the working group, that the agency and the 9 Commission has made no decision yet relative to a 10 preferred option. 11 But in terms of the Advisory Committee, I 12 think you raise a good point. The Advisory Committee 13 would certainly continue, in my judgment, in my view, to 14 advise the Commission as it has in the past, but if we were to head more towards an alliance structure, there 15 may be additional advisory considerations that the 16 17 Committee could play in terms of the broader National Materials Program alliance structure. 18 19 CHAIRMAN CERQUEIRA: So it hasn't really 20 been considered. I quess one question I would ask you is it 21 22 seems a little bit self-serving that the NRC hires the 23 states to come up with a plan and basically the 2.4 conclusion is make no change at all.

If we go back to the Institute of Medicine

review, which the NRC commissioned and which was released 1 in what, '95 and '96, they clearly made the point that it 2 3 should all go to the states, which I guess if we look at 4 page 1 in the very back, description of options and 5 assumptions for resource estimates, it would really be 6 the independent state option. 7 Why was that not, you know -- I mean, based 8 on that report, they felt that that was the best option, 9 to basically minimize the federal regulations and put it 10 at the state level, which 95 percent of all the radiation 11 that's used, ionizing radiation, is state regulated. MR. LOHAUS: What I might do in this case is 12 13 defer to Jim as co-chair for the working group. I mean, 14 they went through a lot of discussions, a lot of deliberations, obtained a lot of feedback in, I think, 15 their report, and their recommendation in that report is 16 17 reflective of the views of the working group, which was 18 both NRC and agreement state staff, as well as the 19 various input that they received. 20 CHAIRMAN CERQUEIRA: What about the stakeholders, the physicians? Were they involved in any 21 22 way or was their input sought? 23 MR. LOHAUS: Jim? 2.4 MR. MYERS: Yes. Dr. Cerqueira, good to see 25 you again.

CHAIRMAN CERQUEIRA: Yes.

2.4

MR. MYERS: It's been a while.

Let me just kind of paint a little bit of what the vision of this is, with the understanding that the Commission has not made a decision about alliance structure or any of the other structures that were proposed.

The working group wrestled with, and I think quite openly came to the table and sat down and said, "Well, okay. What's wrong and what do we need to do to fix it, given the scope of the SECY paper that the Commission asked us to look at some things?"

The issue is, and I think that initially almost everybody came to the table and said, "Well, heck, you know. Maybe this whole thing just needs to be thrown out and we'll start again."

But I think through the process of discussions, of laying out some very good objectives for the working group to achieve, to try to do it in a rational fashion, what we really came up with is that what we have today is a pretty good system. It's not perfect, and there's maybe no expectation that it would ever be perfect, but there's certainly some things that we can do that would in the context of what the Commission asked us to do, would be to improve the

process and basically to seek more input and advice and perhaps even using products that are developed by the states to do, you know, certain things in medical or it could be GLs or whatever, to use those kinds of things and incorporating them more into a national program than they are now.

And maybe what comes to mind is that -- I don't know. Since everybody is here and didn't see this, but the FDA approved a new drug called Zevulin today. That's just out. That uses Indium-111 and it used Yittrium-90, and it's basically a therapy drug.

But if we used this as an example, you know, you can envision today that there would be like 33 different regulatory agencies that would approach how to license or regulate this particular therapy drug, and what we would say is that maybe we need to have, for lack of better terms, more of the working group approach, where we get somebody who has some expertise in this maybe -- I'll say the State of Texas, for example, maybe the State of Georgia or Rhode Island, whoever has worked on this -- and some NRC folks together to come up with a template or a concept of how to regulate this and what would be required.

That would then be subsumed by the national program, meaning all of those organizations. So we don't

2.4

have to reinvent it 33 times. We would take something 1 that's good, modify it for the individual use of the 2 state or the NRC slightly, and then be able to use it 3 4 right away. 5 And that was the idea of trying to get more 6 input from the states and do more of that. Clearly, the 7 working group recognized that perhaps it's not totally efficient to drop NRC out entirely, but clearly the role 8 9 seems to be diminishing, and you can look at the 10 different scenarios down here. 11 Even if you had no other NRC licenses except those in the military and the VA and some others, it's 12 13 still a tremendous cost to the agency, but it doesn't 14 solve the questions that the Commission asked us to look at, is what do we do now that we don't have the 15 expertise. How do we regulate medical if we don't have 16 17 any hospitals and we don't have that emerging technology like Zevulin or stuff to deal with? 18 19 So that's kind of how it came about, and the 20 report is kind of lengthy, but there is an executive summary to it, and this report here that we just handed 21 22 out, I think, also kind of characterizes a lot of that 23 thinking. 2.4 CHAIRMAN CERQUEIRA: Jeff? DR. WILLIAMSON: Yeah, well, it sounds a lot 25

like the Institute of Medicine report in terms of the layout of your options, and certainly that was a highly controversial report and probably one reason it was discarded by the Commission and not followed, was that the regulated community fragmented in terms of what option they supported.

This Committee extensively reviewed that report and looked at the options, and you know, the 50 independent state regulatory associations, that was rejected by this Committee out of concern that there would be absolutely no uniformity in any of the basic regulatory structures or training and experience requirements and so on that would really hamper the practice of medicine.

So, you know, I think that would remain a concern probably of this group if we came up with it again, is how can uniformity be preserved, given this tendency for the states to become agreement states.

MR. MYERS: If I can respond to that, on page 2 of the handout that we did, about the middle of the page, there's some bullets there. These are essentially kind of the evaluation or they are actually the evaluation criteria that the working group used, obviously, protecting health and safety, optimizing resources of federal, state, professional, and industrial

2.4

organizations, at the same time, we need to account for individual needs and abilities of agencies, promoting consensus, promoting an exchange of information, and you know, harmonizing regulatory approaches.

These were all factors that we looked at, and this is the way it breaks out if you use a decision matrix and use these as part of your evaluation criteria. You end up with the concept of the alliance as being the one that is the most favorable in terms of achieving those some six or seven objectives.

And I think that addresses your issue about fragmentation and other things. Clearly there has to be a partnership, I think is what the working group was saying; is that somehow it has to come together so that you do talk, do share information, and you have good information exchange and a number of other things, and we're to have a harmonious program nationally.

MR. LOHAUS: You know, the question of national harmony, I mean, we use the term compatibility. That's in our statutes, but that's an issue that has been with the agreement state program from its inception and will continue to be with us in the future, and I think that there was focus within the working group, and it's reflected in the criteria that Jim mentioned on this question, that you need to maintain a degree of

2.4

flexibility so that individual programs can address legislative direction and other aspects.

But at the same time, there needs to be a degree of consistency and harmony so that there is not disruption, there's not major differences between individual states and those under NRC regulatory jurisdiction.

And we've tried to address this in the Commission's adequacy and compatibility policy and our implementing procedures, but it will continue to be an issue. There will not be complete uniformity and agreement among all the states from my experience in the program. You will see differences, but my goal, and I think the goal of this agency is to insure that there is a level of harmony and coherence and consistency within the programs across the nation, which we accomplish through our compatibility part of the program.

The two aspects are the adequacy component and the compatibility component, and what I've seen on the part of some of the working groups is that in sharing in the process of developing the regulatory product, irregardless of what it is, but there's greater agreement on the product and greater agreement on wanting to move forward and implement that product in a consistent manner.

2.4

And that's part of the concept, I think, 1 that is reflected in the alliance concept, is that using 2 3 a working group process, you would hopefully end up with 4 a product where there is agreement and there isn't wide 5 variation in terms of how that product would be 6 implemented. 7 So there is good consistency, and the 8 regulated community has assurance that it's going to be 9 predictable, consistent, and understandable. And I think 10 that's a goal not only of our program, but I think of the states as well. 11 12 But at the same time, from my experience you 13 will see some differences, and there's not going to be 14 complete consensus in all cases. And to me it's a 15 strength that we see in the program because given some of the differences in view and given different approaches, 16 17 that considering those and reflecting those actually 18 results in a better product that's going to serve all of 19 us in a better way. 20 And that's one of the strengths that I see in that program. 21 22 CHAIRMAN CERQUEIRA: Dr. Nag. DR. NAG: Yeah. What would the policy be of 23 2.4 the Materials Program? Would it have authority over the

states and be, you know, more like a coordinating body

1	among the various groups?
2	MR. LOHAUS: Are you speaking with respect
3	to NRC or the alliance itself?
4	DR. NAG: The alliance.
5	MR. LOHAUS: See, the NRC, over oversight
6	responsibility in our oversight program would not change.
7	When you look at the alliance option, there's a very
8	clear role that NRC would continue with the integrated
9	materials performance evaluation program, the current
10	program we use for review of both the state and our
11	regional materials programs.
12	So NRC would continue with its oversight
13	program, and that responsibility would not change. So,
14	you know, if there are cases where there are both issues
15	with respect to the adequacy in a program and issues with
16	respect to compatibility, we would be able to address
17	those through our review program.
18	DR. NAG: Right, but is the National
19	Materials Program a separate entity, a separate body? If
20	it is, what is the authority between the National
21	Materials Program, the NRC, and the different states?
22	I'm somewhat confused. I might be
23	MR. LOHAUS: Again, you raise to me a very
24	good issue with respect to the alliance, and I'm going to
25	ask Jim to also comment here, but part of what you do

come away with when you do think about this is you think 1 of the alliance as a separate entity, and it may not be 2 3 a wholly identified separate entity as much as a 4 structure or process structure in which the NRC and the states will function in the future. 5 6 And, on one hand, you could say, well, we're 7 going to have an alliance organization, and I've had 8 difficulty in my mind trying to understand if there was, 9 quote, an alliance organization. What is that? What's 10 it made up of? What does it do? Who's it responsible for, et cetera? 11 But, on the other hand, I can also look at 12 13 it from the standpoint that it's a process relating to 14 how NRC and the states will interact and function in the 15 future, and as such it's not a clearly identifiable 16 entity. 17 But, Jim, I know you all wrestled with this, and maybe you can help add some perspective on this. 18 19 CHAIRMAN CERQUEIRA: How is it different 20 than what we're doing now, I guess, is one question that can be asked. 21 Jim? 22 23 MR. TERAO: Yeah, this is a real, real tough 2.4 thing to kind of characterize, but it is more of a

process than a physical entity. That's for sure. It's

a process that's made up of the different organizations, and that would include ACMUI. It would include other standard setting organizations. They are kind of plug and play. As they need to come in and interface into the alliance process or into a rulemaking process, we would expect that that would happen.

I think what we see is what's different about this is the fact that as the current system exists, there are conflicts and there are stresses and there are demands that are placed upon all of the states and on NRC that are many times conflicting, and they consume a lot of resources, either, you know, money or it could be energy, a lot of different things.

And through the process of like the conference where we have some committees that work and those are well established, the OAS was another organization the Commission asked us to integrate into this working group; in looking at the whole thing, what we saw was that, well, the process itself that we use today really isn't terrible. It just isn't, but there are some conflicts with it, and there certainly seems to be a better way of doing business.

And how to do that would be perhaps to come together. This is in theoretical space, is that at some national meeting or it could even be a virtual meeting as

2.4

1 far as we were concerned; is that you would establish some national priorities, maybe getting some regulatory 2 3 guidance out, and how to regulate Zevulin, for example 4 would be a national priority at this point in time. And we would bring together what we call 5 6 centers of expertise to work on that issue, and then they 7 would, again, share that with the alliance, and for 8 everybody to use versus individuals going out and doing 9 the work, which seemed to be counterproductive. 10 CHAIRMAN CERQUEIRA: I think we all 11 understand the concept and the potential for doing it, 12 but I guess just in terms of being pragmatic, I'm just 13 not quite certain what new entity or structure you're 14 going to create that would create this harmony, compatibility. 15 We've had multiple discussions here amongst 16 17 the group just in terms of training and experience requirements and how the difficulties we're going to have 18 19 once those get implemented and this three year lag 20 period. But I think Ruth has had her hand up, Niki, 21 22 and then Jeff always has a question. So --23 MS. McBURNEY: Just coming from a stark 2.4 regulatory perspective, the way that I see this occurring

is it's going to have a greater role and responsibility

for the state, for the agreement states in that the 1 states are going to have to put forth more resources. 2 3 An example of that was that there were two 4 state people on the Part 35 working group, and they had 5 to commit a lot of time away from their regular jobs to 6 do that, but the states are willing to do that and also 7 a greater role in setting the priorities for rulemaking. 8 9 For example, several years ago the State of 10 decided that the training of industrial Texas radiographers was a key priority, and we went ahead and 11 12 set up a certification program. And several years later 13 then the Nuclear Regulatory Commission adopted similar 14 regulations. So it is now a national program. 15 So the way I see this National Materials Program working is that the states, along with the 16 17 Nuclear Regulatory Commission, would set some national priorities for rules and procedures and so forth, and 18 19 then establish the working groups to work together to 20 come up with that so that everybody is not trying to reinvent the wheel, that we're not having to commit a lot 21 22 of resources just to do it in our own state, that it can 23 be more of a national program. 2.4 CHAIRMAN CERQUEIRA: Again, I think the

concept is commendable, but just the structure is a

1	little bit unclear.
2	Maybe, Niki, you were having a comment?
3	MS. HOBSON: Well, that's precisely my
4	question. Could you draw us an organization chart and
5	show how this thing is going to work?
6	DR. WILLIAMSON: Let me just express my
7	question, which is relevant. Could you describe the
8	potential statutory changes that would have to be made to
9	implement the alliance? Maybe that would help us
10	understand.
11	MR. LOHAUS: Okay. I'll answer the
12	questions in the order.
13	CHAIRMAN CERQUEIRA: In two minutes.
14	MR. LOHAUS: One is I don't think we can
15	provide an organization chart for the, quote, National
16	Materials Program or for the recommended alliance option
17	at this point in time because I don't think they're
18	sufficiently clearly defined.
19	But what we need is a recognition and a
20	sensitivity, and it's reflected in your comments and your
21	concerns in the issues you're raising. And you are
22	raising very good questions and very good issues, that as
23	we move forward, there needs to be a recognition that NRC
24	shouldered and really, you know, NRC licensees, given our

fee system, shouldered, and the lion's share of the

regulatory cost, if I can use that term, for maintaining the infrastructure of supporting regulations and standards.

And from an equity and fairness standpoint, if you look at this from the standpoint of proportion of licensees, a question is: given that the states are regulating about 70 to 75 percent of the total licensees, should they play a greater role and responsibility in the resource costs for maintaining that infrastructure?

And along with that goes the responsibility to maintain consistency and coherence, and that's the issue that the Commission framed for the working group, and that's the issue that is still there, that we're continuing to wrestle with, and it's a National Materials Program issue.

And you can look at different approaches on how we might want to address that. You can look at legislative issues. For example, one legislative issue could very well be with respect to whether NRC should assert broader regulatory jurisdiction over naturally occurring in accelerator produced materials, for example, or whether it should be limited to all accelerator produce materials or just those that are used in medical applications.

But I think, Jim, you may want to comment

2.4

	232
1	here.
2	I think the sense of the working group was
3	that there were probably only two areas where legislation
4	might be required, and that really depended on where you
5	saw the National Materials Program headed.
6	One related to the regulatory jurisdiction
7	over norm, and the second related to the question of
8	whether jurisdiction over federal facilities, which is
9	sort of a reserved federal authority, whether there
10	should be some consideration of either changing that or
11	providing a mechanism where the states could pick up
12	CHAIRMAN CERQUEIRA: So those are the two
13	areas, but maybe
14	MR. LOHAUS: Jim, did you
15	CHAIRMAN CERQUEIRA: I want to try to wrap
16	this up a little bit, maybe get a few questions from the
17	Committee, and then see if the Committee is going to
18	recommend some action on this.
19	Ralph, I want to thank you for bringing this
20	to our attention.
21	MR. LIETO: Well, you know, everybody is
22	trying to get a handle on, you know, physically what this
23	is, and I don't know if this would be an appropriate

Would this be sort of a concept that would

analogy, and I would ask this to Jim.

24

1	be similar to CRCPD except you've got a federal? It's
2	sort of a federal type of a situation with the Conference
3	of
4	CHAIRMAN CERQUEIRA: CRCPD?
5	MR. LIETO: CRCPD, excuse me. And
6	CHAIRMAN CERQUEIRA: No, no, no. What does
7	it
8	MR. LIETO: Conference of Radiation Control
9	Program Directors.
10	DR. NAG: What do they do?
11	MR. LIETO: Well, that's sort of a national
12	group of all the state radiation control program
13	directors that meet. I'm going to say it's more a
14	professional group rather than a regulatory group, but
15	they come out with national recommendations of state
16	regulations, and so forth.
17	And it sounds like this is sort of analogous
18	to that, except one of the partners in this group is the
19	federal agency, the NRC. And would that be an
20	appropriate analogy, taking into account that every
21	analogy has its weaknesses, but would that be some way so
22	that the Committee could get a handle on what this
23	working group is intended to try to develop?
24	MR. MYERS: I think it's what we were
25	envisioning as something that's Conference-like. Okay?

And the difference is that Conference has, for good reasons, has its hands in a lot of different things, and it's a very complex organization. What I think has to happen with it is that the concept would have to be broadened somewhat so that you get more of a national regulatory perspective, again, involving all of the federal players, whether it's FDA, NRC and others that have an interest in radiation protection, to bring them into this kind of a partnership or alliance concept basically to kind of set out national priorities and then to follow up on the accomplishment of those tasks associated with the priorities.

We didn't envision that we would create another NRC-like structure of some 3,000 people or so to kind of oversee all of that, but it would be basically made up of perhaps parties who had special expertise. It could be volunteers on the part of the states or other NRC employees to work on that at the direction of their organizations, to kind of ride herd on that process at least initially.

CHAIRMAN CERQUEIRA: I guess, you know, part of the discomfort that I'm sort of sensing from the Committee is that, you know, these are all very nice concepts, abstract, organizational structures, but we don't see enough of the framework on how to best

2.4

1	structure it.
2	And I guess, you know, I'd sort of like to
3	find out from the Committee. I mean, is this something
4	that we should have been involved in? Is this something
5	that we should be involved in in the future?
6	And certainly as a user, I guess the
7	question I would ask is how is this going to make my life
8	any different? Is it going to relieve all of this
9	regulatory burden that I experience down at Georgetown
10	every day?
11	If it does, I'm all for it. But if it
12	doesn't, you know, big government is great, but if it's
13	not going to help me, I'm not so sure.
14	So what's the sense of the Committee?
15	Should we have been involved?
16	MR. LIETO: Well, one reason I brought this
17	up is because it talked about stakeholder input.
18	CHAIRMAN CERQUEIRA: Right.
19	MR. LIETO: And it wasn't clear to me who
20	the stakeholders were, and it appears now it was just the
21	states.
22	CHAIRMAN CERQUEIRA: And the NRC.
23	DR. NAG: And the NRC.
24	PARTICIPANTS: No.
25	MR. LIETO: Well, I mean, they were not

1	MS. WAGNER SCHWARZ: But the users are not?
2	MR. LOHAUS: I'd like to maybe separately
3	have Jim respond to the opportunity for stakeholder input
4	because there was a lot of opportunity.
5	CHAIRMAN CERQUEIRA: Sure. Can you describe
6	that perhaps, Jim?
7	MR. LOHAUS: Please, yes.
8	MR. MYERS: Yes. We are very concerned
9	about stakeholder input, and everything we did was
10	totally public. It was all announced. It was all there.
11	CHAIRMAN CERQUEIRA: Yet the Committee
12	didn't know about it, and we are representing
13	professional medical societies.
14	MR. MYERS: I would say that, you know, we
15	made sure that things were Internet available constantly.
16	We had a stakeholders meeting specifically in Arlington,
17	Texas in January of 2001.
18	CHAIRMAN CERQUEIRA: And who attended from
19	the medical community?
20	MR. MYERS: I don't have the list here, but
21	I can provide that to
22	CHAIRMAN CERQUEIRA: Any organizations?
23	MR. MYERS: Oh, yes.
24	DR. NAG: Who are the stakeholders? You are
25	talking about stakeholders. Who are the stakeholders

1	MR. MYERS: At that particular meeting, and
2	I'm sorry. I just didn't bring the notes on the meeting,
3	but basically we invited folks from Health Physics
4	Society. There was a gentleman from Texas who was with
5	the Texas Health Physics Society. There was others.
6	We even got people in low level waste
7	issues, you know. So that was quite a broad based thing.
8	MS. McBURNEY: I thought somebody was there
9	from the Society of Nuclear Medicine.
10	MR. MYERS: And we had some folks from the
11	Society of Nuclear Medicine and others there.
12	Regrettable
13	CHAIRMAN CERQUEIRA: The therapeutic
14	community?
15	MR. LOHAUS: I believe ACR may have been
16	represented.
17	MR. MYERS: Yeah, ACR was there.
18	MS. WAGNER SCHWARZ: And ASTRO.
19	MR. MYERS: And ASTRO as well.
20	CHAIRMAN CERQUEIRA: I guess I'm just not
21	tuned in. I mean, Dr. Diamond, were you aware?
22	DR. DIAMOND: No one at ASTRO let me know
23	about it.
24	MR. LOHAUS: One thing. You know, being
25	sensitive to your point, Dr. Cerqueira, one thing we can

1	do in the future is meet with you at your regularly
2	scheduled meetings or periodically and give you an update
3	on where we are.
4	Again, another point maybe to try and put
5	this in perspective for you in terms of timing, I don't
6	see this happening immediately. This is going to be a
7	long process.
8	CHAIRMAN CERQUEIRA: No. Part 35, we've
9	been involved in what, Jeffrey? Fifteen?
10	DR. WILLIAMSON: Five years, six years.
11	CHAIRMAN CERQUEIRA: Yeah, and so I think,
12	again, this is the reason we're all here, is that we
13	represent stakeholders in the medical use, and we
14	certainly would like to find out about changes that are
15	going to affect this and would like to have input.
16	And perhaps that was provided, but certainly
17	the people at the table who were fairly involved were
18	unaware of it.
19	Maybe it was the fault of the societies for
20	failing to give us the information, and I don't think we
21	disagree with some of these approaches, but I think I've
22	learned to be a little bit more pragmatic about these
23	things, and I think that would be helpful.
24	What's the sense of the Committee? Is this
25	something we should be involved in and what role?

MR. LIETO: Can I? I just want to expand 1 about the stakeholder issue. 2 3 CHAIRMAN CERQUEIRA: Yeah. MR. LIETO: And when I found out about this. 4 5 I don't mean to portray this negatively, but one of the 6 things I wanted to bring to the Committee, because it 7 seemed to me to indicate this is a direction where the 8 NRC is going, which as an Advisory Committee obviously we 9 want to be at least sensitive to maybe some significant 10 changes in where the Commission plans on taking the regulation of radioactive materials. 11 12 So that was one reason that I think we need 13 to be aware of because I think this alliance concept kind 14 of -- it's much different than what I think any of us had 15 thought NRC would be going in terms of the future. And the other thing that came out at least 16 17 of this article on the summary of the working group was 18 that it pretty much said that the NRC needs to seek 19 authority to regulate NARM material, and that it seemed 20 to be sort of a linchpin in order to make this alliance concept to go forth. 21 22 Now, maybe that's a strong term, "linchpin," 23 but it seemed like it was very, very critical to making 2.4 this work with the states. I mean, I'm definitely in

favor of it personally, but I think, again, it was to

1 make the Committee aware of where what's going on with the Commission, that maybe we're not quite aware of on 2 the medical side, especially in light of PET. 3 You know, Sally was bringing up yesterday, 4 5 you know, it's really important that we need to have some consistency in the regulation of radioactive materials 6 7 both, I think, on the NARM and the byproducts side. MR. MYERS: If I could just make a quick 8 9 comment in there, the working group did not, and in fact, 10 the way the report is written, it's pretty clear we did 11 not say that the agency had to seek that authority to 12 regulate NARM materials and then to go to alliance. 13 Actually you could go through the alliance 14 process and seek the regulation. It's just that if the 15 agency would seek that and seek to regulate it, we believe that you would have a more uniform program 16 17 because it would begin to kind of pull things together that are kind of untidy out there from a regulatory 18 19 standpoint. 20 And as you know, NRC does not regulate that stuff right now, and that's an issue. 21 CHAIRMAN CERQUEIRA: Yeah, that's obviously 22 23 an issue that's been present all along. 2.4 I'd like to try to wrap this up because 25 rather than an hour and a half for lunch, I'd like to

1	give us an hour, and we'd reconvene at quarter to one.
2	But, Ralph, did that address any other
3	comments?
4	Dr. Nag had one last.
5	DR. NAG: Yeah. As far as funding and who
6	is footing the bill for the extra bureaucracy? And is it
7	going to be from the licensee again? You know, we made
8	separate funding for the agreements, state licensing, and
9	then the NRC, and then a different program.
10	MR. MYERS: I would say that as envisioned
11	by the working group and absent the decision by the
12	Commission as to what option that they want to choose, we
13	did not see that there would be any additional cost in
14	doing this because it's part of kind of rechanneling some
15	of the resources that are already out there and making it
16	more efficient versus in other words, I wouldn't
17	envision you would get a bill from the alliance for their
18	services for the next year.
19	CHAIRMAN CERQUEIRA: Not directly perhaps,
20	but
21	MR. MYERS: But it would be somehow folded
22	into existing processes and as the states do today. I
23	mean, they provide resource and so forth, and that's not
24	really
25	CHAIRMAN CERQUEIRA: Yeah. If the state or

the federal government are doing it, it's better than the 1 stakeholders. 2 3 Sally, one last comment, and then I want the 4 Committee to give me some direction on where we should 5 go. 6 MS. WAGNER SCHWARZ: I actually do have a 7 question just about whether the NRC has actually made 8 progress or made steps to actually contact states to find 9 out those interested in giving over state regulated 10 materials to the NRC. Have they actually begun discussing this with the states? 11 12 I did see something that was sent to the 13 State of Missouri. This is why I'm curious, and I wasn't 14 aware that it was a formal effort, but that something was 15 sent and asking about the interest of having the NRC take over regulation of NARM. And I'm wondering if that was 16 17 done to all non-agreement states. MR. LOHAUS: There were two things -- I'm 18 19 sorry. Go ahead, Ruth. 20 MS. McBURNEY: There have been resolutions passed at the Organization of Agreement States meeting in 21 22 I believe the Conference of Radiation Control Program 23 Directors encouraging this legislation. 2.4 MR. LOHAUS: That's correct, and there were 25 two things that were done. One is the Chair of the

1	Organization of Agreement States did do a I'll use the
2	term "informal survey" of the states, and when we were
3	developing the paper for the Commission in response to
4	their asking for some feedback from staff on this issue,
5	we did work with the Conference of Radiation Control
6	Program Directors to help identify whether there were
7	strong views among the different states one way or the
8	other.
9	So we had some sense of where the states are
10	when we reported back to the Commission. So that is the
11	genesis, I think, of this.
12	MS. WAGNER SCHWARZ: Were they favorable,
13	the majority?
14	MR. LOHAUS: Yes, they were, yes.
15	CHAIRMAN CERQUEIRA: All right. Jeff, maybe
16	you could ask your question afterwards because we should
17	break.
18	DR. WILLIAMSON: I just wanted to make a
19	comment.
20	CHAIRMAN CERQUEIRA: All right. One
21	comment.
22	DR. WILLIAMSON: My comment is I think I'm
23	rather concerned and alarmed at the thought of NRC
24	expanding its jurisdiction over additional materials
25	because it was not too long ago when NRC regulations

1	destroyed the economic viability of certain treatment
2	modalities.
3	And so for me personally, it would take a
4	lot of
5	CHAIRMAN CERQUEIRA: Yeah, that's that's
6	
7	DR. WILLIAMSON: convincing before I
8	would find that acceptable.
9	I think if the problem is paying for the
10	regulatory infrastructure that NRC provides for byproduct
11	materials, perhaps you should go back to Congress and ask
12	for a different funding mechanism so that it's paid for
13	out of the general revenues rather than penalizing the 18
14	non-agreement state licensees.
15	MR. LOHAUS: That's certainly an option, and
16	I believe that's Jim, correct me if I'm wrong
17	that's recognized within the working group report.
18	CHAIRMAN CERQUEIRA: Right. Now that's
19	good.
20	Now, what are the wishes of the Committee?
21	I mean, I certainly got the sense that people feel that
22	this is an important development and there should be more
23	involvement, input from the Committee. Is that the
24	general consensus? I mean, anybody would disagree?
25	DR. NAG: I would support that.

1	CHAIRMAN CERQUEIRA: And how do we do that,
2	John and Paul, Jim? I mean
3	MR. LOHAUS: One thing
4	CHAIRMAN CERQUEIRA: we haven't been
5	asked, you know, to come to the dance, but is there a
6	dance card? Can we sign up?
7	MR. LOHAUS: I mean, I guess one thing that
8	I can do is provide information to the Committee, you
9	know, for example, as we're doing today. Give you a
10	briefing and
11	CHAIRMAN CERQUEIRA: That would be a good
12	start, and just, you know, even a full
13	MR. LOHAUS: keep you up to date.
14	CHAIRMAN CERQUEIRA: Yeah.
15	MR. LOHAUS: And if there's areas that you
16	see are of concern or interest and you want to report out
17	on those areas, it gives you an opportunity to do that
18	early and have an opportunity to influence the outcome
19	and considerations.
20	CHAIRMAN CERQUEIRA: That would be a good
21	start, and I think just sort of a list of the
22	stakeholders who attended these meetings. Again, the
23	fact that a lot of us weren't aware of it, I mean, I
24	would just like to see if there was representation from
25	the cardiology community, from the radiation oncology

1	community. I think that would be important.
2	MR. LOHAUS: We could provide that to you,
3	sure.
4	CHAIRMAN CERQUEIRA: How can the Committee
5	get more involved in this?
б	DR. NAG: May I suggest
7	CHAIRMAN CERQUEIRA: Sure.
8	DR. NAG: that you examine either by an
9	observer or if you want to nominate someone else.
10	Someone from ACMUI, whether an examiner or someone else,
11	be part of that working group or at least be an observer
12	in the working group.
13	MR. LOHAUS: The working group is sunsetted.
14	It completed its product. So the working group is
15	basically sunsetted. It no longer exists. The product
16	is completed, and as I said, what we're doing now is
17	working on a follow-on paper to address the
18	CHAIRMAN CERQUEIRA: But is there a final
19	document that's gone to the Commission?
20	MR. LOHAUS: Yes, there is. We can provide
21	that to the Committee.
22	CHAIRMAN CERQUEIRA: Well, but the
23	recommendations weren't that clear, you know, in just the
24	cursory time that I've had to look at it in terms of
25	where to go. Maybe there's more in the

1	MR. LOHAUS: You will find no recommendation
2	in the Commission paper from the staff, but the
3	recommendation of the working group in their report was
4	the alliance option. That was the working group's
5	recommendation.
6	But I want to emphasize again these are
7	issues that are under consideration. There has been no
8	decision reached, and you're correct. That paper does
9	not have a recommendation there.
10	There are options that were provided for
11	consideration, and
12	CHAIRMAN CERQUEIRA: Well, I think, you
13	know, the Commissioners said that they really value the
14	input of this Committee into these kind of decisions
15	makings, and I think here's a situation where, you know,
16	we weren't even asked to participate or be involved, and
17	so you know
18	DR. NAG: We weren't even aware of it.
19	CHAIRMAN CERQUEIRA: Yeah. That's even more
20	distressing.
21	And so what are the wishes of the Committee?
22	So we can't be involved in this because it's been done.
23	I mean, Ralph, we should see the final report, but should
24	we make some recommendations to the Commissioners on
25	this?

1	MR. LIETO: Well, I guess I'm going to kind
2	of ask John. I mean I take it that the working group's
3	sunset. The parties are still there, okay, and that
4	whatever, you're waiting to hear back from the
5	Commission. Is that what the next step is?
6	MR. LOHAUS: The paper is before the
7	Commission.
8	CHAIRMAN CERQUEIRA: Well, when did it go
9	into the Commission?
10	MR. LOHAUS: In May, but I want to make it
11	clear
12	CHAIRMAN CERQUEIRA: In May?
13	MR. LOHAUS: In May of last year, but again,
14	there was no staff recommendation. There were items;
15	there were options that were provided for consideration,
16	and there's an expectation that the Commission has that
17	there will be additional material provided to them to
18	assist them in consideration of that paper and in
19	reaching a decision at the right point in time.
20	So it's under consideration. That's why I
21	want to emphasize these are issues that are under
22	consideration. There's not a hard decision that's been
23	reached, and they are issues that we're going to
24	collectively need to continue to wrestle with.
25	One thought I'll pass on for consideration.

1 We can provide a copy of the report to you. CHAIRMAN CERQUEIRA: Well, we agree that 2 that's critical to be done. 3 MR. LOHAUS: And maybe in looking at that 4 5 report if you see areas where you believe there would be benefit and there are views that you'd like to provide to 6 7 the Commission, it's an opportunity to provided those. DR. NAG: May I suggest that once you have 8 9 provided us the report, we look through it, make a 10 comment, and then send it to the Chairman, and then the 11 Chairman can compile a joint report from all of us and 12 send it to the Commission. 13 CHAIRMAN CERQUEIRA: I think that would be 14 the best way to do it. I'd also like to personally, you 15 know, contact the Commission and say that, you know, to not be involved or informed is really not taking 16 17 advantage of the Committee and the time that we've put into it. 18 19 You know, in a sense I feel, you know, 20 slighted. We're basically not -- you know, we have a Committee. We all spend lots of time and effort in 21 22 coming to these meetings, and here's an issue, which is probably as important as Part 35 revision, and we've 23 2.4 basically been left out of the loop. If I could, Dr. Cerqueira. 25 MR. MYERS:

CHAIRMAN CERQUEIRA: Yes.

MR. MYERS: I would say this. I don't think anybody on this Committee should feel slighted or anything. We at the working group level really, I think, spent a lot of time trying to make sure that we made interested parties or folks, stakeholders, as we want to call them, aware of this, and there were a huge number of folks in different organizations that were contacted.

I will have to say, and as co-chair I will take the hit for this, is that I don't really think that we thought about ACMUI in that process. So if we -- if anything was wrong, we didn't think about you all, and the fact that although we know that you guys would have some input and concerns and questions about it, it's just thinking back on it is like I don't think that we, the working group, really looked at that thing, and that's important.

So what we'll do is we'll make sure that you get a copy of the report, and as you know, the Commission has not made a decision. The working group folks are still there, but we're kind of like old baseball players, I guess, or something. We're on the bench for a while, whatever.

So if the Commission decides that it needs more input, the Commission would have to decide that it

2.4

1	would constitute the group, reconstitute the group, a new
2	group. You know, I can't
3	CHAIRMAN CERQUEIRA: I think that would be
4	that should be done, but we'd still I think the
5	feeling of the Committee is we should still get the
б	report and get some comments.
7	MR. MYERS: Sure.
8	CHAIRMAN CERQUEIRA: So Jeff and then Niki.
9	DR. WILLIAMSON: yeah, I would make a motion
10	that the Chairman direct the ACMUI to review the report
11	and subsequently develop a position or consensus within
12	the Committee as to the wisdom of enlarging NRC's
13	jurisdiction.
14	MS. WAGNER SCHWARZ: I second that motion.
15	DR. WILLIAMSON: To include NARM.
16	CHAIRMAN CERQUEIRA: Okay. Discussion?
17	(No response.)
18	CHAIRMAN CERQUEIRA: The motion
19	MR. HICKEY: Well, Mr. Chairman, could I
20	just clarify that? That's a resolution that does not
21	necessarily relate to this working group report directly.
22	CHAIRMAN CERQUEIRA: Right.
23	MR. HICKEY: It can be taken as a separate
24	issue.
25	DR. WILLIAMSON: But I think it's an

1	important issue for us to consider
2	MR. HICKEY: Okay.
3	DR. WILLIAMSON: and be aware of the pros
4	and cons. And there may be pros that I, for example, am
5	unaware of, and I think it's well for this Committee to
6	have a point of view
7	CHAIRMAN CERQUEIRA: Right.
8	DR. WILLIAMSON: on this matter and be
9	prepared to communicate it to the Commission at the
10	appropriate time.
11	MS. WAGNER SCHWARZ: I agree. I think that
12	this is a significant
13	DR. WILLIAMSON: So this is really very
14	serious.
15	DR. NAG: I think that we should, after we
16	have reviewed this report so that we have an idea what
17	the report
18	DR. WILLIAMSON: That's what I just said.
19	I said that the Chairman I move that the Chairman
20	direct the Committee, the ACMUI, to review the final
21	report of this group and then develop at our next meeting
22	a consensus on the wisdom of enlarging NRC's
23	jurisdictional mandate to include NARM.
24	CHAIRMAN CERQUEIRA: Well, review the report
25	and make recommendations. You know, the wisdom to expand

1	may not be part of it. I'm not sure we can so I think
2	the recommendation to review and comment on the report is
3	probably, you know, the more appropriate.
4	Do we have a second on that?
5	DR. NAG: I would second the revised motion.
6	CHAIRMAN CERQUEIRA: Okay.
7	DR. NAG: And I would like to add a time
8	line, please. I mean, by what time? Are we going to
9	meet forever? Are we going to have a one month or you
10	know? Are you going to write the report within one week?
11	You know, some type of time line should be added.
12	CHAIRMAN CERQUEIRA: Well, how hard does the
13	Committee want to a month? A month? Jeff, a month?
14	Okay. A month, good. All right. That
15	sounds reasonable. So we had a second with the
16	amendments.
17	Any further discussion?
18	(No response.)
19	CHAIRMAN CERQUEIRA: All right. I move that
20	we vote.
21	MR. MYERS: I have one question
22	CHAIRMAN CERQUEIRA: Yes.
23	MR. MYERS: just so we can cover this.
24	How many members are on the ACMUI now? Eight?
25	MR. HICKEY: Thirteen.

1	MR. MYERS: Thirteen? Okay. So I'm just
2	trying to figure out how many copies.
3	MR. HICKEY: We're not all here.
4	MR. MYERS: Okay. So we need at least 13
5	copies. Okay.
6	MR. LOHAUS: We'll try and get 13 copies to
7	you today.
8	CHAIRMAN CERQUEIRA: Well, if you can get
9	them today so that we can carry them home. How many
10	pounds is this, 30?
11	MR. LOHAUS: It's a two volume report. It's
12	maybe about, I'd say, a quarter to half an inch thick
13	total. Does that sound about right, John.
14	CHAIRMAN CERQUEIRA: All right.
15	MR. MYERS: It's probably about
16	MR. LOHAUS: This is available
17	electronically also, Jim, on our Web site. So we can
18	give you the URL for it also.
19	CHAIRMAN CERQUEIRA: I'm not sure it's
20	critical to get it to the Committee today. I think we
21	should make it available, and I think Angela could
22	overnight it to people. If people want it
23	electronically, I think that would be the preferred
24	method.
25	But we have a motion that's been seconded

	255
1	and discussed, and I call for a vote on this. All in
2	favor?
3	(Chorus of ayes.?
4	CHAIRMAN CERQUEIRA: And opposed?
5	Abstentions?
6	(No response.)
7	CHAIRMAN CERQUEIRA: None. Okay. So I make
8	the recommendation.
9	And how do people feel? Should I talk to
10	the Commissioner about that this Committee feels left
11	out, slighted?
12	MS. WAGNER SCHWARZ: Yes.
13	MS. HOBSON: I can hardly believe that a
14	major policy change like this has just sort of slipped
15	through with, you know, not very much public comment at
16	all, and I think that's really not a very desirable
17	thing.
18	And then I would also like to ask you: did
19	you invite any patient groups to participate? Because
20	patients are the ultimate stakeholders.
21	MR. LOHAUS: Jim?
22	MR. MYERS: I'm thinking. I think we did
23	ask, but I don't believe that we had anybody come that I
24	recollect. We did have some folks from some of the
25	public interest groups initially, but recognizing that

medical is one part of this complex puzzle that we were dealing with, I'd have to say initially no. I don't think that there were anybody that were patient advocate groups that were there.

Also recognize that this report was provided to the Commission and thought we sought a lot of public comment and stakeholder comment on it, and I think that the working group did a really good job of trying to get everybody involved, what happens is that once the Commission makes a decision about whatever it wants to do, that's probably more in the realm of policy, and that's where more comment and more favorable things that would be coming from the public would be put into this as well.

And I think that --

CHAIRMAN CERQUEIRA: Right, but the problem with that is once you've got a draft of something, you've spent the time. It's much more work to undo something that's been created than it is to be involved in initial development and do it right.

And certainly without the input of, you know, certain patient groups -- and again, I'd like to see the involvement of the professional medical community. I think it's important.

MR. LOHAUS: Yeah, I hear you. I hear you.

WASHINGTON, D.C. 20005-3701

2.4

1	And we'll give you the listing of people that attended
2	the stakeholder meeting, and that was part of the reason
3	for holding that meeting, was to provide opportunity when
4	there was a product that could be reviewed to give folks
5	an opportunity to look at it and give the working group
6	some feedback, but we'll give you the list of people that
7	attended.
8	And we may not have had all the right people
9	there, but I think the intent and our goal was to involve
10	a cross-section of stakeholders.
11	CHAIRMAN CERQUEIRA: Well, we're not
12	questioning the intent or the product, but it's just more
13	of the process, and again, I'd like to thank Ralph for
14	putting it on the agenda, bringing it to our attention
15	MR. LIETO: Thank me or blame me.
16	CHAIRMAN CERQUEIRA: Okay. Now, let's
17	everybody be back here by one o'clock. We don't want to
18	come back any earlier.
19	(Whereupon, at 12:04 p.m., the meeting was
20	recessed for lunch, to reconvene at 1:00 p.m., the same
21	day.)
22	
23	

1	A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N
2	(1:04 p.m.)
3	CHAIRMAN CERQUEIRA: I hope everyone had a
4	good lunch. Dr. Williamson was observed to be taking
5	part in the dance lessons in the hallway there. He does
6	a pretty mean swing, but not too good on the tango.
7	(Laughter.)
8	CHAIRMAN CERQUEIRA: Just kidding, Jeff.
9	And now we're back to Dr. Ayers.
10	DR. AYERS: Yeah, hoping to pick up where we
11	left off. Maybe we've got all of the questions out of
12	the way, but I doubt it.
13	(Laughter.)
14	DR. AYERS: As I said, partial recognition,
15	and what we haven't gotten into is the process of
16	responding to the Board's applications and going back and
17	forth and working out together where the endpoint will
18	be.
19	CHAIRMAN CERQUEIRA: When will that happen.
20	You know, obviously you can't do it until the regulations
21	get approved, but once they get published, will you be
22	able to initiate the process so that by the time it
23	becomes law you'll be able to
24	DR. AYERS: I defer that to John.
25	MR. HICKEY: Yes, we would do that prior to

1	the effective date, but now the response has to reflect
2	the discussions we've had yesterday and the work that the
3	subcommittee and the staff are going to be doing as to
4	what solutions are there.
5	But the reviews have pretty much been
6	completed so that if you set aside the discussions
7	yesterday and today, we could go ahead and notify all of
8	the Boards the results of the review.
9	CHAIRMAN CERQUEIRA: What about the Boards
10	that aren't affected? You know, it looks like the AB&M,
11	the ACR, CBNC, and some of the other exams would
12	DR. AYERS: All are affected except two.
13	CHAIRMAN CERQUEIRA: Okay, and you're going
14	to tell us which two.
15	DR. AYERS: Yeah.
16	MR. HICKEY: Well, one is at the Board of
17	Nuclear Medicine. They've already been notified.
18	DR. AYERS: That's correct, and the other
19	one is the CNBC; is that right?
20	CHAIRMAN CERQUEIRA: CBNC?
21	DR. AYERS: CBNC.
22	MR. HICKEY: Well, tell people what that
23	stands for.
24	CHAIRMAN CERQUEIRA: Certification
25	DR. AYERS: Cardiologist oh.

1	CHAIRMAN CERQUEIRA: Certification Board of
2	Nuclear Cardiology.
3	DR. AYERS: Yeah. In fact, they had to
4	manage informing the Board rather late, and compared to
5	others and actually incorporated all of the requirements
6	right into it. So it's really straightforward.
7	CHAIRMAN CERQUEIRA: I didn't mean to take
8	you off on a tangent there, Bob.
9	DR. AYERS: Okay. The next slide.
10	I think you're all aware of the problems
11	which are kind of reflective of many of the Boards with
12	the American Board of Health Physics, for example. They
13	don't have the specific requirements which are required
14	by the regulations.
15	Now, mind I'm not including any of the
16	discussions in the last couple of days, and if we do have
17	some rule changes, we'll have to all go back to the
18	starting point on this whole thing, but this is purely as
19	it relates to the existing draft of new 10 CFR, Part 35.
20	So they don't meet the one year full-time
21	radiation experience in medical applications, nor the
22	corresponding written preceptor statement.
23	Next slide.
24	CHAIRMAN CERQUEIRA: Well, Bob, can we go
25	back to that?

1	And I guess, you know, again, these
2	discussions I'm sure we
3	DR. AYERS: Well, I will add at the end I
4	list all of these problems for discussion. I was just
5	pointing to individual
6	CHAIRMAN CERQUEIRA: Okay. So the preceptor
7	statement, there's no way we can require that and then
8	the one year training?
9	DR. AYERS: I go through the individual
10	Boards
11	CHAIRMAN CERQUEIRA: Sure, okay.
12	DR. AYERS: and then we go to the general
13	discussion and then relist all of the across the board
14	features
15	CHAIRMAN CERQUEIRA: I apologize.
16	DR. AYERS: with Boards.
17	All right. The letter to the American Board
18	of Nuclear Medicine did say that we were planning to
19	grant NRC recognition for the modalities they requested,
20	except for the RSO under 3550(a) because, again, they
21	don't they have not presented evidence that they meet
22	the one year and the preceptor statement, although most
23	of the medical boards, they can become radiation safety
24	officers for their specific modality based on their
25	authorized user status, and that includes medical

physicist. 1 2 CHAIRMAN CERQUEIRA: Right. 3 DR. AYERS: What they can't do is qualify 4 for broad scope RSO big programs under A. 5 Next slide. 6 As I said, we just see no issues on this 7 one. Next slide. 8 The only thing I guess I'll add as a comment 9 10 to that, they're only requesting 290 and the regulation 11 requires that the preceptor have 190 and 290 experience, and I agreed with them in the draft letter that it would 12 13 seem pointless that they have 190 experience for their 14 preceptor since they're not authorizing that modality. Here's the key point. For radiation safety 15 officer authorizations, a large number of the Boards, 16 17 essentially all of them or -- I'm sorry -- all that asked, but a great number asked for recognition under the 18 19 full radiation safety officer qualifications under 20 3550(a), but none at this point has been able to document they meet that one time or one year full-time medical 21 22 experience under supervision of a qualified radiation 23 safety officer, nor do either present evidence for the 2.4 preceptor statement that goes along with that.

MS. McBURNEY: Bob, if the American Board of

1	Health Physics did change their requirements for
2	certification to include a preceptor statement and
3	documentation of experience
4	DR. AYERS: Yeah, that's really coming up on
5	the next slide.
6	MS. McBURNEY: Oh, okay.
7	DR. AYERS: Okay. But as I said, many of
8	the Board diplomates would qualify under 3550(c). In
9	fact, the only one that wouldn't would be that I don't
10	remember that acronym accurately, but that specialty
11	Board for Nuclear Medicine.
12	CHAIRMAN CERQUEIRA: CBNC or
13	DR. AYERS: No
14	MR. LIETO: American Board of Science and
15	Nuclear Medicine?
16	DR. AYERS: American Board of Science and
17	Nuclear Medicine, that one, because they don't have any
18	corresponding authorized user status in any other
19	category, nor are they asking for one.
20	Next slide.
21	With the medical physics authorizations,
22	again, for both ABR and American Board of Medical
23	Physicists Physics, they have lack of, as we've talked
24	about many times, the Board requirements for the
25	specified trading in all of the modalities and the

1	corresponding signed preceptor statement.
2	And we already talked about the partial
3	recognition, and this could apply to all Board, and in
4	the next slide, I think we get into the big generic
5	issue, I hope.
6	CHAIRMAN CERQUEIRA: Before we go on, Jeff,
7	do you have a question?
8	DR. AYERS: Yeah.
9	DR. WILLIAMSON: I recently reviewed the
10	eligibility requirements for ABR, American Board of
11	Medical Physics. They certainly do require signed
12	letters testifying to the competence. So I'm wondering
13	what is the
14	DR. AYERS: That's the next slide.
15	DR. WILLIAMSON: legal deficiency of that
16	requirement compared to the
17	DR. AYERS: Okay. I intend to talk I
18	believe the next slide has that.
19	DR. WILLIAMSON: Okay.
20	DR. AYERS: Yeah, the next slide, please.
21	The generic issue is, as I said, applicable
22	to all the Boards except the Board of Nuclear Medicine
23	and the Board of Nuclear Cardiology, is the absence of
24	the exactly specified signed preceptor statement or
25	statements in accordance with the new Part 35

1	requirements for the various Board certification
2	processes.
3	Now, ABR, for example, asks for a reference
4	letter for a physicist and a
5	DR. WILLIAMSON: From a radiation
6	oncologist, I believe, too.
7	DR. AYERS: Well, in one they call it a
8	reference letter, and in the other one they call it
9	something else. The name escapes me. Sometime somewhat
10	similar.
11	The problem is and the Boards could
12	easily if they chose or maybe I shouldn't say "easily."
13	The Boards could one option would be to change their
14	procedure. The biggest blocking point from any of the
15	Boards is a signed preceptor statement. They have -
16	CHAIRMAN CERQUEIRA: Well, tell me
17	DR. AYERS: requirements that are
18	similar, but not the same.
19	DR. WILLIAMSON: What's missing from the
20	ABR when they say letter of reference from a certified
21	physicist and a physician? What's wrong with that?
22	DR. AYERS: Two things that stick up
23	immediately is they don't say that they've supervised
24	them and they've been they're trained and qualified in
25	the specific numbered parts of the regulations.

1	And the second one is there's no requirement
2	that that letter, recommendation, reference I think
3	it's called recommendation in place of reference and
4	others there's no requirement on the part of the
5	Boards that those be from what we would deem a qualified
6	preceptor, that is, an authorized user that is authorized
7	for those modalities.
8	CHAIRMAN CERQUEIRA: Jeff, how difficult an
9	issue would that be to get that letter? I mean, is most
10	of the training done by authorized user or AUP or AMP?
11	DR. WILLIAMSON: I think largely that is so.
12	I think the major problem would be that the certificate
13	itself would have to be amended to specify HDR, gamma
14	stereotactic, and teletherapy. I think that is the big
15	blocking point, is that there is no mechanism by which,
16	you know, footnotes can be made to the diplomate
17	certificate indicating the different modalities.
18	You know, this letter is not something
19	they're going to be willing to share with you.
20	DR. AYERS: Well, it wouldn't be if they
21	chose to have some subset and say we require the
22	appropriate preceptor statement or this subset and that's
23	a partial part.
24	DR. WILLIAMSON: Yeah, but they don't do
25	that for any subset. They're don't do it for Cobalt

1	DR. AYERS: I know that.
2	DR. WILLIAMSON: 60, HDR or gamma
3	stereotactic, and it's unlikely they will.
4	DR. AYERS: It's a little more
5	straightforward for the medical Boards, for ABR, for
6	radiation oncologists, for pharmacists. The same
7	problem; it's across the board with all of these Boards.
8	I keep forgetting.
9	None of the medical Boards that I've
10	reviewed have at this point presented any evidence to us
11	that they require and goes in the file for their Board
12	diplomate, the required certification.
13	The other alternative, of course, is
14	changing the requirements, which you've already presented
15	to the Commission.
16	The other alternative under the existing
17	regulation would be for the Boards to adjust the
18	requirement.
19	And some of the medical Boards may be a
20	little further away in that the letters they require are
21	from their clinical director who may or may not be active
22	or may or may not be what we would deem an authorized
23	user. I don't know. We've got to ask these questions
24	CHAIRMAN CERQUEIRA: Ralph, you know, you're
25	not weighed down by all of the baggage of past

1	discussions. How do we get out of this and come up with
2	a way that
3	(Laughter.)
4	MR. LIETO: What I see is what we're trying
5	to do is put a square peg into a round hole.
6	DR. AYERS: Exactly.
7	MR. LIETO: And I think
8	CHAIRMAN CERQUEIRA: So how do we shave it?
9	MR. LIETO: It seems like the discussion
10	I've been hearing is how do we get the Boards to do this.
11	How do we get this to change? And I don't think that's
12	the way to go. Okay?
13	I was thinking at first, well, maybe there
14	should be sort of this form letter of recommendation that
15	says, you know, "I, Dr. So-and-so, attest to the fact
16	that Physicist XYZ meets the criteria for taking the
17	Boards because of his experience, and lists some of
18	these modalities, but these things are going to change
19	with time.
20	DR. AYERS: And certify that
21	CHAIRMAN CERQUEIRA: That he's competent.
22	MR. LIETO: Well, the Board exam
23	CHAIRMAN CERQUEIRA: That the person is
24	competent.
25	MR. LIETO: You know, passing the exam would

WASHINGTON, D.C. 20005-3701

1	establish his competency. So my feeling is that I think
2	any discussion of trying to get changes in the Boards or
3	applications to the Boards is going to be very lengthy,
4	time consuming, because they have to go through their
5	mechanisms of approval, and I don't really think in the
6	long term it's going to solve the problem. I think the
7	issue is, as we discussed this morning, is change in
8	rulemaking.
9	CHAIRMAN CERQUEIRA: The rulemaking.
10	MR. LIETO: I really think that's where we
11	have got to go.
12	CHAIRMAN CERQUEIRA: Yeah.
13	DR. AYERS: And that's why I said I'm
14	confining my remarks to not changing the rule. The rule
15	changes; the whole thing starts over. It's a whole new
16	ball game with regard to what I'm presenting.
17	CHAIRMAN CERQUEIRA: And, Richard, in terms
18	of the RSO, is that also the situation?
19	DR. VETTER: Yeah. For example, the
20	American Board of Health Physics certifies people in all
21	areas of health physics. If they changed their
22	certification process, they would need to have a
23	preceptor statement for everyone whether they're going to
24	be in medical or not.
25	I mean, it just doesn't work. Like Ralph

1	said, it's a square peg in a round hole or vice versa.
2	And they're not going to change it.
3	CHAIRMAN CERQUEIRA: No. In nuclear
4	medicine, I mean, you know, the preceptor statement
5	specifically lists the isotope and the number of hours
6	that people have had, and we've been using those
7	preceptor statements for the longest time. Isn't that
8	something that could be generalized?
9	DR. AYERS: Well, we've been using the
10	preceptor statements under the old rule for non-Board
11	certified individuals, physicians, medical physicists,
12	RSOs, and so forth. That's always been there.
13	What's new with new Part 35, and I think why
14	a lot of people missed that it was a change is that the
15	Boards are now being vetted against the training and
16	experience requirements in the second and sometimes third
17	parts of the rule.
18	And I don't know how the Boards that are
19	recognized now by us achieved that process. That was
20	before my time.
21	CHAIRMAN CERQUEIRA: And, Ralph, Jeff, and
22	Richard, the Boards have been approached and it's not
23	doable?
24	DR. VETTER: Well, I've talked with two
25	Boards, and it just doesn't fit their objective. They're

1	looking to certify the competency, the knowledge base,
2	and that really has nothing to do with where they got it.
3	It just doesn't fit for them.
4	CHAIRMAN CERQUEIRA: And it's not specific.
5	Again, for some of these things, for the agents.
6	DR. VETTER: Right.
7	DR. NAG: Yeah, I have a problem. Directly
8	in radiation oncology is that in the Board certification
9	it says you are now qualified to do radiation oncology on
10	the whole. I may never want to do a gamma knife, and if
11	you say you are going to require everyone to have that
12	knowledge, you're not going to have many people, you
13	know, passing the Board.
14	You know, they want to certify a general
15	overall knowledge. Now, you can use that knowledge, and
16	then if you're going to do gamma knife or some of these
17	special procedures, you can take some special training
18	for that.
19	But you cannot make that a requirement for
20	every radiation oncologist to know about gamma knife
21	CHAIRMAN CERQUEIRA: But if we had an
22	interventional cardiologist, he would say, "Well, why
23	can't we take them and have them do a limited subset of
24	training and experience to be able to meet their
25	requirements, to sort of be the sole user?

1	DR. NAG: Yeah, but the problem is you need
2	an overall general knowledge, and then you need to
3	supplement that with specific knowledge. You can't just
4	say I want to have only the specific knowledge without
5	the general fundamental knowledge to back you up.
6	So if you do a separate requirement just for
7	gamma knife, it is not good because you can't just make,
8	you know, 200 hours at gamma knife without knowing the
9	rest of the general radiation basics.
10	DR. WILLIAMSON: There's another problem.
11	Even if the Boards adjusted their procedures so that
12	prospectively new candidates complied with these rules,
13	it's not retroactive. The problem would still exist that
14	the vast majority of Board certified physicians and
15	physicists could not meet these regulatory standards.
16	DR. AYERS: Well, I think the grandfathering
17	might be a large part, but
18	CHAIRMAN CERQUEIRA: So is that possible
19	under the
20	MS. McBURNEY: Yeah, grandfathering.
21	DR. AYERS: That's my next slide, which has
22	some issues there, but I'll get to that.
23	CHAIRMAN CERQUEIRA: Why don't we go to the
24	next one? Are you done with this one?
25	DR. AYERS: Yeah, I think the problem is

1	well identified. There are really three branches to
2	this, work to the existing Part 35, and most Boards won't
3	qualify and will have to come in under training and
4	experience; change the rule and get it where most people
5	are happy. I don't know if you can ever make everybody
6	happy.
7	CHAIRMAN CERQUEIRA: That's not our mission
8	here.
9	DR. AYERS: Okay. Let's go to the next
10	slide.
11	CHAIRMAN CERQUEIRA: But, again, we do have
12	this subcommittee that's going to look at this and come
13	up with some recommendations on how to resolve this
14	DR. AYERS: And I guess one question you
15	raised was that, well, the Boards have responded to this.
16	Well, the letters haven't gone out yet. So our query to
17	them about this hasn't went out to them yet. So there
18	hasn't been any forma interchange between the Boards and
19	NRC until those letters go out.
20	Okay. On the grandfathering, I wasn't
21	prepared to talk about it last time, and I wasn't sure,
22	and I agreed that the language was a little ambiguous,
23	but the states in consideration are very precise. For
24	medical physicists, pharmacists, and RSOs, which is
25	really not relevant, it's mostly for medical physicists.

1	What the statements in consideration very precisely say
2	is you will get what you have. If you're an authorized
3	teletherapy physicist, that's all you get. If you're
4	authorized for teletherapy and HDR, you get those.
5	You get what you have now. You don't get a
6	broad recognition.
7	DR. WILLIAMSON: Which undercuts the last
8	point that was made. So there is an issue with
9	grandfathering the previously boarded
10	DR. NAG: What about authorized user, NRC
11	authorized user?
12	DR. AYERS: I'm sorry?
13	DR. NAG: Authorized user? I mean, are they
14	not grandfathered?
15	DR. AYERS: No, the authorized user is
16	35.57(b), which wasn't an issue. The language differs in
17	that a little, and it's much clearer. So this was the
18	issue item from last time.
19	DR. WILLIAMSON: Can the statements of
20	consideration be modified? Are they as unmodifiable as
21	the rule?
22	MR. HICKEY: The answer is yes, and that
23	will be within the scope of what the subcommittee and the
24	staff looks at. Certainly if the rule can be changed,
25	the statement of consideration can be changed.

1	MS. McBURNEY: But not for this printing.
2	It would be a new rulemaking and a new statement of
3	consideration, right?
4	MR. HICKEY: If the question is how quickly
5	can it be done, it's easier to change something that's
6	not a rule than it is to change a rule.
7	DR. AYERS: I think the Commission would
8	probably have to be on board on that, but don't hold me
9	to that.
10	MR. HICKEY: That's correct.
11	DR. AYERS: And you have presented your
12	views to the Commission, and that's outside of the scope
13	of what I'm talking about.
14	MR. LIETO: Bob, could you just refresh my
15	memory? What's 35.57(b)?
16	DR. AYERS: That's the grandfathering
17	clause. That means everybody that is currently listed as
18	an authorized user at the time the new Part 35 takes
19	effect will be grandfathered for the authorities that
20	they now have essentially.
21	MS. McBURNEY: I understand all the stuff
22	about the Board certification was in the proposed rule as
23	it is in the final, but not a whole lot changed.
24	DR. AYERS: I was not involved in the
25	rulemaking. So I can't if somebody else wants to

1	speak to the history, I know it went through several
2	revisions because at one time there was consideration of
3	a written test on radiation safety, and where the changes
4	occurred along the path, I guess Marjorie is coming up to
5	the microphone. She's more knowledgeable of the history
6	of rule development than I am.
7	MS. McBURNEY: And whether there were
8	comments about that or did people just sort of assume
9	that their Boards would be accepted?
10	DR. AYERS: I'll let Marjorie address the
11	question.
12	MS. ROTHSCHILD: Okay. Well, the proposed
13	rule published in August of 1998, the language that is
14	now at issue was virtually identical in the proposed
15	rule, and I can point you to that. Okay? It's 3550
16	if we're taking like authorized medical physicist as an
17	example, that proposed rule language was, "The licensee
18	shall require the authorized medical physicist to be an
19	individual who," and then under A it states, "is
20	certified by a specialty Board whose certification
21	process includes all of the training and experience
22	requirements in Paragraph B of this section and whose
23	certification has been approved by the Commission."
24	Now, that last phraseology there
25	DR. AYERS: That's the same, yeah.

MS. ROTHSCHILD: -- may have been changed
slightly, just the last phrase, and there was a
provision, you know, in this proposed Rule 3551 for
passing an examination, but the language at issue, taking
this provision as an example was virtually the same in
the proposed rule published August '98.

And the kind of brief review I've had time to do in terms of comments and responses in the statements of consideration, I didn't see this precise issue as raised by commenters or any of the professional societies.

DR. AYERS: Yeah, I looked through that. There were no comments on this issue that I could find in my review through the package. The intent of this whole thing was to take naming the Boards out of the regulation where it prohibited us from adding or deleting new Boards or Boards that changed without -- we'd be rulemaking to add or delete the Board as it exists now in the old Part 35.

And I guess when you say we're going to recognize Boards, you've got to put something in, and this appears where the miss occurred, at least from the perspective of the Committee here. You've got to put something in that says this is what it takes to be qualified to be recognized.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

Now, the recognition criteria could be 1 different obviously than what they are if we're rewriting 2 3 the rule or if you went back listing them in the rule 4 itself, you again tie Board recognition to rulemaking 5 process in the future. 6 CHAIRMAN CERQUEIRA: All right. Jeff? 7 DR. WILLIAMSON: I think a couple of 8 comments have been made by the Commissioners and maybe 9 others on the staff -- I think Don Cool -- that there was 10 something that could be done in the implementation of 11 these regulations that would at least temporarily 12 ameliorate the consequences or mitigate the consequences 13 of this problem, and I'm wondering if John or Bob could 14 expand on this. I'll defer to John. 15 DR. AYERS: I don't think I can add 16 MR. HICKEY: 17 anything to what's been said. We agreed that --DR. WILLIAMSON: I gathered that this was --18 19 this is what I understood them to be implying, although 20 it wasn't made clear, that there was the possibility when the regulations are implemented that basically a hold 21 22 could be put on some component, subcomponent of the 23 regulations if it turned out there was an unforeseen 2.4 difficulty in implementing them without postponing the

implementation of the rest of the new Part

1	requirements.
2	DR. AYERS: Yeah, I think that can be
3	considered. However the Commission, they haven't
4	addressed the issue of a fragmented effective date
5	directly, but they's stated that they don't want to
6	revise the rule in pieces.
7	So if there were a proposal to implement it
8	with different effective dates for this part, that would
9	be an issue, but I think that does need to be considered
10	nevertheless.
11	DR. WILLIAMSON: So that is a possibility.
12	That was my question.
13	MR. HICKEY: Everything is a possibility
14	DR. AYERS: Yeah, I think most of what
15	you're talking about now is at the Commission level, and
16	it was great that everybody had a chance to bring these
17	issues to the attention of the Commission yesterday, and
18	now it's on the radar so to speak.
19	I can't predict what will happen.
20	CHAIRMAN CERQUEIRA: Okay. We have a
21	question from the audience.
22	MR. UFFELMAN: I'm Bill Uffelman, Society of
23	Nuclear Medicine, ACNP, but on behalf of the American
24	Board of Science and Nuclear Medicine.
25	With the six month delay or call it the six

1	month delayed effective date of the rule, those and
2	you made the comment somebody who is already an RSO is an
3	RSO and, you know, they're grandfathered. But somebody
4	who was previously an RSO, but is now working as an RSO
5	because they've changed jobs or whatever, can they go
6	back and be an RSO without going through the whole
7	rigmarole? That's question one.
8	Question two, those
9	CHAIRMAN CERQUEIRA: Wait. Why don't we get
10	an answer to question one, and then we can
11	DR. AYERS: Question one, I don't know. I
12	haven't looked at that issue.
13	CHAIRMAN CERQUEIRA: That was easy.
14	MR. UFFELMAN: Okay. Question two, ABS&M's
15	exam is given in June at our annual meeting in L.A. this
16	year. Those who pass the exam in June and become
17	diplomates of ABS&M, because they're in this window
18	between the March publication and September-October
19	effective date, what is their status, you know? Under
20	which rule are they applying for recognition of their
21	qualification?
22	DR. AYERS: Well, they're applying under the
23	current Part 35 until such time as the new rule becomes
24	effective.
25	MR. UFFELMAN: Okay. So that's different

than what you said last year. That's why I was checking. 1 MR. HICKEY: This is John Hickey. Let me 2 3 point out that they have to be listed on a license. It's 4 not good enough just to be certified as of the effective 5 date of the new rule. 6 MR. UFFELMAN: So they've got to have this 7 RSO job lined up for, you know --MR. HICKEY: We said -- I agree I don't 8 9 offhand know the answer to the first question because the 10 rule says "identified." So I'd have to get an interpretation as to whether that means currently 11 12 identified or previously or currently. 13 But the answer to the second question is you 14 have to be certified, and if you haven't been listed on 15 a license, you need to get listed on a license before the effective date of the new rule. 16 17 DR. AYERS: Yeah, a job offer wouldn't do 18 I mean, you'd have to actually go through the 19 process and be listed on the license to be grandfathered. 20 CHAIRMAN CERQUEIRA: All right. Well, I guess we overlooked a few things at different levels, and 21 22 I think we've identified the problem. We've spoken to 23 the Commissioners. We've established a subcommittee 2.4 that's going to look at it, and we kind of need to 25 address it possibly as a new rule.

1	I guess the one question is that for the
2	Boards who have already applied and have been reviewed
3	and have met most of their criteria, I don't see any
4	reason that they should be held up. Is that the feeling
5	of the Committee?
б	There's no
7	DR. AYERS: Well
8	MR. HICKEY: Wait a minute. He's asking the
9	Committee.
10	DR. AYERS: I'm sorry.
11	MR. HICKEY: Sorry.
12	DR. WILLIAMSON: And these Boards, just to
13	refresh our memory are the nuclear medicine, two nuclear
14	medicine Boards, right?
15	MR. HICKEY: That's right.
16	CHAIRMAN CERQUEIRA: What about the ACR?
17	DR. NAG: ABR you mean.
18	CHAIRMAN CERQUEIRA: ABR. I'm sorry.
19	DR. AYERS: A preceptor issue, a preceptor
20	statement issue.
21	DR. WILLIAMSON: It's important to
22	recognize. It sounds like right now radiation oncology
23	certification is not going to make it for either the
24	brachytherapy, teletherapy, or the radiopharmaceuticals.
25	Only nuclear medicine certification.

1	DR. AYERS: The same applies to the
2	radiopharmacy and the medical physics and RSO. It's
3	essentially everything else.
4	DR. WILLIAMSON: So the scope of the
5	disaster widens.
6	CHAIRMAN CERQUEIRA: It's definitely a
7	problem.
8	Ralph?
9	MR. LIETO: I just wanted to make maybe a
10	comment regarding the grandfathering. You said you
11	weren't too sure about if somebody was not listed now,
12	but had been previously, would they be grandfathered. I
13	guess
14	DR. AYERS: Yeah, and I don't know, and
15	there is some provisions in our current regulations that
16	gives a window of time in which you can
17	MR. LIETO: My suggestion was going to be as
18	long as that meets the recentness of training requirement
19	
20	DR. AYERS: That's the window.
21	MR. LIETO: that they be allowed to
22	grandfather.
23	DR. AYERS: Again, I don't know at this
24	point without
25	MR. LIETO: Just a comment.

DR. NAG: One possible solution for the short run, since we now have a separate meeting, until the results of the subcommittee comes out -- that means the new will not be implemented until the subcommittee comes out.

CHAIRMAN CERQUEIRA: I don't think we can do that procedurally. I mean, basically the Commission has made the decision, I think, which was supported by the Committee, you know, that they didn't want to fragment the rule out, break it out in different ways, and I think the option that has been given to us is basically implement a rule and then come up with a new rulemaking, which is part of the charge of this Committee.

But in the meantime I'm not sure it's in the interest of the stakeholders. If some of the Boards basically have been approve by this new standard, I think it would make sense since they weren't affected as directly by some of these other ones to basically let them get approval.

DR. WILLIAMSON: Well, I think I concur with our chairman. There seems to be no reason not to go ahead and recognize the certifications of the two nuclear medicine Boards. It sounds like if the fragmented date of implementation strategy is used, it could be carefully calibrated to avoid the 35, 200 and 100 modalities and

2.4

focus on the 300, 400, and 600 modalities where the 1 2 problem occurs. DR. AYERS: Well, I think the last two days 3 4 have introduced a reason. Now that the Board 5 certification process may be back on the table, and what 6 we're prepared to do now may not be valid tomorrow. 7 (Laughter.) DR. WILLIAMSON: Well, that's a good point. 8 9 CHAIRMAN CERQUEIRA: All right, but the 10 decision on this is going to have to be made soon, very 11 soon, I mean, and if Congress gives approval to go ahead, 12 then I think the Commissioners are going to need to make 13 some decision on how to deal with this. 14 I didn't get the feeling from yesterday's 15 meeting that they had a solution for us. They're willing to have us look at it, but there's no immediate 16 17 resolution that's been put forward by the Commission, by 18 this Committee, or by the NRC staff. 19 DR. AYERS: And I think if the rule goes 20 through as planned, we'll immediately get those letters out. One of them is, in fact, granting recognition to 21 22 the second diagnostic Board, and we've accomplished what 23 you're asking for. It's just merely we're just waiting 2.4 until we know for sure which way to jump.

Right.

CHAIRMAN CERQUEIRA:

1	DR. NAG: And I agree with having the two
2	Boards, you know, approved, but what is going to happen
3	with the other four or five Boards? Once implemented, I
4	mean, you know, what are the consequences of that?
5	CHAIRMAN CERQUEIRA: Well, the people that
6	are already out there, I mean, should it change? They
7	would be grandfathered, correct?
8	DR. NAG: No, but the new graduates are
9	coming out this year.
10	DR. VETTER: But they would be approved
11	under the filling out all of the forms of the
12	preceptor statement, training, and so forth.
13	DR. AYERS: And these letters are going
14	to
15	CHAIRMAN CERQUEIRA: And the people who
16	would be most affected would be the people who are
17	starting training now; is that correct?
18	DR. NAG: No.
19	DR. AYERS: Well, the letters going to the
20	Boards are not denying recognition. It's asking
21	questions. What I'm getting from the Committee is we may
22	not get the right answers back, but it's not going out
23	and saying you're not qualified. It's saying we don't
24	see where you do A or B, and could you please advise us
25	how you do this?

1	CHAIRMAN CERQUEIRA: Yeah, I think there was
2	precedent for some of this. I mean, when my predecessor
3	Barry Segal was here, there was quite a little
4	controversy for the people who didn't have Boards but
5	were trying to meet the requirements for authorized user
6	under training and experience as to whether there could
7	be two 500 hour blocks, whether they were simultaneous or
8	concurrent, and a vote was taken that, you know, if there
9	were issues, it could come to this Committee for review.
10	I think we maybe reviewed one or two, and
11	potentially this Committee could assume some of that
12	responsibility, but we're talking about large numbers now
13	if we're talking RSO.
14	DR. AYERS: Yeah, the issue of multiple 500
15	hour blocks was addressed in a letter from the Chairman.
16	I'm trying to remember the addressee right offhand, but
17	that we wouldn't for a radiation oncologist for a
18	number of different modalities, we wouldn't sum those 500
19	hour blocks. That was addressed in a response from the
20	Chairman.
21	CHAIRMAN CERQUEIRA: Well, we need to do
22	something, and I think it's going to be implemented, and
23	we need to initiate this process. It doesn't seem like
24	we've gotten any indication that the guidance documents
25	would deal with it effectively, and it seems like the new

1	rule may be the only way to do it.
2	And I guess the best thing would be to try
3	to get this started.
4	DR. AYERS: I think the problem is guidance
5	is intended to tell you or to provide information how to
6	comply with the rule not change the rule.
7	DR. WILLIAMSON: Well, that's correct, but
8	the guidance, you know, it would seem to me we've made
9	the recommendation as a Committee that the guidance
10	should bend over backwards within the confines of the
11	rule as written to preserve as much of the existing
12	recognition of Board certification as possible, and I
13	still think you should take that as your goal.
14	MR. HICKEY: Yes. From what our review has
15	indicated so far, it's clearly there is an issue with
16	medical physicists and RSOs. There may be more
17	flexibility to soften the impact with respect to the
18	authorized users.
19	DR. WILLIAMSON: Can you give us your draft
20	guidance on how to what would be required to establish
21	your screening criteria, so to speak, for establishing
22	compliance with the authorized medical physicist
23	provisions?
24	DR. AYERS: I can say all that I'm using now
25	is the rule. That's the guidance, and the corresponding

1	statements of consideration.
2	MR. HICKEY: We will do that. We're going
3	to put a priority on addressing this first issue of what
4	needs to be done to fix the rule, but we also will do
5	that.
6	We have a letter from I believe it's the
7	American from AAPM that has a proposal that we need to
8	respond to.
9	CHAIRMAN CERQUEIRA: All right. Niki.
10	MS. HOBSON: Well, this morning one of the
11	speakers referred to that there could possibly be a
12	transition period where there would be some
13	enforcement
14	MS. McBURNEY: Discretion.
15	MS. HOBSON: discretion. Could that
16	apply in this instance?
17	And also, what is the absolute shortest time
18	that this rule could be amended? What is the absolute
19	shortest time?
20	MR. LIETO: Not amended, but rewritten.
21	CHAIRMAN CERQUEIRA: Not amended, but, well,
22	just a new rule dealing
23	MS. HOBSON: The new rule, the new rule.
24	DR. NAG: IBS.
25	CHAIRMAN CERQUEIRA: John? Best case?

1	MR. HICKEY: I can't comment on that.
2	DR. NAG: IBS.
3	DR. AYERS: The only comment I'd have is
4	this is not an enforcement issue. It's a licensing issue
5	in a sense, an indirect licensing. It's kind of unusual.
6	We haven't been in this kind of space.
7	DR. DIAMOND: Bob, I actually disagree with
8	that. Dr. Frant earlier today was very clear, 100
9	percent crystal clear that there's going to be some
10	leeway with respect to how implementation is done,
11	interpretation, maybe windows for implementation and so
12	forth.
13	So please don't be as strict as you're
14	telling us.
15	DR. AYERS: Oh, no, it's just wording.
16	Implementation I have no disagreement with, but all I
17	just said is it is not an enforcement issue. It's
18	clearly an implementation issue. Ms. Hobson presented it
19	as an enforcement issue, and that it isn't.
20	Implementation, which she talked about, of
21	course it is.
22	CHAIRMAN CERQUEIRA: The sense that I'm
23	getting from the Committee is that, you know, we kind of
24	agreed that we were correct on the nuclear medicine
25	aspect of training and experience and Boards, and we

that in the sense of approval of the Boards that have 2 been reviewed and found to meet the criteria. 3 And I don't think -- that pretty much covers 4 all of the stakeholders for nuclear medicine, but then 5 6 we've got this other problem with, you know, potentially 7 the radiation oncologists authorized users, but 8 definitely with the radiation safety officers and the 9 medical physicists, and we haven't really come up with a 10 solution, and I think we kind of need to escalate this to, you know, maybe have a -- we met with the 11 12 Commissioners yesterday. I think we were just kind of, 13 you know -- the full implications of this were made known 14 then. 15 You know, maybe we should try to talk to the Commissioner again, talk to Commissioner Meserve to sort 16 17 of see what the options are. You know, maybe Richard on behalf of the Committee and I could talk to him to see 18 19 what the solutions would be. 20 Is that a reasonable way to go forward on this? 21 Well, I guess I'm a little 22 MR. LIETO: confused now. Where is the subcommittee that was charged 23 2.4 this morning fit into this? CHAIRMAN CERQUEIRA: Well, the subcommittee 25

should probably once the rule goes into effect implement

1	would basically do the leg work. The thing is there's a
2	whole bunch of unknowns. You know, how much can be
3	incorporated in guidance? How much could be incorporated
4	in grandfathering? Can we conceivably stagger the
5	implementation, which is something that the Commissioners
6	have said they did not want to do?
7	Nobody can give us a time line for the new
8	rulemaking, and you know, we kind of need to have that
9	information to see how we can basically solve it.
10	DR. WILLIAMSON: Well, I was going to
11	suggest maybe a motion that we could vote on, that the
12	ACMUI recommends that the staff petition the Commission
13	to stagger the dates of implementation of the training
14	and experience requirements to preserve the existing
15	training and experience requirements for radiation
16	oncologists, authorized medical physicists, nuclear
17	pharmacists, and radiation safety officers until such
18	time as a revised regulation can be implemented.
19	CHAIRMAN CERQUEIRA: Do we have a second on
20	that?
21	DR. NAG: I'll second the first place.
22	CHAIRMAN CERQUEIRA: I'm sorry?
23	DR. NAG: What you were asking in the first
24	place.
25	CHAIRMAN CERQUEIRA: Right, right.

1	DR. NAG: You know, I second that.
2	CHAIRMAN CERQUEIRA: Yes, so you second it.
3	DR. WILLIAMSON: I just think we need to
4	think outside of the box here a little bit, and that we
5	should not impose a very confusing and conflicting
6	transitional structure on the community if there is some
7	possibility of avoiding that, given that everybody
8	there's a general consensus among the Commissioners, the
9	staff, and the regulated community that this needs to be
10	addressed by a rulemaking initiative.
11	So to me it only makes sense to avoid
12	imposing a very confusing and flawed system upon the
13	regulated community for a brief interval of time.
14	CHAIRMAN CERQUEIRA: And fully assuming some
15	responsibility ourselves for not having clearly
16	identified the problem that is
17	DR. WILLIAMSON: Everybody screwed up on
18	this, and there's a lot of blame to be shared for why
19	we're in this position, but it only seems like the
20	rational thing to do.
21	CHAIRMAN CERQUEIRA: Ruth?
22	MS. McBURNEY: My only comment on that is
23	that I don't think it would be the proper mechanism for
24	the staff to petition the Commission; that we as a
25	Committee can make that recommendation.

1	CHAIRMAN CERQUEIRA: Right.
2	MS. McBURNEY: But I don't think putting
3	that responsibility on the staff to go to the Commission.
4	DR. WILLIAMSON: I would amend it then to
5	say that the ACMUI
6	CHAIRMAN CERQUEIRA: Okay. That's
7	appropriate.
8	DR. WILLIAMSON: recommends to the
9	Commission and otherwise unchanged.
10	DR. AYERS: Marjorie, you were wanting
11	protocol input, is waiting.
12	MS. ROTHSCHILD: Well, actually not on this
13	particular motion. It was just Dr. Cerqueira's request
14	for some information on a time line for rulemaking. I
15	didn't mean to interrupt.
16	CHAIRMAN CERQUEIRA: No, no, no. If you've
17	got some information factually that's good.
18	MS. ROTHSCHILD: Oh, okay. I was going to
19	say generally with rulemaking under the Administrative
20	Procedure Act, you have to have notice and comment. In
21	other words, you give people notice as in a proposed
22	rule, what you're planning to do, and then there's an
23	opportunity for comment, which of course, is what
24	occurred in this rulemaking.
25	Now, the duration of that comment period,

you know, it can be very short or it can be, you know, 1 2 very long. 3 I'm sorry? MS. McBURNEY: Is there a minimum? We in 4 5 the states have a minimum number of days --6 CHAIRMAN CERQUEIRA: Comment period? 7 MS. McBURNEY: -- for comment. MS. ROTHSCHILD: Well, the thing is there 8 9 are other legal requirements, I guess, that figure into 10 the comment period. Typically we have to allow for a 11 minimum usually of 75 days, and so there are some other 12 -- besides the Administrative Procedure Act, there's some 13 other statutory requirements, but I know that, you know, 14 there have been comment periods in the past as short as 15 two weeks. The problem is people don't generally 16 17 consider that. Usually what we get are requests for extension of comment period times. 18 19 shorter Now, as far as, you know, 20 rulemakings, it's possible you can have immediately effective final rules, but those, the agency is 21 22 subjecting itself to -- it becomes vulnerable in terms of 23 the legal challenge when you have an immediately 2.4 effective final rule. There's also something called a direct final 25

1	rule, but my understanding is for that it has to be an
2	issue that's not controversial. I think based on all
3	this discussion we could not say that.
4	So I hope that's somewhat helpful in terms
5	of the rulemaking process and time periods.
6	DR. NAG: Do you have like a number out of
7	the hat? Would you say like one year, two years, five
8	years?
9	MS. ROTHSCHILD: Oh, for the duration of a
10	rulemaking?
11	DR. NAG: From now till when the new rule
12	becomes
13	MS. ROTHSCHILD: I mean, it depends on how
14	long your comment period is.
15	DR. NAG: Minimum, minimum.
16	MS. ROTHSCHILD: Minimum?
17	DR. NAG: Overall from today.
18	MS. ROTHSCHILD: I can't make I mean I
19	can just speak to what rulemakings that I'm aware of, you
20	know, how much time has been consumed. Sometimes, you
21	know, because of, say, statutory requirements where we
22	have to act, you know, we can do start to finish in less
23	than a year, but that
24	CHAIRMAN CERQUEIRA: Let me ask Richard and
25	Jeff and Ralph. Is this controversial? Do we

1	anticipated that there will be
2	MR. LIETO: That's a good question.
3	CHAIRMAN CERQUEIRA: groups
4	MR. LIETO: My feeling is it appears from
5	the discussion here that everybody is on the same page.
6	I don't really think I think what should happen you
7	know, I think in all due respect to Jeff's motion, I
8	think we're a little premature.
9	I think, first of all, the rule hasn't been
10	published yet. Okay? And we know what the problem is.
11	So with the Committee already being charged, and I guess
12	I would ask if it's possible that they could come back
13	with some proposal 30 days, you know, 45 days from now,
14	and then turn it over to staff for the rulemaking
15	process.
16	I mean if we had that and it's not
17	controversial, isn't it possible we could have this all
18	done by the end of the year?
19	MS. ROTHSCHILD: You know, I can't make any
20	commitment. I just think the amount of discussion that
21	the subject of training and experience generates, that
22	that one aspect of direct final rule in this case I
23	doubt, you know, whether this rulemaking, you know, would
24	be appropriate for a direct final rule.
25	But you know, I'm just speaking now, you

1	know, personally.
2	CHAIRMAN CERQUEIRA: Certainly based on my
3	experience with this rule, I mean, you've got a public
4	comment, drafts, publish the draft. People get to
5	respond. You've got to respond to the questions that
6	you've gotten, and it's got to be published again for
7	another public comment period. It's going to take a
8	while.
9	DR. AYERS: And there's the internal
10	process, too, which includes the Commission's approval
11	and the publication period.
12	CHAIRMAN CERQUEIRA: And OMB.
13	DR. AYERS: And OMB, yeah.
14	CHAIRMAN CERQUEIRA: Ruth.
15	MS. McBURNEY: Looking at the issues of the
16	attempts to try to get more uniformity of the
17	requirements throughout the country, I would prefer that
18	these rules go ahead and go into effect, and even if
19	people have to be authorized as authorized users and
20	medical physicists under the alternate training and
21	experience, in the meantime, before we can get these
22	other proposed rules because it may take up to two years
23	to do that.
24	In the meantime the states are going to have
25	to start working on compatibility rules and so forth, and

to have that total lag on all the rules and especially on 1 the training experience trying to keep those more 2 3 equivalent, that would be problematic. CHAIRMAN CERQUEIRA: I agree with that. 4 So we have a motion. 5 6 DR. WILLIAMSON: I'm not sure I understand 7 the point. It seems like that is going to happen if the 8 implementation dates are not modified in this staggered 9 way, the states are going to have to approve Part 35 as 10 it is now within three years, and then in another 18 11 months a new modification of the rule is going to come along, and then they're going to have to start working on 12 13 that at the same time. 14 It seems to me it would make sense to leave 15 the part alone that everybody agrees needs to be changed, implement the rest, and then when the final rule comes 16 17 out, then the state should start working on it. CHAIRMAN CERQUEIRA: 18 Ruth? 19 MS. McBURNEY: No, I think that by the time 20 the states get to the point of actually or many of the states get to adopting compatible rules, we would have at 21 22 least a proposed change ready to go, and they could enfold that into their proposed rules. 23 2.4 DR. WILLIAMSON: But what would happen is we 25 would propagate this error through the whole agreement

state system that would disenfranchise --1 CHAIRMAN CERQUEIRA: Yeah, but the agreement 2 3 states had three years upon which to act, and during that 4 time they can operate under the ole rules and, you know, even under the best case a lot of them will. 5 DR. WILLIAMSON: Well, they can't -- for 6 7 three years they can, but they're going to start implementing the new rule, and some of them will 8 9 implement the new rule if it's implemented in toto, and 10 that is going to propagate to the other 32 states 11 potentially this error. So I actually think the most rational thing 12 13 is to keep that part of the old system intact until a new 14 part can be thought out and implement the rest. 15 CHAIRMAN CERQUEIRA: Ruth. MS. McBURNEY: But during that time if the 16 17 Committee's recommendations get adopted by the staff and 18 put forth as a proposed rule, there will be parallel 19 rulemaking or parallel rule development among the -- for 20 the suggested state regulations that will be out and available to the states along with that in that time 21 22 frame. 23 DR. NAG: I think to be realistic it's going 2.4 to be at least two or three years. I mean, nothing

happens in one year. I mean as a minimum, all that we

1	talked about realistically look at two or three years
2	DR. WILLIAMSON: So I think if there's a
3	concern with nuclear medicine, since that's
4	uncontroversial, more or less, that could be exempted,
5	but I do think in the therapy area, why propagate this
6	error unnecessarily?
7	CHAIRMAN CERQUEIRA: Niki?
8	DR. AYERS: Well, I would point out it isn't
9	as simple as keeping the old training or Board
10	certification training experience requirement. If you
11	keep those, they will now refer to sections that no
12	longer exist.
13	MS. McBURNEY: That's right.
14	DR. AYERS: You're going to create a real
15	problem.
16	CHAIRMAN CERQUEIRA: Niki.
17	MS. HOBSON: Yeah, I'm just wondering what
18	the practical impact on patients that this is going to
19	have. Now, I mean, just sort of visualize. You know,
20	we're stringing this out over two or three years. Well,
21	people are going to change jobs. They're going to die.
22	They're going to retire. Are we going to be left with
23	enough people out there to provide, you know, these
24	essential services?
25	I think that the holes will just get bigger

and bigger, you know, unless we do something to kind of 1 2 plug the gap until we can get the new rule. 3 CHAIRMAN CERQUEIRA: Richard, and then let's 4 go back to Jeff's motion because if we're going to get 5 out of here on time, we'll have to. DR. VETTER: In response to Niki's comment, 6 7 I think the greatest impact would be on a licensee who 8 needs to hire a new RSO, and that new RSO, if they aren't 9 an RSO on some other license, they have to become 10 approved as an RSO, become qualified under the new rules, 11 and if they're Board certified or not, they are going to 12 have to go through the process of filling out all of the 13 paper work and so forth. 14 So the licensee in effect would hire a new 15 RSO who cannot be approved on the license until they've gone through that entire process. It's going to be a 16 17 problem for licensees. DR. AYERS: Yea, I don't think it bars 18 19 people, but it's a process issue, and the alternate 20 process is more lengthy than --CHAIRMAN CERQUEIRA: Jeff, could you restate 21 22 your motion? 23 DR. WILLIAMSON: Yeah. My motion was that 2.4 the ACMUI recommend to the Commission that the 25 implementation dates of new Part 35 be staggered so as to

1	delay the implementation of training and experience
2	sections for authorized nuclear pharmacists, authorized
3	user/radiation oncologist, authorized medical physicist,
4	nd radiation safety officer until such time as a revised
5	rulemaking can be completed to rectify the problem.
6	CHAIRMAN CERQUEIRA: Now, I think some
7	people had some issues with that just in terms of, you
8	know, the staggered implementation.
9	DR. WILLIAMSON: Well, I think it's
10	important to you know, the message is come up with
11	some administrative strategy to try to retain the old
12	system until
13	CHAIRMAN CERQUEIRA: So could we make
14	DR. WILLIAMSON: the rule can be fixed
15	and
16	CHAIRMAN CERQUEIRA: the motion sort of
17	more general rather than trying to give them a specific
18	solution for it?
19	DR. WILLIAMSON: Okay. I'll rephrase it
20	then. The ACMUI recommends that the Commission retain
21	the old training and experience requirements for
22	authorized nuclear pharmacist, authorized user of 35-600
23	materials, authorized medical physicist and radiation
24	safety officer until such time as a rulemaking initiative
25	can be implemented to rectify the problem of training and

1	experience requirements.
2	CHAIRMAN CERQUEIRA: Can we get comments
3	from people that would have problems voting positive for
4	that?
5	MS. McBURNEY: I think I still think that
6	you're going to have problems in doing that as Bob Ayers
7	mentioned, referencing parts that don't exist anymore.
8	The requirements for diagnostic authorized user are
9	actually going down, I believe, on the number
10	MR. HICKEY: Yeah.
11	MS. McBURNEY: of hours of training, and
12	you
13	DR. WILLIAMSON: But that's excluded from
14	this.
15	MS. McBURNEY: Let me finish.
16	And the no, it's not excluded.
17	DR. WILLIAMSON: I just excluded it in my
18	motion.
19	MS. McBURNEY: I didn't hear that.
20	DR. WILLIAMSON: Well, I focused, just to
21	repeat it, for authorized nuclear pharmacist, authorized
22	medical physicist, authorized user in 35-600, and
23	radiation safety officer. That's the scope of my motion.
24	MS. McBURNEY: And it's going to leave some
25	doubt and confusion among the states as to what rules

1	need to be implemented, and in making their rulemaking,
2	do they use the old criteria or the new criteria, and so
3	forth?
4	DR. VETTER: The NRC is going to do what
5	they have to do to implement the new rule. I would vote
6	in favor of this motion to send the message, and they're
7	going to do what they have to do.
8	DR. WILLIAMSON: I think the basic message
9	is think outside the box and see if you can come up with
10	some way and solve all of these administrative problems
11	that Ruth and Bob have mentioned.
12	CHAIRMAN CERQUEIRA: But if you make that
13	motion without putting in specifics and delaying the
14	implementation of portions of it, which I think are going
15	to be controversial, I think that will send them the
16	message.
17	And I think we also agree that maybe Richard
18	and I should call Commissioner Meserve and talk to him to
19	see what other options are available.
20	DR. WILLIAMSON: I think, you know, we're
21	not the legal experts. It's their job to figure out how
22	to do this.
23	CHAIRMAN CERQUEIRA: Right.
24	DR. AYERS: I would comment I think you're
25	addressing the wrong issue there with the training and

1	experience requirement. It's the Board recognition
2	that's the issue, and if the Boards had to be vetted
3	against the existing requirements, I think they'd have
4	the same problem.
5	DR. WILLIAMSON: Well, that's correct, and
6	so that's why I said leave it. Right now the existing
7	training and experience requirements don't create that
8	dilemma. That's why I phrase the motion
9	DR. AYERS: Nor do the new ones. It's the
10	recognition process that's the problem.
11	DR. WILLIAMSON: But the old regulations
12	don't require a recognition process. That's why the
13	dilemma is not raised. It's avoided by my motion.
14	CHAIRMAN CERQUEIRA: Well, the NRC and this
15	Committee because we had a lot of input into it.
16	So state your motion again, Jeff.
17	DR. WILLIAMSON: Okay. The ACMUI recommends
18	that the Commission retain the existing training and
19	experience requirements for authorized nuclear
20	pharmacist, authorized medical physicist, authorized user
21	of 35-600 modalities, and radiation safety officer until
22	such time as a rulemaking initiative can be completed to
23	rectify the problem of recognition of the Boards as
24	pathways for achieving this status.
25	CHAIRMAN CERQUEIRA: We should probably get

1	a second on this new motion.
2	DR. DIAMOND: I'll second that.
3	CHAIRMAN CERQUEIRA: Any further discussion,
4	which I hope okay. So we should vote.
5	All in favor of Jeff's motion?
6	Opposed?
7	Okay, and you abstain? Okay.
8	Yes.
9	MR. LIETO: Dr. Cerqueira, are you and Dick
10	still going to plan on conversing with the Chairman?
11	CHAIRMAN CERQUEIRA: I would leave that up
12	to the Committee. If the Committee feels that would be
13	appropriate and helpful, okay.
14	DR. WILLIAMSON: I think you should.
15	CHAIRMAN CERQUEIRA: Okay. Now okay. We
16	can do that.
17	All right. Bob, thank you.
18	All right, John. So I guess we've got
19	actually three items left. The update on the new IVB
20	devices undergoing current review; security of
21	radioactive materials by Cathy Haney.
22	Has Cathy been in the audience? She's been
23	her in all of this.
24	MR. HICKEY: Could I request that we have
25	Cathy Haney go next since she's on a tight schedule and

	308
1	
2	CHAIRMAN CERQUEIRA: Sure.
3	MR. HICKEY: I'm going to be here for the
4	remainder of the meeting?
5	CHAIRMAN CERQUEIRA: Sure. FCSS, SSSB.
6	What does that stand for?
7	MS. HANEY: It stands for Fuel Cycle Safety
8	and Safeguards, and the Safety and Safeguard Support
9	Branch.
10	(Laughter.)
11	MS. HANEY: And then I can tell you about
12	the next tier down, which are the sections, but I think
13	that's probably good enough.
14	CHAIRMAN CERQUEIRA: Okay. Well, that's
15	god, Cathy. Welcome back.
16	MS. HANEY: It's a long way from the
17	Division of Industrial and Nuclear Material Safety.
18	PARTICIPANT: Actually, do you have an
19	overhead?
20	MS. HANEY: Yeah, and I think my
21	presentation will be a lot less controversial than the
22	last ten minutes that I just heard. So you all can sit
23	back and enjoy for a few minutes.
24	DR. WILLIAMSON: Sort of like old days, huh?
25	MS. HANEY: Sort of like old days, right.

DR. 1 DIAMOND: You've been never 2 controversial. 3 MS. HANEY: No, never, never. It was so 4 nice to be sitting on that side instead of up there where 5 John usually sits. 6 What I want to talk to you about today is 7 mostly this is just an informational presentation, and it's maybe a little bit of a look into the future of 8 9 where the medical and the other materials licensees may 10 be in two to three years. 11 So this is I'm just kind of planting a seed, 12 and also just since you are representatives of NRC, if 13 people know, you know, that you're on the Advisory 14 Committee and they say, you know, "What's NRC doing about 15 security at the nuclear power plants?" it will give you a little bit of -- a couple of tidbits of information so 16 17 that you all can answer that question. I have a long list of things to talk about, 18 19 but it really will not take me that long. I just want to 20 point out what the NRC mission is, and you're so used to hearing about safety aspects, as I was when I was in the 21 22 other division, and now that I'm in Fuel Cycle, it's all 23 of a sudden there is another side to NRC, and that's the 2.4 safequard side. So we'll touch on that for a second.

Just review some of the security regulations

and some of the aspects of a security program, and what I'm going to really be talking about is coming from the reactor world, but when you sit back and look at them, they apply to all of your facilities when you look at security and safeguards as an overall issue.

I'll tell you about what we did immediately following September 11th, and what we've done, some longterm actions, and then talk about where we're going from there, and then just touch real briefly on what are the implications for this Committee, and in two years what will I be talking with you about, and I'll be back in the controversial seat. So that's why I'm starting now.

So as far as the NRC mission goes, I think everyone realizes that it's to protect the public and promote, but once you get beyond that first line, people are not as familiar with that second line, which is we really do have a role in promoting the common defense and security aspects of use of byproduct source and special nuclear material. So it is much larger than just a safety and worrying about public dose and occupational dose.

If you look at the regulation of security aspects, it's very similar to what you see with the safety aspects. First, we're regulating through a licensing. There is inspection and oversight.

2.4

Now, in your particular hospital settings or 1 university settings, about the only regulation that 2 3 you're going to look to is Part 20, Section 1802 that has 4 to do with security of material, which is a little short, two or three liner in 10 CFR. 5 6 When you get into some of the larger 7 facilities, you're looking at whole sections of 10 CFR, and I don't see you going there. So don't get panicked 8 9 thinking, "Okay. She's really setting me up for two 10 years." I'm really not. 11 But we occasionally do rulemaking in the 12 security area. If we were going to change regulations 13 with regards to -- I mean, if we were going to change our 14 posture about security of licensed material, we would be 15 looking to possibly rulemaking. There is a lot of research that goes on in 16 17 this area, especially post 9/11. Our research in the 18 security aspect has also increased, as well as our 19 intergovernmental coordination. 20 I mean, we always in this area had a lot of coordination with the FBI, with CIA as far as looking at 21 22 intelligence information that was coming through, but now 23 with the Office of Homeland Security, that's increased 2.4 drastically.

We have also reached out to a lot of the

other intelligence communities, working closely with. We are talking about possibly putting some staff a couple of hours a week down at the FBI building and long term maybe even down at the CIA.

So we are looking at really doing some outreach with the other government users, and what we're looking at this is really from a national infrastructure standpoint. The government as a whole is deciding what area to put their resources into to protect. There needs to be some hierarchy of identifying what are the key infrastructures that need to be protected, and that's really -- NRC is playing in that area. So I want you to know that we are particularly involved in that.

If you're looking at a safeguards and security program, there are a couple of key terms that you need to look at, and I'm not going to go through all of this in depth, but the first one that I want to mention is design basis threat.

And the reason I want to mention this to you is this is something that we will be considering relative to larger material licensees, and basically what a design basis threat is is identifying the key components that we want a facility to protect against, and then once the NRC would identify those, this is turned over to the licensees, and then the licensees develop a security

2.4

protocol for doing it.

2.4

Typically it's a denial strategy, which is basically keep the bad guys on the other side of the fence. So it's something very simple.

We are doing a top to bottom review of our security program, the safeguards program. I'll get into that in a few more minutes, but one of the things that we'll be looking at is the design basis threat and whether what we currently have should be changed in light of the heightened threat environment and also who should the design basis threat apply to.

Right now it really only applies to reactors and to our very large fuel cycle facilities. So it's a very small population. But should certain aspects of that design basis threat apply to a hospital, apply to a university?

And if you're thinking, "Okay. That sounds great, Cathy, but what does that mean real world?" you know, when you take it down to the hospital setting, I mean, maybe that's putting up some extra vehicle barriers to keep like a truck from approaching the facility very close. It's just looking at your physical layout to see if there are any changes that would need to be made.

When you're looking at security programs, it's really broken into three areas. One is physical

security. Second is personnel security, and then information security.

There's been a lot recently on the Internet about the information security, and this has to do with vulnerability of access to modems and your communications systems, and I'm sure individuals at your facilities are really looking at this already, but again, it does go beyond just a nuclear environment when you get into the information security.

And then we talked a little bit about the NRC oversight program already, that it is in a way similar to what you're familiar with.

And the last item is security levels, which is probably something that you have not heard before mostly because it hasn't applied. And again, I'm not sure that I would if I was going to crystal ball it say that it would apply to you, but let me tell you a little bit about them.

Right now NRC has three security levels. Immediately following the terrorist attacks, we went to our highest security level for our licensees, which is a Level 3, and this has the licensees increase security at their site and make changes to really all of their physical security, their background checks on personnel, as well as their information security.

2.4

There's an effort underway at the government 1 level to take all of the different threat levels or 2 3 security levels that each agency has and go to some type of uniform level. This is an effort that's underway 4 under the Office of Homeland Security. And as a result 5 6 of that, you know, when one agency says we're at one 7 level, the other agencies are at similar levels. So there will be more to come on that. It's 8 9 just in the initial stages at this point, but just be 10 aware that there are different security levels that NRC does have now for some of its facilities. 11 I think what I'm going to do is skip over 12 13 the next couple of slides so that I can keep you on 14 schedule here. I've been responsible for keeping you 15 late before. So I don't want to be responsible today. Let me tell you what NRC did immediately 16 17 following the attacks. The first thing is we activated 18 our Emergency Operations Center, and that was activated 19 within a couple of minutes, and we went to 24 hour staffing on that particular area. 20 We had our executive team, which is a 2.1 22 representative from each one of the offices in NRC, like 23 the Office of Nuclear Material Safety and Safequards; 2.4 Marty was there, which is our Director; Office of Nuclear

Reactor Regulation had their office director there; and

the Chairman of the NRC was also there. And we staffed that for 24 hours.

Our first step was to issue a threat advisory, which took all of our licensees to their highest security level, and then subsequently we've issued updates to those threat advisories. I think all total we've probably issued in the 20 to 30 type of range of advisories, and for various reasons.

If we saw a change in the threat environment, we would inform licensees or if there were certain actions we wanted licensees to take, we would issue an advisory. And most of the advisories went to the power reactors.

There were some -- I think there was one advisory that went to all materials licensees. There were some where we went to just the large material licensees, those with emergency plans. But these were typically the licensees that already had a very formal security program in place where we thought that they should make some changes in that particular item.

If with the larger licensees we did contact them and discuss what actions they had taken in response to the advisories, we maintained constant coverage of monitoring the intelligence traffic to see if there was anything changing that we needed to know about and

2.4

317 whether we needed to increase or decrease security at our 1 2 sites, if there was a specific threat against any of our 3 reactors. We also coordinated with the states, and we 4 did have someone down at the FBI's what's referred to as 5 6 SIOC, which is the Strategic and Information Operations 7 Center. And then I'm sure when you came in today you saw 8 a different security system than you had previously seen 9 So, I mean, even in house we increased our 10 security. 11 Post 9/11, and this is where we start to 12 look at where will we be going from here, and you guys, 13 some effects on your particular licensees. We were 14 looking at augmenting licensee's capabilities, and this 15 is recognizing that pre-9/11 there was a certain threat environment that our licensees were expected to protect 16 17 against, but then post 9/11, we did want them to increase 18 that security. 19 So we're taking it up a notch or two or 20 three or four, depending upon who you ask, but we are increasing licensee security requirements to what the 21 22 Commission believes is prudent in light of the current

NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

other government agencies. Two are noted up there. One

We also have coordinated federal assets with

threat environment.

23

2.4

is the Coast Guard and the Combat Air Patrol. Depending upon what action we were taking, if it was gathering information from these other agencies or providing information from our sites to these other agencies, we were doing significant outreach to the other federal agencies.

I've mentioned that we are doing a top to bottom review of the safeguards program, and this is something that is very much -- most of the work will be done in fiscal year '02. There is some that extends out into '03, and then there's a very little bit that goes into '04, but the thought is that the majority of the work will be done this year and next year.

There are a couple of things that we're looking at, is looking at that design basis threat to decide if any changes need to be made to that. We're looking at vulnerability assessments at the sites where we're actually going out to some sites or having contractors go out to sites and look at the particular sites and look for what are the vulnerabilities, and given the increased threat environment, do adversaries have better access to those sites typically referred to as critical target areas? And are there any -- we have not gotten down at this point to looking at your small hospitals. The majority of the work is in the reactor

2.4

area in the fuel cycle arena.

2.4

We may be looking down into some of the large irradiators, and again, the focus is on risk. What risks do the specific facilities pose, recognizing that from the standpoint of the medical facilities, you've been complying with 20.1801, looking at security of material all along. So with the hope that you would just keep doing what you're doing and consider any of the increased threat environment if there is anything that you would need to make changes.

There may be possibilities for legislative changes in this particular area. There are several Congressmen that are very interested in what NRC does. So it's possible long term you could see some changes in that area.

Also, there will be some changes, I believe, in the interagency coordination aspects, again, just trying to work together. We're all trying to work together as one federal government to come up with a position that would be uniform between the different government agencies.

As far as what's going on in the threat world, because if you listen to CNN, you hear a lot about it, hopefully we'd like to hear about it before it hits CNN, and that usually works.

There's one case where I was driving home 1 from work and heard something on CNN. It was like when 2 I left work everything was fine, and an hour later what 3 4 am I hearing on the public radio? Once 9/11 hit, we asked all of the sites to 5 6 report suspicious activities to us, and to be quite 7 honest, we had hundreds of reports in, and some of them were fly-overs where you'd have small planes flying over 8 9 the reactor sites at very low levels, caused some concern 10 because there really was no reason for the planes to be 11 down that low. You know, when you go back and look at them, 12 13 you know, they could not track where the airplane came 14 from. So it makes you wonder as to what's going on. 15 A lot of strange people. It's amazing the number of people that feel it necessary to take pictures 16 17 of nuclear power plants. (Laughter.) 18 19 MS. HANEY: So now those people have found it into our database of the number of incidents in that 20 particular area. 21 When we got an unusual case, it was 22 typically reported to local FBI, and local FBI would go 23 2.4 out and investigate it if it was something that was deemed crossed a threshold of this seems awful strange;

maybe we should look at it.

2.4

And obviously, there were some differences on some of the risks that were posed. I think there was one case where we had someone being interviewed by local FBI that was just two tourists that happened to want to be taking a picture of the lake and then on the other — they didn't realize that on the other side of the lake was the nuclear power plant. So there were, you know, things like that.

But in some of the fly-overs, it led you to be a little bit more concerned about what was going on.

All right. Flip this one.

Okay. Surveillance and planning, and the reason that we looked into this particular area was that, you know, it's obvious that the September 11th attacks did not just occur, and there have been multi-year surveillance going on, and this is why it's important in your facilities to -- you know, the constant attention that you do pay to security because if something is going to happen, it's usually not just, you know, I decided to do something wrong today. It's something that someone may have been thinking about for a while.

And looking at different systems that you can have in place with regards to this surveillance information collection, just sensitizing people in the

departments to be aware of any unusual activities.

Your security system challenges, I mean, you

have security systems in the hospitals for reasons beyond

the radioactive materials, but again, making sure that in

your particular departments that you are involved in

decisions made with regard to this security because it

This insider infiltration sounds awful serious in the area where you are, in the reactor areas, the fuel cycle facilities. It is a big concern, but to bring this down into, you know, the world of the university and the hospital, this is the misuse of the radioactive material where you're, you know, putting in someone else's food or something like that.

does have implications for the radioactive material.

I mean, we've had incidences over the year. so it really does apply, and I think what I'm trying to say is, well, you know, most of this program, security and safeguards program is set for the power plants and the fuel cycle facilities. It really does have implications into the university setting and the hospital setting.

Okay, and then the last one is really what are the possible implications for the material licensees. What will I be back here talking to you about in two years?

2.4

And these are my crystal ball, I guess, if 1 you want to refer to it that way. One is the 2 3 vulnerability analyses. As I said, right now we're really not 4 focused down into the university or into the hospital 5 setting, your small community hospital setting. 6 7 It's possible that long term that we do start looking a little bit closer at what are the 8 9 vulnerabilities at the hospitals, and when we would 10 approach it from a hospital setting, we'd start with the 11 higher risk sources as compared to your community 12 hospital that's only doing 35, 100, and 35, 200. 13 There may be some statements that come out 14 from NRC with regards to increasing security at your 15 We have proposed what we've called interim compensatory measures for the larger licensees, and it's 16 17 possible that long term that we may be proposing some 18 security measures that would be at hospitals. 19 Again, you're not on the top of the list 20 right now, but long term, you know, we would be looking at these areas. 21 And then as we do go on and make changes in 22 23 our safequards and security regulations, there may be 2.4 some of those changes that would affect your facilities,

and that would be something that we would be coming back

1 to talk to you about. So as I said, these are long-term changes. 2 3 Obviously when we are doing this top to bottom review of 4 the safeguards and security programs, we're thinking of 5 all licensees. So you're not lost; you're not forgotten. 6 We are using a risk approach, the larger 7 licensees, higher risk licensees first, but recognizing that some of the changes that come out of those programs 8 9 could have implications to the medical setting. 10 So that is the quick overview of the safety and safeguards and what NRC has done post 9/11. I'd be 11 12 happy to answer any questions, just not about Part 35. 13 (Laughter.) 14 MS. HANEY: I had to get that in, Jeff. DR. VETTER: We kind of laughed when you 15 mentioned people taking pictures of nuclear power plants, 16 17 but we've had people taking picture of our oxygen supply 18 at our hospital, of our own nuclear -- not nuclear. I'm 19 sorry -- our own power plant. We have two, one for our 20 clinic, one for our hospital. And so we're getting a little bit -- some of these have been investigated by the 21 22 local law enforcement, and you know, it's innocent enough 23 just like you've mentioned. Nevertheless, you can't help 2.4 but get a little bit paranoid. And then because of my own naivete, I've 25

learned today that the location of where we store our brachytherapy sources and our nuclear medicine generators and all of that is on ADAMS. It's there for the world to see, and I didn't know that because our information security is so tight I can't get to ADAMS. I can't get through the firewall. I can get E-mail, you know, and all of that. You can get out, but when it comes time to getting back in, our firewall is so secure I haven't been able to go up to ADAMS.

I'm going to work on an alternate pathway, but what I'm really getting at is I hope I'm not the most naive RSO in the world. I would submit that most RSOs don't know that the location for the storage of their radioactive materials is on ADAMS.

If they did know, they might think a little differently about the security of their area. And in fact, if I knew that in my last license reapplication, broad scope license application, which we turned in in December, I might not have furnished room diagrams. I would have challenged the NRC to have Enforcement or Licensing come out and look at it rather than give you a room diagram showing the location.

I'm just a little concerned about that, and the challenge I would have for you is, or the NRC, whomever, is to notify radiation safety officers that, in

2.4

fact, all of this information is on ADAMS in case they 1 didn't know about it, and you know, they may want to 2 3 heighten their own awareness of security issues because 4 of that. Well, I think that's a good 5 MS. HANEY: 6 Early on NRC took down its Web site completely. 7 DR. VETTER: But they didn't take down 8 ADAMS, did they? MS. HANEY: Well, there were a couple of 9 10 days where it was down. Everything was down. 11 couldn't access anything on NRC because of just some concerns about what information was on there. 12 13 Bit by bit the Web site has gone back up, 14 but I think you're correct about the ADAMS issue, and 15 that would be one thing. I will take that challenge, and I guess as you're interacting with your associates, you 16 17 know, also to make them aware because that's a good way 18 of getting the word out, sometimes better than what NRC 19 is doing. 20 And I think it is good to think about what information you are sending into NRC, and it's time to 21 22 question it because, you know, information that we didn't 23 used to worry about pre 9/11 coming into the agency, and 2.4 then the aspect of NRC trying to share the information

with the public, to be open. Things have changed, and I

1	think you raise a very valid point.
2	MS. WAGNER SCHWARZ: Cathy, is there some
3	way that that portion of the information can be withdrawn
4	and not I mean, because of security reasons, not made
5	available?
6	MS. HANEY: We can look into it. I would
7	say it certainly is a valid concern. There are ways that
8	you can take information out of ADAMS, such as that
9	So I mean, I'll take that as an action item
10	for John.
11	(Laughter.)
12	MS. HANEY: John's over there saying you
13	like that. You just vote me on that one.
14	But I think it's something that we probably
15	should look into and consider.
16	CHAIRMAN CERQUEIRA: David.
17	DR. DIAMOND: Cathy, thank you very much.
18	If memory serves, I think I'm the one that suggested that
19	we have this little briefing, and I found it very, very
20	informative.
21	I would like to echo what Dick said, which
22	is that certainly we're not the highest risk licensees,
23	but at some point it would be useful to send out some
24	general memorandum to the hospital based licensees just
25	to gently remind them regarding the importance of these

issues.

My question is without giving us any
information which would make you uncomfortable, just
stemming from some discussions we had earlier today with
Dr. Frant, has there been any concern in the government
of prior credible threats about folks, bad folks, trying
to avoid these very high risk targets and starting to
look into these dirty bomb issues or dispersal of
radioactive materials, such as Iridium-92 or cobalt?
Can you tell us if that's been a credible
concern or is it just our paranoia reaching down?
MS. HANEY: Well, I guess for as much as I
can say, I guess there is a concern obviously looking at
the <u>Washington Post</u> and the <u>Washington Times</u> . There have
been numerous articles about dirty bombs, and I'm sure in
your local newspapers you've seen some, and there's been
some reporting.
So I think it's fair to say that it is a
concern and something that people are looking at. Beyond
that I'm not sure I can give you much more information on
that.
CHAIRMAN CERQUEIRA: Ruth.

comments and the fact that license information is on ADAMS, in our state once we send out our security

MS. McBURNEY: Getting back to Richard's

advisories to our major licensees, we had some calls from one of the major manufacturers there in the state who was concerned that the location of their radioactive material was available under open records.

We don't have that same information on our

We don't have that same information on our Web site, but I did assure him that we are looking at whoever. We take the names and so forth of people who come in to look at files and have been a little more aware of who's looking at what in that case.

CHAIRMAN CERQUEIRA: Richard.

DR. VETTER: Cathy, I wanted to also thank you for being here. This has been very, very enlightening. You said you didn't have much to offer hospitals relative to vulnerabilities, but of course, the obvious one is the room exists; the storage facilities exist. Hopefully they've all got the door locked.

But we're from, especially in the hospital environment, from a value system that we find it very difficult to think like a terrorist, and so if in your studies of this issue, if you have come up with vulnerabilities that could, in fact, be applied to a hospital environment, I think it would be really worthwhile to share that with us.

MS. HANEY: And I think that's the long-term intent that we would be doing that. Obviously if we had

2.4

1 reason to believe that there was a threat against a hospital, we would make the hospital aware of it, and it 2 3 would not be a delay, you know, factor. What our tendency has been, we have the 4 5 routine review of the intelligence traffic, and if a 6 facility by name were to come across or even by category, 7 we would notify that category. But beyond that, you're right. 8 As we 9 identify vulnerabilities at different sites, there are 10 some items that are common to the hospital setting, and 11 we would certainly share that with you. 12 And what we are looking at also is going 13 beyond. Obviously our focus is the radiation aspect of 14 the material, but at some of our sites, there are certain 15 chemical hazards that NRC does get into the oversight with because it is inherent to the processing of the 16 17 radioactive material. So we are looking even broader than just the 18 19 radioactive material aspect. 20 CHAIRMAN CERQUEIRA: Other questions for Cathy? 21 If not, I'd like to thank her for coming 22 23 back to the ACMUI. 2.4 MS. HANEY: You're welcome. It's always a 25 delight. I like coming back here.

1	DR. DIAMOND: We miss you.
2	MS. HANEY: I miss you guys, too. I really
3	and I wanted to come to the Commission meeting
4	yesterday. I had it on my calendar, and I couldn't get
5	down there. So I felt better because I thought I'd get
6	to come down and say hi today. So I'll see you all when
7	you come back.
8	DR. DIAMOND: Maybe we can get you back for
9	the next round of rulemaking.
10	MS. HANEY: I don't know.
11	(Laughter.)
12	MS. HANEY: Is that what I want? You need
13	me back? Okay. Well, they'll just transfer me down the
14	hallway. Actually all I am is around the hallway. So
15	they'll send me back around. So whatever I can do,
16	please let me know, and take care.
17	CHAIRMAN CERQUEIRA: Again, thank you.
18	We have several items on the agenda. People
19	wanted to try to end by three o'clock. So we may try to
20	keep some of these brief rather than in detail, but
21	obviously if there's need for discussion we'll do so
22	John, do you want to update us on the new
23	IVB devices?
24	MR. HICKEY: Yes. I will be brief.
25	First of all, I want to say that in

licensing and providing guidance on IVB, intravascular brachytherapy devices, the Committee has provided invaluable advice and suggestions, and our approach has reflected that advice, and we think it has held up very well.

A couple of areas, for example, was in one of the questions was use of the procedures in ways that were not specifically reviewed by FDA when FDA granted approval of the devices.

Another example is the physical presence issue and who should be physically present during the procedure. We think the approach we've used has held up well. We've gotten some questions clarifying, you know, do you really mean an authorized user is actually supervising the use of the material, and we would say, yes, we really do mean that.

But we think the approach has held up very well and will continue to hold up for things that may come in the future. I don't think we're going to have to come back to the Committee for some things that we, you know, didn't anticipate in these initial approaches, although, you know, you never know what we may need to come back to the Committee for.

As far as future devices, there are a couple it's our understanding are in trials, but we don't think

2.4

1	they will raise new issues. They still will use solid
2	material is my understanding. It might be a coded
3	(phonetic) source rather than a sealed source, but the
4	technology I don't think will pose any new issues that we
5	haven't discussed, but if they do, we can come back to
6	the committee.
7	There has been talk of I shouldn't say
8	just talk. There have been proposals and prototypes of
9	liquids and gas, but I think those are farther away, is
10	our sense, but that is always a possibility. I don't
11	think they will raise issues that aren't covered by the
12	existing guidance and positions we've taken.
13	So that's basically a summary. I think so
14	far we have a success story on IVB.
15	CHAIRMAN CERQUEIRA: We have a number of
16	approved devices. How many new devices are currently
17	under FDA review?
18	MR. HICKEY: Well, one is a coded material,
19	but it's still basically a sealed source. Another is a
20	high dose rate type source that could be used in large
21	vessels, using a sealed source.
22	There have been other discussions of liquids
23	and gas, but I think a lot of those have been dropped,
24	but there may be other ones out there that I'm just not
25	aware of because they're farther down the road. They're

1 farther on the way. DR. DIAMOND: I was just going to clarify 2 3 the point. One is a wire foil which is radioactive. So a kind of variation on the theme of a solid source. 4 5 The second one is an extant source design in 6 which the delivery system is modified in a very clever 7 way so as to change the depth dose characteristics. That's the one that's addressing the larger vessels. 8 DR. NAG: I'd be interested in that. 9 10 would like to just make a couple of comments, if I can 11 have the line. intravascular 12 Now, Ι think when 13 brachytherapy came in, it was but in a separate technical 14 emerging technology because brachytherapy was used as a basis for intervention in developing for cancer and 15 required different consideration, and they used different 16 17 technology. But I think we have to reexamine those 18 19 issues because it's true that brachytherapy is normally 20 used for treatment of cancer, but brachytherapy has been used for many years for prevention of non-cancer things 21 22 like halite (phonetic), iridium, and they have the same 23 radiation safety requirement as that for cancer 2.4 brachytherapy. So, you know, the first argument about

placing brachytherapy in a separate category, you know,
doesn't hold.

Through the medical consideration for interventional brachytherapy is different from brachytherapy at other sites, but here are medical considerations at individual sites, like brain. When we started doing brain, we had entirely different considerations. When we went to prostate, we had different considerations. Eye had different considerations, and the specialists from these various sites worked in conjunction with the authorized user to implant radioactive source at these sites.

So how is that different from a cardiologist working in a vessel, working with an authorized user? If radiation safety issues in interventional different brachytherapy are from the regular brachytherapy for cancer, the same regulation should So why have a separate category for apply. interventional brachytherapy and a separate emerging under 1,000?

The other thing is interventional brachytherapy uses separate technology from cancer brachytherapy. Again, that's not true because for each type of interventional brachytherapy you have in conventional brachytherapy and will give you some

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

1	examples.
2	And the radiation safety issues
3	CHAIRMAN CERQUEIRA: Subir, again, I don't
4	mean to this was sort of added to the agenda, and just
5	for the sake of time
6	DR. NAG: I just have my recommendation for
7	that.
8	CHAIRMAN CERQUEIRA: Okay.
9	DR. NAG: And therefore, I think but
10	these are important my recommendation is to eliminate
11	the special consideration of intravascular brachytherapy
12	as an emerging technology and place equally
13	interventional brachytherapy in the corresponding
14	brachytherapy category, and all the radiation safety
15	regulatory requirements as needed for other brachytherapy
16	procedures should apply for interventional brachytherapy
17	and that will give you these examples.
18	Under the guidelines you have remote HDR,
19	the Cordis, the same as your manual iridium. Novoste is
20	the same as your strontium eye brachytherapy. A new
21	liquid Radiance is the same as your gliacyte which is
22	being used for brain tumors.
23	And the other thing is many of these new
24	technologies that are being developed for brachytherapy

for interventional brachytherapy is also being applied

for cancer brachytherapy, like the beta HDR development 1 guidance is being multiplied and used for intraluminal 2 3 HDR for biliary and esophagus. The check developed for 4 interventional brachytherapy has been used for bronchial radiation. 5 6 So it doesn't make any sense to have a 7 different regulatory guideline for interventional 8 brachytherapy when you are using the same equipment and 9 the same category for brachytherapy elsewhere. 10 And again, you are having an unintended 11 consequence when you substitute the "or" or the "and" 12 because now you can have interventional brachytherapy 13 performed by the cardiologist with the authorized user or 14 the physicist. So basically what you did is that it 15 required a signature of your user without their 16 17 involvement in many cases, and therefore, you can 18 potentially compromise radiation safety. 19 I don't want to go into all the details, but 20 you can have similar examples at almost every site, and I believe this issue has to be reexamined. 21 22 CHAIRMAN CERQUEIRA: Well, I quess in a 23 sense by putting it into the emerging category was to 24 sort of delay it, and I think we're getting to the point

where some of these things are out there and, you know,

as we know, there is a lot of work going on between the 1 intravascular -- the people doing intravascular 2 3 brachytherapy, the oncologists and the cardiologists. You know, again, I'm not sure that this is 4 5 a time for us to take action on this, you know. 6 rules, we had a lot of discussion and put it into the 7 1,000 category. I think the Commission recognizes that 8 there are issues related to, you know, safety as well as 9 who's doing it, and I think the fact that they've 10 appointed an interventional cardiologist to the Committee sort of recognizes that, and I think there's preparation 11 to do this. 12 DR. NAG: Right, but the thing is if you're 13 14 having a different rule and you are using the same 15 brachytherapy for interventional and you have a separate rule when you're using it for other brachytherapy, that 16 17 doesn't make sense. It has to follow.z CHAIRMAN CERQUEIRA: Jeff? 18 19 DR. WILLIAMSON: Well, I actually think that 20 there's a contradiction in what you're present. To argue that the Novoste and the Cordis system be treated as 21 22 manual brachytherapy sources, as you do, and actually 23 reduce the regulatory burden because there is no NRC 24 requirement that either a physicist or physician be 25 present when the sources are put into the patient.

1	So you know, there certainly are standards
2	of practice in radiation oncology that are independent of
3	what NRC says. But if the best Cordis system were
4	treated strictly as manual brachytherapy, there would be
5	no requirement of physical presence whatsoever in the
6	operating room. So now there is.
7	So you know, to say, you know, your two
8	wishes are inconsistent to say there should be an
9	"and," physicist and authorized user and should be
10	treated as a 3400 is a contradiction.
11	DR. NAG: Then you're going out for the HDR.
12	For HDR you have the N, and in an HDR application, then
13	you need both. You need an HD for HDR application for
14	cancer, you need the physicist and the authorized user,
15	but when you have an HDR interventional brachytherapy,
16	you don't need both.
17	DR. WILLIAMSON: But that's not what you
18	said. You said that the Cordis should be treated as a
19	35-400.
20	DR. NAG: No.
21	CHAIRMAN CERQUEIRA: I would kind of leave
22	it up to the Committee. Do you want to continue the
23	discussion? I mean this was sort of an added item to the
24	agenda. We agreed that because of flights we would try

to basically get out of here in the next 20 minutes.

1	You know, I think this is a legitimate
2	question that needs to be addressed. I think the
3	Committee and the Commissioners
4	DR. NAG: This is what I wanted to bring
5	forward.
6	CHAIRMAN CERQUEIRA: have made a process
7	in place and I think will come to it.
8	David?
9	DR. DIAMOND: Yeah, I don't think we need to
10	discuss this further right now. I would convey to the
11	Committee, however, a sense that VBT or vascular
12	brachytherapy really heretofore has been a success story.
13	If you go back now two and three years when
14	this first came out, if you remember the discussions we
15	had about real horror stories about people using this
16	inappropriately, off label, it going crazy, people
17	getting hurt, public fears.
18	I think that we really need to congratulate
19	ourselves once in a while and say, you know, we kept a
20	handle on this for a while, and then starting about a
21	year ago, we said things look like they're going well.
22	People are practicing good, safe medicine. We took some
23	of the brakes off. We said, "Don't be too overly
24	prescriptive with respect to off-label use."
25	Since that's gone through to my knowledge,

1	as one of the largest operators of this technology in the
2	country, people have continued to use it with very good,
3	judicious intent. Dr. Triparenini is probably even a
4	more higher volume user than I, and he would, I would
5	hope, share the same feelings.
6	People really have with this multiple
7	disciplinary approach, really have been very, very good
8	at protecting the public and preventing bad things from
9	happening. So once in a while we do need to give
10	ourselves a little pat on the back.
11	CHAIRMAN CERQUEIRA: I think we deserve it
12	after yesterday and today's discussions on our failure
13	with certain guidelines.
14	Well, this is very informative, and
15	obviously this issue will come back, and I think we'll
16	definitely get it on the agenda.
17	Thank you, Subir.
18	We should move along on the agenda, I guess.
19	Joe DeCicco on the mixed doses.
20	MR. DeCICCO: Both sides so I can remember
21	who I am.
22	This is going to be very brief. I don't
23	even have a presentation per se. I don't have any slides
24	or anything because all I wanted to do was update you and
25	let you know that we're still discussing and working on

mixed dose, the mixed dose issue. 1 And in your handout there is just a brief 2 summary of how we've addressed the issue since the last 3 meeting, as a matter of fact, in October. 4 5 What we have done is taken the existing 6 regulations and kind of looked at it with a fresh eye and 7 maybe redefined the box that we're supposed to be thinking in and used the footnote in the weighting factor 8 9 table in Part 20 that basically allows the agency to use 10 other weighting factors other than one for external dose. 11 So that with either a case-by-case 12 evaluation or guidance that would be issued by the 13 agency, some other method other than deep dose equivalent 14 could be used for determining the external exposure. 15 In your package you have a regulatory issues summary, and a regulatory issues summary is similar to an 16 17 information notice that you might be more familiar with, but the regulatory issues summary focuses on a regulation 18 19 and either a different interpretation that has been done 20 in the past or to allow for a new interpretation of a policy position or a relief in burden. 21 And I think the regulatory issues summary 22 23 that you have in your package kind of addresses the issue

The regulatory issues summary has been

for fluoroscopy when using a protective apron.

2.4

distributed to the state regulatory agencies for comment. 1 It was issued to the states on January 24th, and they 2 3 were given 45 days for comment. It is pre-decisional, which means it's not 4 5 out there for everybody, but the regulatory agencies can 6 look at it and address any comments to either me or to 7 the agency at the Web site that the states have access 8 to. And the comment period for this regulatory 9 10 issues summary draft is March 14th. Hopefully by the end 11 of March or very close to that date, we should have this 12 regulatory issues summary issued and out to licensees so 13 that they can use this guidance that addresses the issue 14 of that mixed exposure when using fluoroscopy and the lead apron and also being exposed to NRC licensed 15 16 sources. 17 So that's about it. That's all I wanted to 18 do is make you aware of. If you have any comments, 19 please provide them to me or any other method that you 20 say. Yes, sir. 21 CHAIRMAN CERQUEIRA: Richard. 22 23 DR. VETTER: So how is the license -- if an 24 interventional cardiologist is involved in fluoro, of 25 course, like in most of the exposure there and doing IVB,

1	how is the licensee to distinguish what exposure came
2	from the brachytherapy source versus the X-ray source?
3	MR. DeCICCO: That's a very difficult
4	technical issue, and it's not addressed in the regulatory
5	issues summary per se because we didn't want to try to
6	address all of the issues.
7	However, the staff has actually looked at
8	that issue, and I don't want to state too much because I
9	don't state policy, but from a technical point of view,
10	the evaluation done when evaluating the X-ray exposure is
11	probably as close to the true dose than any other method
12	used, and I think that particular issue will be addressed
13	after this RIS comes out because that's a much smaller
14	community than, say, the fluoroscopist also doing nuclear
15	medicine.
16	There's probably fewer physicians doing both
17	IVB and fluoroscopy as opposed to physicians being
18	exposed to both source and non-source at separate times.
19	DR. VETTER: Okay. I understand that, and
20	that does make sense. I mean, for the nuclear
21	cardiologist who's also doing intervention, you can have
22	two badges and you can sort it out easily.
23	CHAIRMAN CERQUEIRA: That easy, but for the
24	IVB.
25	Ralph?

MR. LIETO: Boy, I've got a number of 1 One, I think this type of guidance affects 2 things. 3 basically almost totally medical users, and I think that 4 something like this, which I want to say I think it's a 5 very good document; I applaud the summary information and 6 so forth. 7 I've got just a couple of comments on it 8 myself, but I think the point that was brought up about 9 addressing the situation of the person who has like the 10 cardiologist or the radiologist who does nuclear medicine 11 and a lot of fluoroscopy I really think has to be addressed in this. 12 I think to take it at one time and then come 13 14 back later and revisit it I really think is sort of a disservice to this document. I really think that there's 15 a real need for this, and I think the guidance that a lot 16 17 of RSOs and medical physicists that sort of struggle with this is out there. 18 19 You know, one thing may be for consideration 20 is the fact that you don't have to badge a worker who is not likely to get ten percent of the dose limit or you 21 22 know that a cardiologist is not likely to get ten percent 23 of his dose from intravascular brachytherapy. In fact, 2.4 you could almost say that with certainty.

And I can say also it's very likely that a

radiologist who does fluoroscopy is not likely to exceed ten percent of his does from his nuclear medicine activities. It's very hard to get exposed from behind that alternator.

And so I would say that as maybe a suggestion for guidance in this document is that using this guidance and assigning doses for external and internal for NRC licensees would be applicable to those situations where the licensee can document that it is very unlikely, that it's not likely that the worker is going to exceed ten percent from his licensed NRC activities.

And I guess I had one question. Your Item

No. 4 on page 3, you said that any alternative method

that is used incorporating the license must be

incorporated in the licensee's procedures and program.

It almost makes it sound like it's a license condition. Do you understand where I'm kind of going with this? And that it has to be instituted prior to the exposure for which an alternative method has been applied, and I'm just trying to understand why that went in there.

MR. DeCICCO: Yeah. Not to go into too much detail because of time and since it was pre-decisional, I think what we were trying to avoid is this is going to

be a prospective application of the accepted -- the 1 guidance. We didn't want people to go back to previous 2 3 exposure or past years and say, "Oh, well, that exposure 4 really wasn't that. Now we can reevaluate it." We didn't want people to go back. We just 5 6 want this to be a prospective. 7 It being a requirement to be documented, 8 that was put in there primarily to avoid people flopping 9 from one procedure to another to fit their needs. We 10 wanted it to be a prospective application, and therefore, 11 you use that application as long as you feel that that's 12 appropriate prospectively. 13 You don't say, "Oh, well, let me reevaluate 14 this after the fact." And that's why that particular 15 phrase was put in there. 16 MR. LIETO: Okay. MR. DeCICCO: It was to avoid that flip-17 18 flopping or going back to previous exposure. 19 MR. LIETO: Okay. I thought that was kind 20 of handled in number five already, and I just --MR. DeCICCO: Maybe it was; maybe it was. 21 We'll take a look at that. 22 Okay. Thank you. 23 CHAIRMAN CERQUEIRA: So, Ralph, how do you 2.4 suggest we go? I mean, so this is basically a draft 25 form, and has it gone out to any of the stakeholders?

1	MR. DeCICCO: It's gone out to state
2	regulatory agencies for their comment, and the comment
3	period is up until March 14th, and then we'll
4	CHAIRMAN CERQUEIRA: But what about I
5	mean, has a cardiologist had a chance to look at this to
6	give you some feedback?
7	MR. DeCICCO: Not licensees, not non-
8	regulatory agencies because it's a pre-decisional.
9	CHAIRMAN CERQUEIRA: Right.
10	MR. DeCICCO: Pre-decisional.
11	CHAIRMAN CERQUEIRA: Would it be worthwhile
12	getting their input as well as, you know, the health
13	physicist community?
14	MR. LIETO: I was just going to say I think
15	it would be interesting to see what, you know, like the
16	Health Physics Society might have to say about this or,
17	you know, have some input from some of the scientific
18	groups, but I'm not quite sure. When you say it's pre-
19	decisional, I don't know if there's some type of
20	restriction in the distribution of the information from
21	a I don't want to say security standpoint, but
22	MR. DeCICCO: Well, it's not security, but
23	it's a matter of procedure.
24	MR. LIETO: Okay.
25	MR. BROWN: Yeah, this is Fred Brown.

1	This document was shared with you for your
2	comments as professionals in the field, as contract
3	employees of the NRC, and we would appreciate your input,
4	and hopefully it will serve as the type of input that
5	you've proposed, but the Administrative process for this
6	document and the time frame for it basically restrict us
7	to sharing it with you at this point, and we hope to have
8	it out soon.
9	DR. VETTER: So how do we get our comments
10	back to you?
11	CHAIRMAN CERQUEIRA: Back to you, yes.
12	MR. BROWN: Either through Angela or
13	directly by E-mail.
14	CHAIRMAN CERQUEIRA: And what time line do
15	we have on getting the comments back?
16	MR. DeCICCO: Well, the comment period is
17	officially open until March 14th, and until it's signed,
18	you know, I'll take comments up until I can get the final
19	version.
20	CHAIRMAN CERQUEIRA: Yeah, I gather it's a
21	situation where we're this sort of has an impact on
22	certainly the users, the stakeholders being the medical
23	community, and it would have been good to have gotten
24	this ahead of time.
25	So I think all of the people that are

1	basically representing some of these regulated
2	communities should give input.
3	And can we get specific information where to
4	send the input? How do we contact
5	MR. DeCICCO: On the last page of the RIS
6	which is the next to the last page of the document, is my
7	E-mail address, my phone number, where you can send
8	comments.
9	CHAIRMAN CERQUEIRA: Okay.
10	MR. DeCICCO: Or to Angela.
11	CHAIRMAN CERQUEIRA: Okay. All right. Do
12	we need any follow-up on this?
13	I mean we should get Ralph, don't you
14	think we should get some follow-up as to how this is
15	going to eventually come out?
16	MR. LIETO: I think it would definitely be
17	welcomed, especially by the Committee, and there is
18	yeah.
19	CHAIRMAN CERQUEIRA: So should we make it an
20	action item that, you know, at the next meeting we get
21	some follow-up either from Joe or from the NRC staff as
22	to what's happened with this and some time line of when
23	it's going to be implemented as well?
24	Okay. Well, thank you very much, and we'll
25	yes?

1	MR. LIETO: Joe, is there like a time line
2	that you guys are under in terms of having this all
3	complete? I mean, it sounds like there might be some
4	deadline.
5	MR. DeCICCO: Right now my time line is to
6	try to get this thing signed out some time around the end
7	of March, the beginning of April, and that was basically
8	a Commission request on getting this issued.
9	MR. BROWN: Once it's issued, it will be in
10	effect, and it should reflect the discussion that we had
11	at the last meeting with you about how this issue should
12	be handled.
13	So although you haven't seen the draft, when
14	you look at it, it should reflect your comments to me
15	MR. DeCICCO: Yeah, I don't think you're
16	going to see any surprises. It's just a matter of
17	putting officially in black and white guidance that the
18	Agency will guidance that is put out by the Agency for
19	the licensees.
20	We didn't recreate the wheel. We just kind
21	of looked at the wheel a different way.
22	MS. McBURNEY: I would note that we have
23	adopted the similar rules to the suggested state
24	regulations, and it's working well. We've had them in
25	place for several years.

1	MR. LIETO: The only area I foresee issues
2	are in non-agreement states
3	MS. McBURNEY: Right.
4	MR. LIETO: that may not be as
5	progressive as the State of Texas.
6	MS. McBURNEY: I understand.
7	CHAIRMAN CERQUEIRA: Okay. Thank you very
8	much.
9	MR. DeCICCO: Thank you.
10	CHAIRMAN CERQUEIRA: We should move along
11	here, and if we just basically skip down on page 2 of the
12	agenda, I think we've covered the first two items that we
13	were supposed to cover age the break.
14	The ACMUI vacancies, there's a sheet that
15	was distributed by Angela to the Committee, and we're
16	actually in fairly good shape in the sense that we've got
17	two appointees, and it says, you know, 2001, and yet
18	we're into 2002 and we still don't have those people on
19	board.
20	And I think, John, the feeling of the
21	discussion we had earlier is that the sooner we get these
22	people on board, the better.
23	MR. HICKEY: Yeah, we agree.
24	CHAIRMAN CERQUEIRA: And I guess just sort
25	of looking ahead, 2003 we have a whole slew of people who

1	are eligible for reappointment, and we should, you know,
2	basically send requests to these people.
3	And I guess now is the appointment made by
4	the NRC? Do we normally go back to the societies that
5	recommended these people? How are reappointments
6	handled?
7	MR. Hickey: No, the reappointments can be
8	handled internally with the Committee and the Commission
9	if the appointees are still willing to continue to serve.
10	CHAIRMAN CERQUEIRA: So how soon can we
11	reappoint people so that we, in case somebody decides not
12	to continue on the Committee, we can
13	MR. HICKEY: Well, late I'm sorry.
14	CHAIRMAN CERQUEIRA: No.
15	MR. HICKEY: Late in the calendar year prior
16	to the appointment date, I think we would check with the
17	appointees and then confirm their reappointment early in
18	that year.
19	CHAIRMAN CERQUEIRA: But when would they go
20	off on 2003? Would it be the fall of 2003 that they go
21	off?
22	MR. HICKEY: Well, we didn't put months
23	here. We'd have to check on that, but I would say six
24	months ahead of time would be plenty.
25	CHAIRMAN CERQUEIRA: Well, I would say, you

1	know, if we know that people are coming up, we should
2	request if they want to continue, and then make it
3	available for them to be reappointed, and if they say no,
4	then I think we need to initiate the process.
5	MR. HICKEY: Yes. Well, certainly if a
6	member knows they don't want to be reappointed, they
7	should advise the Commission staff immediately. I mean,
8	you know, as soon as they
9	CHAIRMAN CERQUEIRA: Well, they may not
10	actually know the reappointment date. So I'd make a
11	recommendation that, you know, we basically send out
12	letters to these five people. That's a huge chunk of the
13	Committee that basically goes off on 2003, asking them if
14	they wish to, you know, be reappointed, in which case we
15	can initiate the process, and that would identify, you
16	know, clearly identify people who don't plan to come
17	back.
18	Is that a reasonable?
19	DR. NAG: I think on the reappointment the
20	problem is only if they don't want to be reappointed.
21	CHAIRMAN CERQUEIRA: Right.
22	DR. NAG: Therefore, you need about one
23	year.
24	CHAIRMAN CERQUEIRA: At least a year.
25	DR. NAG: Now, if all of these people said

1	they wanted to be reappointed, there's no problem.
2	CHAIRMAN CERQUEIRA: Right.
3	DR. NAG: But if they are not, then there is
4	a problem. In fact, I'm even wondering. The ones in
5	2004, if they are spring 2004, we should start thinking
6	about them because there are one, two there are two
7	people who are going to be rotating off, three.
8	CHAIRMAN CERQUEIRA: Yeah. No, I think
9	that's very, very true.
10	So maybe what you're saying is the first
11	action item is that the reappointees for 2003 should be
12	contacted regarding their desirability to continue on the
13	Committee, and for the people who are going to rotate off
14	on 2004 we should initiate the process for soliciting
15	names and nominations. Does that sound like an action
16	item from the Committee?
17	DR. NAG: I think so
18	CHAIRMAN CERQUEIRA: Ralph?
19	MR. LIETO: I think it's just a consensus to
20	the staff and go from there.
21	CHAIRMAN CERQUEIRA: Yeah.
22	DR. WILLIAMSON: I think so.
23	MR. LIETO: It's something you've already
24	got in the hopper anyhow, I imagine.
25	MR. HICKEY: That's fine. It just seems to

1	me it's a little early now to solicit appointees for
2	2004. I would have to look at how long it has taken in
3	the past.
4	CHAIRMAN CERQUEIRA: Right.
5	MR. HICKEY: I think you're going to find
6	this cardiology position is going to be filled within
7	about three or four months of the Commission stating that
8	they wanted someone appointed.
9	CHAIRMAN CERQUEIRA: No, no. Well, that's
10	good, and that's but, again, we've kind of I think
11	the Committee has been pushing to try to get this done,
12	and so does anybody object to requesting that the NRC
13	staff take those actions?
14	PARTICIPANT: It's a good idea.
15	CHAIRMAN CERQUEIRA: Sounds like reasonable
16	to do.
17	Okay. So maybe we could have that as a
18	follow-up item for the next Committee meeting.
19	Okay. So that sort of takes care of the
20	vacancies and reappointments and people who rotate off.
21	I just have to hold onto 2004, right?
22	And then follow-up discussion, ACMUI
23	recommendations regarding interpretation of 10 CFR 35.57.
24	John?
25	MR. HICKEY: We've already been through

1	that. We don't have to have anymore discussion on that.
2	CHAIRMAN CERQUEIRA: That's right. Okay
3	Meeting summary. Oops. We goofed upon the
4	RSOs and the authorized medical physicist, and we need to
5	take action fairly quickly to try to remedy that. I
6	think that's clearly the one thing that's come out of
7	these two days. I think we've identified a subcommittee
8	to deal with it.
9	And Richard and I will contact Commissioner
10	Meserve to sort of see what action we can get on it
11	MS. WILLIAMSON: Will the subcommittee
12	members then just be contacted by E-mail?
13	CHAIRMAN CERQUEIRA: I think that would be
14	the best way to do it, and Angela can provide the
15	support, but once you get sort of a group mailing for the
16	Committee, I think it would be reasonable to, you know,
17	do whatever you feel is appropriate and, you know,
18	perhaps copy me and John and Angela on the E-mails would
19	be the best way to go forward on this.
20	Next meeting. We traditionally have been
21	meeting twice unless there were like urgent needs. We
22	meet in the sort of, you know, late winter, early spring
23	and then in the fall. So the next meeting would probably
24	be some time in October or November.
25	Does anybody feel we need to meet any

	358
1	sooner?
2	We have a lot of unresolved issues. You
3	know, we still don't know if Part 35 revision is going to
4	be signed into law. If it is signed into law, then we
5	still have to deal with all of the issues related to the
6	RSOs and the authorized medical physicist and the
7	radiation oncologist.
8	MS. HOBSON: How will we handle the
9	recommendations of the subcommittee on the new
10	rulemaking?
11	CHAIRMAN CERQUEIRA: I think it will be
12	distributed to the Committee members by E-mail to get
13	their input.
14	Can we have now, is the Committee allowed
15	to have conference calls and what are the rules for that?
16	MR. HICKEY: Yes. I would suggest, given
17	where we are, that we would plan on handling some things
18	by conference call or E-mail, in some cases hard copy
19	express mail if it's not amenable to E-mail, and then if
20	you could plan on having the fall meeting as a whole
21	It may be appropriate to have a subcommittee
22	meeting or you were suggesting you may meet with the

CHAIRMAN CERQUEIRA: Well, at least have a

Chairman or a subgroup could --

discussion.

23

24

MR. MYERS: -- work with the Chairman or 1 call, have a telecon. with the Chairman. 2 3 CHAIRMAN CERQUEIRA: Yeah, I think that 4 would be preferable. 5 MR. HICKEY: I think the fact that this is 6 going to be done in bits and pieces, it will be more 7 effective and, in fact, will have to be done to a large 8 degree by E-mail and telephones anyway because you can 9 only do so much in a two day meeting anyway. 10 CHAIRMAN CERQUEIRA: Right. Now, in terms 11 of telephone conference calls, what are the requirements? 12 I mean, do they have to be public? Can they just be the 13 -- since it is not the whole Committee but a 14 subcommittee, do we need to have notice? Do we need to 15 make it open? MR. HICKEY: As far as I know, if it's not 16 17 the whole committee, it does not need to be public. I could check that with the -- there's not time to do it 18 19 right now, but I could check that with the attorney. 20 CHAIRMAN CERQUEIRA: I think it would be important to get that because a lot can be done on 21 22 conference calls, and you know, we have no problems with 23 it being open, but I just want to make certain that if 2.4 that's a requirement that we allow that to happen. Richard? 25

1	DR. VETTER: I wouldn't guess that would be
2	a problem because the subcommittee will simply be working
3	up a recommendation.
4	CHAIRMAN CERQUEIRA: Right.
5	DR. VETTER: We can't take any action.
6	We'll simply be writing a recommendation.
7	MS. McBURNEY: Right.
8	DR. NAG: I would suggest that most of what
9	I hear like we would set a date or a tentative date when
10	we are not available and when we may be available.
11	Otherwise somebody
12	MR. HICKEY: Yeah, my recollection is there
13	are certain weeks in November that are bad because of
14	conferences.
15	CHAIRMAN CERQUEIRA: The cardiology meeting,
16	yes.
17	DR. DIAMOND: And in October is our society
18	meeting.
19	MR. HICKEY: Yeah, there's certain weeks
20	that we need to block out.
21	DR. WILLIAMSON: May we need to avoid.
22	CHAIRMAN CERQUEIRA: That's the end of
23	November usually.
24	DR. WILLIAMSON: And ASTRO us usually what,
25	end of October?

1	
2	DR. NAG: Okay.
3	MS. McBURNEY: October.
4	DR. NAG: The ASTRO is October 6th through
5	10.
6	MS. McBURNEY: There's also the Organization
7	of Agreement States, which will probably take not only
8	me, but also several of the NRC staff.
9	DR. NAG: The RSNA, the first week of
10	December. So some time in late October or early November
11	is a possibility.
12	MR. HICKEY: I think we found in the past
13	late October or early November is the window of
14	opportunity.
15	CHAIRMAN CERQUEIRA: Right.
16	MS. McBURNEY: Right, Halloween.
17	CHAIRMAN CERQUEIRA: Well, what about the
18	last week of October?
19	And what days of the week usually work best
20	for us, John?
21	And we're not going to meet with the
22	Commissioners this time. So it's just a matter of
23	DR. DIAMOND: If we do a one day meeting, we
24	had a successful go-round last time by holding it on a
25	Monday, if I recall.

	302
1	MS. McBURNEY: That was great.
2	CHAIRMAN CERQUEIRA: So you want to go
3	for
4	MR. HICKEY: That's more up to the
5	Committee. If something goes wrong over the weekend, you
6	know, there's always the possibility that you're going to
7	have a hard time starting up, but I know a lot of you
8	like having the Monday meetings.
9	MS. HOBSON: Except for the East from the
10	West Coast.
11	CHAIRMAN CERQUEIRA: So October 28th?
12	MS. HOBSON: That means I have to travel on
13	Sunday.
14	MR. HICKEY: Talk to the Committee.
15	DR. NAG: I mean, if we have it the first
16	week of October, you know, middle, the 14th, 21 or 28
17	October. October 28th is also oh, no, that's fine.
18	CHAIRMAN CERQUEIRA: October 28th?
19	MR. HICKEY: The 28th looks good, yeah.
20	MS. HOBSON: Yes.
21	CHAIRMAN CERQUEIRA: All right. So October
22	28th.
23	MR. HICKEY: So we would all have to travel
24	on Sunday, Niki.
25	DR. NAG: Right.

MS. HOBSON: Oh, these people that live 1 close by, they just hop on a commuter. 2 3 MR. HICKEY: There's only one that lives 4 that close. 5 CHAIRMAN CERQUEIRA: There's only one. 6 DR. WILLIAMSON: You don't think under the 7 circumstances of having the possibility of a new rule we 8 really should think in terms of a day and a half or two 9 days? Almost always our meetings have been two days if 10 you view it historically, and we've, generally speaking, 11 filled those two days. It's been hard to get through the agenda. 12 Yeah, the thing is if you're 13 14 having it one day with all of the new requirements, most of us have to leave by three or 3:30 anyway. You know, 15 that way you're ending up with three quarters of a day. 16 17 So you might as well make it for one and a half days. CHAIRMAN CERQUEIRA: The 28th and 29th? 18 19 DR. WILLIAMSON: Yeah, a compromise might be 20 to do it Monday afternoon and all day Tuesday so that 21 then we have --DR. NAG: Yeah, but then you lose the whole 22 Monday morning because no one flies that morning. 23 2.4 DR. WILLIAMSON: Some people could fly in in 25 the morning.

DR. NAG: Then other people have to fly in 1 2 the previous night. 3 DR. WILLIAMSON: Yeah, that's right. CHAIRMAN CERQUEIRA: I think Monday and half 4 5 a day Tuesday is --6 PARTICIPANTS: Yes. 7 MR. LIETO: I don't know if you want an action item. 8 MR. HICKEY: We will reserve this room all 9 10 day Monday and Tuesday and schedule the meeting. If, 11 upon closer, you know, to the time to the meeting it 12 becomes apparent that the agenda doesn't support that, it 13 can always be reduced, but I know you all want to block 14 your calendars. 15 CHAIRMAN CERQUEIRA: I think we should, you know, Monday and half a day Tuesday. 16 17 MS. WAGNER SCHWARZ: Yes. CHAIRMAN CERQUEIRA: The other thing we need 18 19 to talk about is just getting the agenda for the 20 Committee meeting, you know. This time we had the briefing with the Commissioners, and that got done on a 21 22 fairly late basis. I would really like to get, you know, to get the agenda so that we're here doing something 23 24 that's, you know, dealing with issues that are coming up 25 and trying to get as much background material out to the

1	Committee ahead of time as possible so that, you know,
2	our time is better spent here.
3	MR. HICKEY: We will do a better job of
4	getting you the background material.
5	CHAIRMAN CERQUEIRA: Yeah.
6	MR. HICKEY: And we'll work together to have
7	a good agenda, but part of that depends on what you
8	propose and how many members are interested in a given
9	topic.
10	CHAIRMAN CERQUEIRA: I'd say that by
11	September 15th, which is about a month and a half before
12	the Committee meeting, that we have a draft agenda at
13	least together to identify the issues that have come up.
14	So some of these informative things are
15	fairly nice, but if we have other pressing business, I
16	mean, we could make those briefer, get some of the
17	material out ahead of time.
18	DR. WILLIAMSON: I would suggest, too, that
19	the staff be more proactive in, you know, reviewing the
20	activities of the agency and bringing items forward to
21	the agenda for us to consider, like this group that's
22	doing the national materials safety exercise.
23	You know, it so happened Ralph was aware of
24	that, but the rest of us weren't and, you know, we have
25	limited insight into the operations of the Commission.

1	So I think a lot of burden falls on you
2	MR. HICKEY: Yes.
3	DR. WILLIAMSON: to at least identify for
4	us the possibilities, issues to consider on the
5	MR. HICKEY: Yes. We should have done a
6	better job on that. Frankly, we were distracted by the
7	legislation, throwing Part 35 out.
8	CHAIRMAN CERQUEIRA: So what was your point
9	about the follow-up?
10	MS. WAGNER SCHWARZ: On the regulatory
11	guide, the guidance that's coming out, there are meetings
12	that are planned, and how about feedback?
13	MR. LIETO: I was just going to say the same
14	thing, that they're going to have public meetings in
15	April, was it?
16	MS. WAGNER SCHWARZ: Yes, April 23rd and
17	fourth.
18	MR. LIETO: And I don't know if there's
19	going to be the need for us to get back together, not
20	maybe physically, but either via telephone or some other
21	means to follow up on this
22	MR. HICKEY: That's true.
23	MR. LIETO: maybe a couple of times.
24	MS. WAGNER SCHWARZ: Yes.
25	MR. LIETO: So I guess maybe just an FYI to

1	be prepared, I guess, is the best thing I can suggest
2	right now.
3	MS. WAGNER SCHWARZ: It seems like it might
4	be a reasonable thing that at least we talk by telephone.
5	DR. WILLIAMSON: I think so.
6	MR. LIETO: I would imagine if the
7	publication of the rule is delayed, then the April
8	meetings could get pushed back to May. Would that be
9	true?
10	MR. HICKEY: I mean, anything could happen
11	if publication of the rule is delayed. But we will do a
12	better job of communicating with you by E-mail as to what
13	is going on and what's coming up, and then you can get a
14	better feel of what your response should be, you know,
15	how you want to participate in that.
16	MS. WAGNER SCHWARZ: I have one more
17	suggestion. What about agenda items? Do you want to
18	give us a date now that you would like agenda items sent
19	to you?
20	CHAIRMAN CERQUEIRA: Yes.
21	MS. WAGNER SCHWARZ: So that we at least
22	have it on the calendar for
23	CHAIRMAN CERQUEIRA: I said April. I'm
24	sorry. September 15th, but let's see what day of the
25	week that is.

1	MS. WAGNER SCHWARZ: That's a Sunday.
2	CHAIRMAN CERQUEIRA: Well, how about Friday,
3	September 20th?
4	MR. LIETO: A month?
5	CHAIRMAN CERQUEIRA: Yeah. Or do you want
6	to go for like Friday, the 13th?
7	MR. HICKEY: Well, Mr. Chairman, if I could
8	comment, I think we need a preliminary call earlier than
9	that.
10	MS. WAGNER SCHWARZ: Okay.
11	MR. HICKEY: Because once the agenda is set,
12	we prepare the background material to send out. So we
13	need more time to anticipate what the items are going to
14	be and what material needs to be prepared.
15	CHAIRMAN CERQUEIRA: September 6th? So
16	Friday, September 6th is the deadline for having items
17	for the agenda submitted.
18	DR. VETTER: And will the staff be sending
19	us a letter?
20	CHAIRMAN CERQUEIRA: A reminder.
21	DR. VETTER: Soliciting that or
22	MR. HICKEY: Yes. Yeah, we go to the
23	Chairman and "cc" the other members.
24	CHAIRMAN CERQUEIRA: Yeah, and maybe send
25	that out

1	MR. HICKEY: And we may send you
2	MS. WAGNER SCHWARZ: That could come out
3	from Angela even.
4	MR. HICKEY: We may send you more than one
5	note, you know. "Start thinking," you know, and then the
6	next note is "the deadline is."
7	DR. WILLIAMSON: I think we have taken the
8	position already, haven't we at this meeting, that we
9	want to review the regulatory guide when the next draft
10	is available? And so there needs to be between now and
11	whenever that happens provision made to have at least a
12	virtual meeting over that.
13	CHAIRMAN CERQUEIRA: Right, and we actually
14	had wanted to get some input into it, but the Committee
15	is basically sitting idle. Well, not the the working
16	group for the states thing, which I guess is
17	DR. NAG: Well, that's national material.
18	DR. WILLIAMSON: This is Volume 9 of 15.56
19	that I'm talking about.
20	MS. McBURNEY: Right.
21	CHAIRMAN CERQUEIRA: That's a more immediate
22	need, right?
23	DR. WILLIAMSON: We've taken the position
24	that we want to be involved. It's not an "if." I'm
25	responding to John. I think that's already taken care

1	of. So we need to get a copy of that as soon as is
2	possible, and then arrangements made to have a forum for
3	consolidating a review.
4	And I would think that at least a conference
5	call among interested parties would be wise.
6	DR. NAG: I only want to remind the staff to
7	make a list of all of these action items that we came up
8	with.
9	MR. HICKEY: Yes.
10	DR. NAG: Even though you may not have their
11	solution, at least send what the action items are so that
12	we will remember.
13	MR. HICKEY: Yes, we will do that.
14	CHAIRMAN CERQUEIRA: And I think that should
15	go out as soon as we get it to people so people have an
16	idea to see what was on the you know, what was
17	discussed and what needs to be done.
18	DR. NAG: Yeah. That would also be
19	something like a reminder of some of the things we may
20	have to do with our societies.
21	CHAIRMAN CERQUEIRA: Right, right.
22	MS. WAGNER SCHWARZ: So minutes of the
23	meeting, is that kind of what you're thinking?
24	DR. NAG: Not the whole minutes. That
25	becomes too long.

1	MS. WAGNER SCHWARZ: Right.
2	DR. NAG: What are the action items.
3	CHAIRMAN CERQUEIRA: The action items, you
4	know, which could be pulled out, and clearly we
5	identified them in the transcripts. Whatever John,
6	what do you think is the best way to get that out?
7	They're not official minutes. They're just sort of
8	action items.
9	MR. HICKEY: Well, I think we can E-mail it.
10	Tim has been trying to, in addition to the whole meeting
11	being transcribed, Tim has been trying to catch the
12	action items, and I've got them here, too. So I think
13	that
14	CHAIRMAN CERQUEIRA: And I think we all made
15	a
16	MR. HICKEY: can be done as an advanced
17	E-mail that will be reflected in the official minutes
18	CHAIRMAN CERQUEIRA: Good. Any other
19	business?
20	(No response.)
21	CHAIRMAN CERQUEIRA: If not, I'd like to
22	thank the Committee and the NRC support staff for getting
23	us out on time and identifying all of the issues we need
24	to deal with.
25	Thank you.